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INTRODUCTION AND OUTLINE OF THE THESIS  
 
GENERAL INTRODUCTION 
 
1. Perspective 
The invention of optical instruments in the 13th century has changed 
our view on life forever. It brought into daylight the things that we 
couldn’t even dream of at night. Large but distant objects were 
revealed, as well as close but very small particles. The magnified 
image of human cells and bacteria showed us the key players of 
health and disease. Since then, these microscopic elements have 
played a never-ending story in our search for new therapies. We have 
learned that human cells work together and display a tremendous 
spectrum of functions that result from differentiation and 
communication. These complex interactions are all directed toward 
homeostasis and without that we would simply die. Environmental 
changes that disturb homeostasis are countered by several regulatory 
mechanisms in our body and allow us to adapt to the altered 
condition. However, extreme disturbances may lead to malfunction of 
cells and organs, and this makes us feel sick. Micro-organisms are 
masters of disturbance, and many higher eukaryotes, including 
humans, have equipped themselves with a powerful immune system 
that helps to battle them. But what if this armoury is in a bad 
condition and fails, or overreacts? Will the invaders still be cleared, 
or will we suffer from collateral fire? Or will it even react in the 
absence of invaders? These phenomena seem to occur during the 
sepsis syndrome, where malfunctioning of the immune system 
burdens us with its “suicidal tendency”. We can only understand the 
immune system if we know its players and its language. Our skill to 
isolate, grow and observe human cells in an artificial but highly 
controlled environment will help us to explore the biochemistry and 
genetics of complex diseases, such as sepsis, even on a molecular 
level. Today, cell cultures are used as an essential tool to study the 
life sciences, and their behaviour often serves as a simplified model 
to examine the mechanisms that guard or disturb homeostasis. 
Hopefully, they will tell us the truth and reveal new therapeutic 
targets. 
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2. Sepsis and septic shock 
Sepsis is a life-threatening inflammatory condition that develops in 
more than 1 million people in Europe1 and the U.S.2,3 annually. 
Despite advances in hospital care facilities, the improvement of 
therapeutic approaches, and the use of potent anti-microbial agents, 
sepsis is still fatal in about 20% of patients, and it remains the leading 
cause of death in the non-coronary intensive care unit. Over the past 
three decades, the seriousness of this problem has been fed by a 
consistent increase of its incidence.2 
The term “sepsis” (Greek: decay) originally referred to the clinical 
syndrome that is defined by the combination of a documented or 
suspected infection, and physiological changes now known as the 
“systemic inflammatory response syndrome” (SIRS; Table 1).4 
The majority of cultured micro-organisms that are isolated from 
patients with sepsis are either Gram-positive or Gram-negative 
bacteria, while other pathogens are protozoa, fungi, and viruses. 
Remarkably, a documented infection is absent in 40 - 60% of all 
cases,2,5 and in these patients the characteristic features of the sepsis 
syndrome may be initiated by stimuli other than micro-organisms, 
such as severe trauma, burns, or major surgery. Clinical signs of SIRS 
involve fever or hypothermia, increased heart -, and respiratory rate, 
and abnormal white blood cell counts. In addition, sepsis is often 
characterised by tissue hypoperfusion, severe hypotension, and 
dysfunction of vital organs (Table 2).6 
A serious complication that frequently develops in patients with 
sepsis is (septic) shock. This life-threatening condition is defined as 
sepsis with persistent and severe hypotension despite fluid 
resuscitation, and organ dysfunction (Table 1). Mortality among these 
patients may be as high as 70%. Septic shock is characterised by 
serious hemodynamic changes, such as low capillary wedge pressure, 
a low cardiac index, and normal or elevated vascular resistance. 
These alterations are often accompanied by increased vascular 
permeability, which may lead to peripheral edema. After fluid 
resuscitation, these patients typically have an increased cardiac index 
and very low peripheral vascular resistance. Decreased perfusion and 
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impaired supply of oxygen and nutrients to vital organs during shock 
frequently results in organ failure, and induce the multiple organ 
dysfunction syndrome (MODS),7,8 which offers poor chances for 
survival. Apparently, the cardiovascular system has an important role 
in the pathophysiology of the sepsis syndrome and MODS. Many 
vascular functions, including the regulation of blood flow and the 
transport of immune cells, oxygen, fluid and nutrients to the 
different organs of the body, are governed by endothelial cells, which 
cover the inner surface of all blood vessels. Not surprisingly, the 
endothelium has been targeted as a key tissue in the response to 
sepsis. 
 
 
TABLE 1. ACCP/SCCM Consensus Conference Definitions of Sepsis, Severe 
Sepsis, and Septic Shock 4 
SIRS is manifested by two or 
more of the following 
conditions: 
• Temperature > 38.3 °C or < 36 °C 
• Heart rate > 90 beats/min 
• Respiratory rate > 20 breaths/min, or PaCO2 
< 32 mm Hg 
• White blood cell count > 12,000/mm3,          
< 4,000/mm3, or > 10% immature band forms 
Sepsis SIRS with documented or suspected infection 
Severe Sepsis Sepsis with organ dysfunction, hypoperfusion, or 
hypotension. Hypoperfusion and perfusion 
abnormalities may include, but are not limited to 
lactic acidosis, oliguria, or altered mental status 
Sepsis-induced hypotension A systolic blood pressure < 90 mm Hg, or a 
reduction of > 40 mm Hg from baseline in the 
absence of other causes for hypotension 
Septic shock Sepsis-induced hypotension despite adequate 
fluid resuscitation along with the presence of 
perfusion abnormalities that may include but are 
not limit to lactic acidosis, oliguria, or an acute 
alteration in mental status 
Multiple Organ Dysfunction 
Syndrome 
Presence of altered organ function in an acutely 
ill patient such that homeostasis cannot be 
maintained without intervention 
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TABLE 2. Diagnosis criteria for Sepsis 4 
Documented or suspected infection, and one or more of the following: 
General variables • SIRS 
• Altered mental status 
• Significant edema or positive fluid balance (>20 mL/kg 
over 24 h) 
• Hyperglycemia 
Inflammatory variables • Abnormal WBC counts 
• Increased plasma C-Reactive Protein 
• Increased plasma procalcitonin 
Hemodynamic 
variables 
• Hypotension (systolic blood pressure < 90mm Hg; or a 
drop in systolic blood pressure of >40mm Hg; or MAP < 
70 mm Hg) 
• Decreased cardiac index 
• Decreased tissue oxygenation 
Organ dysfunction 
variables 
• Arterial hypoxemia 
• Acute oliguria 
• Increased plasma creatinin 
• Coagulation abnormalities 
• Ileus 
• Thrombocytopenia 
• Increased plasma bilirubin 
Tissue perfusion 
variables 
• Increased plasma lactate 
• Decreased capillary refill 
 
 
3. Pathophysiology of sepsis 
Entering the word “sepsis” in Medline® as a search term in a title or 
abstract reveals an amount of more than 35,000 scientific papers that 
have been generated during the past four decades (or 2,5 each day!). 
This illustrates the huge efforts to understand and control the 
mechanisms behind this syndrome. The massive focus of scientific 
input on one hand and the lack of valuable therapeutic targets on the 
other has established that sepsis is a highly complex, multifactorial, 
and multihit phenomenon. But most important, it is now recognized 
that the sepsis syndrome results from an inadequately regulated host 
response. Two evolutionary preserved systems that are present in 
humans and all other vertebrates are involved in this response: the 
immune and coagulatory systems. Under normal conditions they 
provide a highly adaptive mechanism that counters infection and 
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vascular injury. The activation of these systems is characterised by 
inflammation at the site of injury, recognition and clearance of 
invading pathogens, followed by repair of damaged tissue. 
Impairment of the host response to infection may lead to excessive 
destruction of healthy tissue, and cause an irreversible loss of organ 
function.9 Just like all biological phenomena, the systemic 
inflammatory response can be separated into three parts, namely its 
cause (or input), mediation, and outcome (or response). One of the 
key input factors in sepsis is endotoxin, or lipopolysaccharide (LPS), 
which represents a part of the cell wall of Gram-negative bacteria. It 
has repeatedly been demonstrated that administration of LPS to 
animals induces many of the cellular and humoral responses observed 
in human sepsis. The humoral response to LPS is mediated for a large 
part by cytokines, which belong to a diverse group of small signalling 
molecules produced by activated immune cells, such as monocytes 
and macrophages. A major target of LPS and cytokines are the 
endothelial cells, which represent the first line of defence and help 
localise the infection. Overactivation and damage of the endothelium 
by LPS and cytokines likely account for many of the deleterious 
events observed in sepsis. In this thesis, some important functions of 
endothelial cells in the regulation of the host response to sepsis are 
investigated. 
 
4. The role of endothelial cells in sepsis 
4.1.  General features of the endothelium 
In vertebrates, the vascular endothelium consists of a monolayer of 
highly attenuated cells connected by intercellular junctions. Human 
endothelium contains approximately 1 – 6 x 1013 cells covering a 
surface of several hundreds of square meters. This dynamic and 
branched organ acts as a highly restrictive barrier between the intra- 
and extravascular compartment, and possesses vital regulatory 
functions, such as control of vasomotor tone, coagulation, 
fibrinolysis, the trafficking of circulating immune cells, and the flow 
of nutrients and water.10
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Within the different parts of the vascular tree, endothelial cells 
display considerable heterogeneity in both structure and function, as 
determined by both genetic and environmental factors.11 The local 
endothelial functions are governed by various physical and chemical 
factors, including hemodynamic forces, temperature, pH, soluble 
mediators, cell-cell interactions, and oxygenation. 
Three major endothelial phenotypes have been identified: (i) 
continuous endothelium (as in skeletal muscle, skin, and brain 
capillaries); (ii) discontinuous endothelium (as in bone marrow and 
hepatic sinusoids); and (iii) fenestrated endothelium (as in pancreas 
and kidneys).12,13 Within the continuous phenotype, morphological 
differences exist with respect to cell contents (for example: the 
amount of plasmalemmal vesicles and Weibel Palade bodies, which 
store von Willebrand Factor) and the amount and type of junctional 
complexes present between neighbouring cells. For example, the 
continuous endothelium of the brain contains multiple tight junctions 
that seal the blood-brain barrier, while the endothelium of skeletal 
muscle and post capillary venules is much less tight. Other organs, 
such as the liver, spleen, and bone marrow sinusoids, contain 
discontinuous endothelium that allows the trafficking of cells 
between the interendothelial gaps. The fenestrated endothelial cells 
of the kidneys facilitate selective permeability required for efficient 
absorption, secretion, and filtering of waste products. 
Interposed between the circulating blood cells and tissues, 
endothelial cells also serve as a critical transistor of the immune 
response. They are the primary target encountered by invading 
micro-organisms and their products, circulating immune cells, and 
various soluble host mediators that are released during the 
inflammatory response. Upon activation by these factors, endothelial 
cells temporarily turn into a pro-inflammatory state, and undergo 
several morphologic and functional alterations. For example, during 
inflammation pre-capillary endothelial cells release vasorelactant 
mediators, such as nitric oxide (NO) and prostaglandins. 
Subsequently, arterioles are a widened, which results in an increase 
of local blood flow and supply of circulating blood cells. At the 
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postcapillary venules the release of vasoconstrictive molecules, such 
as endothelin-1 (ET-1) and platelet activating factor (PAF), cause a 
narrowing of efferent blood vessels. This leads to an increase of the 
hydrostatic pressure in the capillary bed, and thereby favours edema 
formation. Several other soluble mediators that are released during 
inflammation alter the integrity of the endothelial barrier, and 
induce leakage of plasma proteins and fluid into the tissue.14 Upon 
activation, the endothelium also temporarily expresses various cell 
adhesion molecules (CAMs), which mediate the rolling, attachment, 
and migration of activated leukocytes to the site of infection. 
Meanwhile, local platelets become activated, and chemokines, such 
as interleukin-8 (IL-8), are released by endothelial cells and cause the 
attraction of activated immune cells to the injured site. In addition to 
IL-8, activated endothelial cells produce several other cytokines, such 
as IL-1, tumor necrosis factor-α (TNF-α), MIP-1α, and RANTES, and a 
plethora of other mediators, like tissue plasminogen activator (t-PA), 
thrombomodulin (TM), and tissue factor (TF). These factors are 
involved in the attraction of activated leukocytes, vasoregulation, 
coagulation, and fibrinolysis, and demonstrate the multitude of tasks 
that the endothelium performs to regulate the host response.15 
During a controlled inflammatory reaction the endothelial alterations 
are reversed by a tightly regulated anti-inflammatory response, which 
return the endothelial cells to a quiescent state. Without the 
existence of such a counter mechanism, the endothelium would 
remain in an activated state, continuously favouring edema formation 
and attracting activated leukocytes. This seems to occur in patients 
with sepsis, where the balance between pro- and anti-inflammatory 
regulatory mechanisms is severely disturbed. 
Prolonged and widespread activation of the endothelium may result 
in loss of its barrier function and lead to the accumulation of 
activated leukocytes at sites that are not primarily involved in 
inflammation. The subsequent release of granular components, such 
as myeloperoxidases, from migrating neutrophils and macrophages 
may lead to the destruction of healthy tissue. The consequences of 
systemic activation of the endothelium during sepsis, and particularly 
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its barrier function and adhesion molecule expression, are discussed 
in more detail in the following sections. 
 
4.2.  Endothelial barrier function 
The endothelium is a highly selective barrier that regulates the 
transport of water, solutes, cells and other compounds between the 
intra- and extravascular spaces.14,16 The exchange of fluid, nutrients, 
and oxygen between blood and tissues is particularly developed in 
capillaries and post-capillary venules, where the metabolic activity of 
the surrounding tissues requires an extensive and rapid transit of 
these substances. The wall of these so called “exchange vessels” is 
virtually limited to the endothelial cell and its basement membrane.12 
According to Fick’s law, diffusion of a molecule is proportional to the 
surface area available for diffusion, and inversely proportional to the 
thickness of the barrier. The capillary endothelium meets both 
requirements for rapid diffusion. Diffusion of a solute across the 
endothelium also depends on the interactions of the transported 
molecule with the endothelial cell layer. These interactions may be 
governed by various factors, such as the presence of specific surface 
binding proteins (or: receptors) on the endothelial membrane, the 
permeability characteristics of the endothelial phenotype (e.g. the 
size and amount of the pores present), the electrostatic charge of the 
endothelial membrane surface, and the structure and composition of 
subendothelial matrix proteins. Furthermore, the diffusion properties 
of a solute depend on the size, shape, charge, and binding 
characteristics of the transported molecule.13,17,18
Solutes may cross the endothelium either by active uptake and 
transfer, or by passive diffusion. Active transport of molecules 
involves receptor-mediated uptake of a molecule into shuttling 
transport vesicles, and transfer of these vesicles from the luminal 
(vessel) site to the abluminal (tissue) site of the endothelium. Passive 
diffusion may occur either transcellularly, which is mediated by cell 
diaphragms and fused vesicles; or paracellularly, which is mediated 
by intercellular junctions and gaps. Under normal conditions, 
paracellular transport of large molecules, such as albumin, is highly 
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restricted by junctional complexes that are present between 
neighbouring cells. The passage of such molecules occurs mainly 
through the transcellular route, and in the case of albumin, is 
mediated by receptor-mediated uptake and transport.19 However, 
inflammatory conditions may disrupt junctional integrity of the 
endothelium and open the gate to diffusion of albumin through the 
paracellular gaps.19,20 Within an hour, this may cause a 10-fold 
increase of the flux of liquid and solutes from the circulation into the 
tissues. 
The restrictiveness of interendothelial junctions is regulated by 
several regulatory proteins that are linked via a complex of anchoring 
proteins to actin filaments present in the cytoskeleton.21 Disruption 
of these filaments and altered expression and/or distribution of the 
junctional proteins result in cell shape changes, and lead to increased 
paracellular diffusion.22,23 One of such a mechanism involves the 
activation of myosin light chain kinase (MLCK), which causes actin-
myosin-based cell contraction, and result in a reversible disruption of 
intercellular junctions. Several vasoactive agents, such as thrombin, 
may induce the activation of MLCK.24 Another mechanism involves the 
protein kinase-dependent phosphorylation of linking proteins, such as 
vinculin, α-actinin, or VE-cadherin, that bridge the actin-filaments to 
the junctional complexes. Phosphokinases, such as protein kinase C 
(PKC) and tyrosine kinase, also indirectly facilitate the activation of 
MLCK, and may thus provide an important mechanism for actin-
reorganization, cell rounding, and increased paracellular transport of 
the endothelium.14,25-30 Kinase activity may be induced by several 
vaso-active agents, such as histamine31 and thrombin,32,33 and other 
inflammatory mediators, like hydrogen peroxide34, TNF-α and IL-1β.28
 
4.3.  The role of extracellular matrix 
As mentioned earlier, the flux of solutes across the endothelium is 
not only influenced by the transport properties and metabolic state 
of the endothelial cells, but also by the structure and composition of 
its basement membrane and the underlying extracelullar matrix 
(ECM). The ECM comprises an organized network of extracellular 
 17
 CHAPTER 1 
matrix proteins, including collagen, fibronectin, and vitronectin. The 
presence of an intact ECM has been shown to reduce the permeability 
to albumin by more than 10-fold, and thus imposes a considerable 
restriction to solute transport. Net alterations in the ECM, which may 
result from proteolytic activity of matrix metalloproteases (MMPs) on 
one hand, and from synthesis and the incorporation of ECM-proteins 
on the other hand, may contribute to a change of vascular 
permeability. The proteolytic activity of MMPs can be induced by 
inflammatory mediators, such as TNF-α.35 The ECM is further involved 
in the maintenance of endothelial integrity, since it contains specific 
binding sites that anchor the endothelial cells. For this purpose, 
endothelial cells express several integrins on their membrane that 
bind to collagen and fibronectin molecules in the ECM. The important 
role of integrin-matrix interactions in the maintenance of endothelial 
integrity has been demonstrated in studies where the addition of 
competitive soluble peptides that contain the fibronectin binding site 
to endothelial cultures caused cell rounding and detachment.36,37 In 
addition to integrins, several other proteins are involved in the 
anchoring of endothelial cells to the ECM. For example, the 
transmembrane molecule CD44 links the endothelial cells to 
hyaloronic acid present in the basement membrane.38 Increased 
endothelial permeability may thus be regulated on multiple levels, 
and involves alteration of the structure and function of endothelial 
cells and the underlying ECM. 
 
4.4.  The role of adhesion molecules 
The recruitment of leukocytes from the circulation into the 
extravascular space is critical for inflammatory responses and repair 
of tissue injury. The initial interaction between leukocytes and the 
endothelium appears to be transient, resulting in the rolling of 
leukocytes along the vessel wall. The rolling leukocytes then become 
activated by local factors generated by the endothelium, resulting in 
their arrest and firm adhesion to the vessel wall. Finally, the 
leukocyte transmigrates across the endothelium into the surrounding 
tissue. These complex processes are regulated in part by specific 
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endothelial-leukocyte cell adhesion molecules.39,40 The dynamic 
changes in the expression of these surface proteins provide the 
endothelium with a mechanism of regulating cell-cell interactions. 
Many different CAMs are expressed on the surface of endothelial cells 
in a tightly regulated manner, and each one has a unique role in the 
attraction of different leukocyte subsets. The expression of each CAM 
is stimulus-, cell-, time-, and organ specific. Furthermore, several 
CAMs signal inside the endothelial cell upon receptor engagement, 
and provide another regulatory pathway involved in the immune 
response. The initial rolling interactions of leukocytes are mediated 
by selectin-molecules (e.g. E-Selectin) expressed on the membrane of 
endothelial cells, whereas firm adhesion and diapedesis seem to 
depend on the expression of CAMs that belong to the immunoglobulin 
superfamily. The involvement of different types of endothelial CAMS 
in inflammation and sepsis is described in more detail in the following 
paragraphs.   
 
4.4.1. E-Selectin 
Endothelial (E-)selectin (CD62e), one of three known members of the 
selectin family, is a 115-kD transmembrane protein that binds to 
sialyl Lewis X-like (CD15s) molecules present on the surface of 
neutrophils, monocytes, and natural killer cells.41 The human E-
Selectin gene is located on chromosome 1. Expression of E-Selectin is 
normally not detected in resting endothelium, but inflammatory 
cytokines and LPS can strongly and rapidly induce it. E-Selectin 
appears on the endothelial cell surface within one to two hours after 
stimulation, is expressed maximally at 4 – 6 h, and then rapidly 
disappears, even in the continuous presence of the stimulus. The NH2-
terminal site of this molecule contains a calcium-dependent lectin-
like domain, which in addition to an EGF-like domain, is critical for 
ligand binding. The cytoplasmic domain of E-Selectin contains 
tyrosine residues that have been suggested to mediate rapid 
internalization of transmembrane proteins, which may account for 
the short half-life of this molecule at the cell surface. The induction 
of E-Selectin expression requires the binding of nuclear transcription 
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factors, such as nuclear factor kappa-B (NF-κB), to several positive 
regulatory domains in the E-Selectin promoter.42,43 Its expression may 
be further regulated by cell-type specific hypomethylation of the 
cytokine response region present at the E-Selectin promoter site. 
 
4.4.2. ICAM-1 and VCAM-1 
Many activated endothelial cells express intercellular adhesion 
molecule (ICAM)-1 (CD54) and vascular cell adhesion molecule 
(VCAM)-1 (CD106), which both belong to the immunoglobulin 
superfamily. The human ICAM-1-gene is located on chromosome 19 
and codes for a core protein with 5 extracellular Ig-like domains. It is 
constitutively expressed at low levels by endothelial cells, and by 
various other cell types including leukocytes, fibroblasts, epithelial, 
and mesothelial cells.44,45 The expression of ICAM-1 is induced by LPS, 
cytokines, and various other inflammatory mediators. Like E-Selectin 
and many other inflammatory genes, the expression of ICAM-1 often 
involves the activation of NF-κB, amongst a limited number of other 
transcription factors.46,47 Furthermore, synergistic induction of ICAM-1 
may occur as a result of multiple response elements in the ICAM-1 
gene. 
The ligands for ICAM-1 are several β2 integrins, including CD11a/CD18 
(LFA-1), and CD11b/CD18 (Mac-1), which are present on the 
membrane of various leukocytes. The binding of these counter 
receptors to ICAM-1 depends on the glycosylation state of specific 
binding sites present in the NH2-terminal domains of ICAM-1. The 
cytoplasmic domain of ICAM-1 binds to α-actinin, a cytoskeletal 
protein that anchors actin filaments to the cell membrane. The 
linkage of ICAM-1 with the cytoskeleton provides a mechanism that 
localizes ICAM-1 within regions of the endothelial cell membrane 
involved in leukocyte adherence and transmigration. 
Another important member of the immunoglobulin superfamily that is 
involved in leukocyte trafficking is VCAM-1. Expressed on most 
endothelial cells, VCAM-1 is a 110 kD transmembrane molecule that 
binds to integrins, such as α4β1 and α4β7, present on circulating 
monocytes and lymphocytes. In vitro, VCAM-1 is upregulated on 
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endothelial cells after exposure to various cytokines, including IL-1β 
and TNF-α, and LPS. The induction of VCAM-1 by cytokines is also NF-
κB mediated. 
Upon stimulation, the expression of VCAM-1 and ICAM-1 peaks by 6 h 
and 12 h, respectively, and both proteins persist for at least three 
days after induction. The relatively delayed and sustained ICAM-1 and 
VCAM-1 response to cytokines corresponds with the preferential 
adhesion and infiltration of mononuclear leukocytes typical for 
chronic inflammatory conditions. The specificity required to regulate 
the distinct patterns of gene expression of the different CAMs may be 
determined by the formation and assembly of NF-κB and several other 
transcription factors to unique higher order nucleoprotein 
complexes.48 Furthermore, it has been demonstrated that 
combinations of cytokines and other inflammatory mediators, such as 
thrombin and oxygen radicals, can differentially modulate the 
induction of E-Selectin, ICAM-1, and VCAM-1, and that the expression 
of these adhesion molecules varies between the different locations of 
the endothelium. 
 
5. The endothelium and mediators of sepsis 
While vascular leakage is a key phenomenon during inflammation, it 
can become life-threatening, particularly when it massively occurs in 
the lungs or pericardium, or when it causes hypovolemic shock. The 
disturbed fluid balance during sepsis has been studied in several 
animal and cell culture models. From the early stages of sepsis, 
endothelial functions are believed to be imbalanced resulting in a 
severe and persistent loss of vascular integrity. Loss of endothelial 
barrier function induces clinically recognizable alterations, such as 
systemic edema, organ dysfunction, and shock. In experimental sepsis 
in animals, as well as in septic patients, loss of endothelial integrity 
has been demonstrated by massive morphological and ultrastructural 
changes of the endothelial cells, including vacuolization, cell-
blebbing, loss of cell-cell contacts, and detachment from the basal 
membrane.49-58 Overactivation of the endothelium is also reflected by 
a massive expression of endothelial CAMs, and results in a raise of the 
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plasma levels of the soluble forms of these CAMs. The presence of 
soluble E-Selectin, ICAM-1, VCAM-1, and von Willebrand Factor 
(vWF)59,60 in the circulation has been proposed as predictors of 
survival in septic patients.59 It has also been reported that patients 
with sepsis and septic shock display increased numbers of circulating 
and/or apoptotic endothelial cells,61,62 which indicates a loss of cells 
from the endothelial layer. 
Several other plasma markers may indicate endothelial activation and 
damage during sepsis,59,63-70 such as IL-6,71-75 and factors involved in 
coagulation (thrombomodulin76, thrombin receptor77, anti-thrombin III 
(ATIII)78 and protein C 79-82), and in fibronolysis (plasminogen activator 
inhibitor (PAI-1), tissue type plasminogen activator (tPA), and tissue 
factor (TF)).63
The activation of the endothelium during sepsis may result from its 
direct interaction with pathogens.83 In addition, endothelial cells may 
be directly activated by soluble microbial products,84 such as LPS and 
other toxins.85 However, endothelial activation during sepsis most 
likely results from the exposure to circulating cytokines and other 
inflammatory host mediators. Many of the effects of these mediators 
on endothelial functioning are mediated by the activation of NF-κB 
and other nuclear transcription factors. The potential value of the 
endothelium as a target for sepsis therapy lies in prevention of 
endothelial activation and damage, be it either by inhibition of these 
inflammatory mediators or by inhibition of undesirable endothelial 
cell functions.86
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5.1.  The role of lipopolysaccharide 
The first insight in the molecular pathogenesis of sepsis stems from 
the end of the 19th century, when it was discovered that LPS causes 
many of the characteristic features of the sepsis syndrome.87-90 This 
molecule is released by both living and killed Gram-negative bacteria, 
and may therefore even mediate an undesirable side effect of 
antibiotic treatment.91-94 Considerable concentrations of LPS have 
been detected in plasma of patients with sepsis95 and their levels may 
correlate with disease severity and outcome.73,96-98 The elucidation of 
the chemical structure of LPS in the mid-sixties presented a 
molecular basis for the immunological host response to sepsis. LPS is 
composed of three parts (Figure 1): (i) a hydrophobic fatty acid 
known as lipid-A which makes up the outer layer of the outer 
membrane of most Gram-negative bacteria; (ii) a non-repeating core 
oligosaccharide; and (iii) a distal polysaccharide side chains (O-
antigen).99 The immunogenic activity of LPS is to a large extent 
determined by the Lipid A fraction, and this part varies between 
different Gram-negative bacteria. The interactions of lipid A with 
animal cells have been largely elucidated in the past two decades. 
A special lipid transfer protein present in plasma, lipopolysaccharide 
binding protein (LBP) shuttles lipid A to a receptor complex involving 
CD14 which is present on the surfaces of neutrophils and cells of the 
monocyte/macrophage lineage.100 Alternatively, LBP-LPS may form a 
complex with soluble CD14-receptors present in serum, and transfer 
LPS to CD14-negative cells, such as the endothelium.101-111 The 
intracellular signal that is triggered by the LPS-CD14 complex is 
mediated by a receptor of the innate immune system present on 
macrophages and endothelial cells.112,113 This membrane spanning 
protein has been designated as TLR4 and belongs to the family of 
Toll-like receptors (TLRs), which are distantly related to the IL-1 
receptor.114 Activation of TLRs is now considered to be critically 
involved in sepsis.112,115,116 In isolated monocytes and macrophages, 
LPS-induced activation of TLR4 results in the generation of an array 
of pro-and anti-inflammatory cytokines and several molecules 
involved in the adaptive immune response (Figure 2). In endothelial 
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cells, LPS stimulates the expression of several factors involved in 
coagulation and inflammation,84 including tissue factor (TF),117, 
cytokines,118-120 and cell adhesion molecules.70,121,122
 
 
FIGURE 1. Schematic representation of lipopolysaccharide 
FIGURE 2. Extra- and intracellular pathways involved in LPS-induced signalling 
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5.2.  The role of cytokines 
The orchestration of the immune response depends upon 
communication between cells by a group of small signalling molecules 
given the generic term cytokines, and includes chemokines, 
interleukins, growth factors, and interferons (IFN). Cytokines are 
newly synthesized in response to inflammatory stimuli, are produced 
in a cascadeous manner, and regulate both the amplitude and 
duration of the immune response. They are produced by a large 
variety of cells that are involved in the maintenance of homeostasis, 
host defence, wound healing, and other essential host functions. Most 
cytokines do not exert a single function, and the distinct actions of a 
specific cytokine depend on the type of the stimulus, the cell type, 
the ability to activate multiple signal transduction pathways, and the 
presence of other mediators and receptors. The most important 
cytokines involved in sepsis are considered to be TNF-α and IL-1β, 
which were both discovered in the late 70’s. The list of inflammatory 
cytokines has been constantly growing since then, and now comprises 
more than 30 different proteins. The clinical manisfestations of sepsis 
are probably determined by the disturbed balance of the interactions 
between pro- and anti-inflammatory cytokines.123 The systemic 
release of these mediators has been associated with widespread 
tissue injury and organ dysfunction. Elevated plasma levels of various 
cytokines, including TNF-α and IL-1β,73,124-126 are frequently detected 
in patients with sepsis, and some (i.e. IL-6) of these correlate with 
disease severity and patient outcome, and are currently used as 
biomarkers for sepsis.127-129 There is a strong association between LPS 
and the production and secretion of TNF-α and IL-1β,130 and various 
other cytokines, in different models of sepsis, and most of the 
physiological disturbances that are characteristic for sepsis appear to 
be mediated by TNF-α and IL-1β. In addition to LPS, TNF-α and IL-1β 
stimulate the production of other cytokines, including IL-6, IL-8 and 
IL-10. Some of the latter cytokines further mediate the inflammatory 
response. For example, the release of IL-8 initiates the attraction and 
recruitment of polymorphonuclear leukocytes, and mediates tissue 
inflammation. On the other hand, others, such as IL-6 and IL-10, 
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appear to be involved in the down-regulation of the inflammatory 
response. 
The regulation of cytokine production occurs predominantly at the 
level of gene transcription with de novo expression of cytokine 
messenger RNA. Cytokine gene transcription in turn is regulated by 
various stimulatory and inhibitory transcription regulating proteins 
that bind to specific regulatory binding sites of the promoter regions 
of the cytokine genes. Under normal conditions, the inflammatory 
response is down-regulated by the activity of anti-inflammatory 
cytokines and soluble cytokine receptors, such as the soluble TNF-
receptor (TNFR) p55 and p75, and receptor antagonists, like the IL-1 
receptor antagonist (IL-1ra). While soluble cytokine receptors and 
receptor antagonists may exert their effect by keeping away 
circulating cytokines from the receptors present on the cell 
membrane, anti-inflammatory cytokines may block the production of 
pro-inflammatory mediators by down regulation of gene expression. 
Several innovative therapies that have been attempted in the field of 
sepsis were primarily aimed at interupting the cycle of cytokine 
activation.131-135
 
5.2.1. Tumor Necrosis Factor 
Without doubt, TNF is one of the most widely studied molecules in 
inflammatory diseases. TNF-α is a 17-kDa protein that has been 
originally recognized for its necrotic actions on tumours in LPS-
treated mice.136 In many animal species, infectious, inflammatory, or 
malignant conditions lead to the induction of TNF-α, and therefore 
this cytokine has been implicated in a large number of infectious and 
non-infectious diseases.137-139 Infusion of animals with purified TNF-α 
mimics many of the characteristic features of sepsis, including 
cardiovascular dysfunction, activation of leukocytes, activation of 
coagulation and fibronolysis, lactic acidosis, and induction of the 
cytokine cascade.121,139 Early stages of sepsis are frequently 
characterised by significantly elevated plasma levels of TNF-α, 
although its concentration does not seem to correlate with disease 
severity or outcome.130,133,140 Various activated cell types, including 
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monocytes, macrophages, and endothelial cells, may serve as a 
source of TNF-α. In human and animal models of sepsis, LPS triggers 
the production of TNF-α, with serum peak levels typically appearing 
approximately 1 – 3 hours after administration.130 In addition, TNF-α 
is also induced in vitro in LPS-stimulated macrophages and 
mononuclear cells.141 In fact, LPS may serve as the most potent 
inducer of this cytokine. On the cellular level, TNF-α modulates a 
plethora of responses that are mediated by various different target 
cells, including leukocytes and endothelial cells. Depending on the 
target cell type, TNF-α may activate the transcription of several 
genes involved in immunoregulatory responses, induce cell 
proliferation, growth inhibition, cytotoxicity, apoptosis, cytokine 
production, MHC class I and II cell surface expression, cell adhesion 
molecule expression, tissue repair and damage, and skin necrosis. 
The response to TNF-α is mediated by the p55 and p75 TNF-receptors 
(TNFR1 and TNFR2). The outcome of the response to TNF-α depends 
on the distribution of these receptors and is at least in part 
determined at the level of intracellular signalling, which involves a 
cascade of multiple kinase signalling proteins. The most prominent 
signalling pathways triggered by stimulation of members of the TNF-
receptor family are those leading either to cell death (apoptosis), or 
to the induction inflammatory genes.137 Whereas TNF-α-induced 
apoptosis is mediated by caspases, the expression of inflammatory 
genes is the result of activation of the transcription factors NF-κB and 
AP-1. The activation of these nuclear proteins is mediated by a group 
of scaffolding proteins collectively called the TNF-receptor associated 
family (TRAF).142 Notably, some of the genes that are 
transcriptionally activated by TNF-α in turn suppress TNF-α-induced 
apoptosis, and may thus provide a survival signal in these cells. 
Despite the observation that increased apoptosis may be present in 
septic patients, it is not known if these pathways are decisive in 
pathogenesis.143,144 Unfortunately, anti-TNF strategies have shown to 
be only marginally effective in patients with sepsis.145-147 Although 
individual studies may show small, non-significant benefits, analysis 
of all trial data as well as data from a recent trial in a large 
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population of patients with sepsis show that anti-TNF strategies may 
confer a small survival benefit.  
 
5.2.2. Interleukin-1 
Another major cytokine that is associated with inflammatory diseases 
is IL-1. The IL-1 gene family comprises three members, the 17 kDa 
proteins IL-1α and IL-1β, and the IL-1 receptor antagonist (IL-1ra). 
Both IL-1α and IL-1β are potent inflammatory cytokines,148 mainly 
produced by monocytes and polymorphonuclear cells, and activate a 
single type of receptor present on a wide variety of cells. IL-1 is 
induced by both non-microbial stimuli and by LPS and serum peak 
levels typically appear approximately four hours after stimulation. IL-
1 shares various biological activities with TNF-α,149 and infusion with 
this cytokine mimics many characteristic features of sepsis, including 
fever, hemodynamic abnormalities, anorexia, malaise, headache and 
neutrophilia. IL-1 affects the expression of over ninety genes, many 
of which code for other cytokines such as IL-6, IL-8 and TNF-α. In 
addition IL-1 induces the expression of several cytokine receptors, 
acute-phase reactants, growth factors, tissue remodelling enzymes, 
extracellular matrix components, or cell adhesion molecules. On the 
cellular level, the IL-1 signal is mediated only through the type 1 IL-1 
receptor (IL-1RI), whereas the type 2 (or: decoy) IL-1 receptor does 
not transduce a signal and may function as a sink for IL-1. Activation 
of IL-1 receptor molecules in animal, man, insects and plants, leads 
to activation of NF-κB-like transcription factors, and represent a 
common and ancient signal of the response to stress and infection. In 
the case of IL-1RI, receptor activation results in the intracellular 
recruitment of IL-1 receptor associated kinase (IRAK) and TRAF6, 
which lead to the activation of transcription factors quite similar to 
that induced by TNF-α.113 The cytplasmic domains of the IL-1RI 
receptor shares a highly significant homology with the Drosophila 
melanogaster Toll protein, and this finding has lead to the discovery 
of the superfamily of TLRs.113,150 About one third of patients with 
sepsis have elevated levels of IL-1β, and the mean levels are higher in 
septic patients when compared to that in critically ill patients 
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without sepsis. However, this cytokine does not predict severity or 
mortality.133,151 Further evidence for the primary role of IL-1β and 
TNF-α in experimental sepsis has been provided by studies where 
combination therapy with IL-1ra and soluble TNF-α receptors was able 
to reduce mortality.152
 
5.3.  The role of Nuclear Factor – κB 
Among the transcriptional regulatory proteins that may be involved in 
sepsis, nuclear factor-κB (NF-κB) seems particularly important. This 
transcription factor has a key function in the regulation of the 
expression of various genes of the innate and adaptive immune 
response. The activation of NF-κB leads to the transcription of several 
cytokine genes, and those of various other inflammatory mediators, 
including cell adhesion molecules such as E-Selectin and ICAM-1, and 
may be induced by many different pathways, including LPS, TNF-α, 
and T-cell receptor signalling, but also by stress signals, pathogens, 
etc. Under unstimulated conditions, NF-κB proteins are present in the 
cytoplasm in association with inhibitory proteins that are known as 
inhibitors of NF-κB (IκBs). Upon activation, which may be mediated 
by a large number of inducers, these IκB proteins are degraded and 
allow NF-κB to translocate to the cell nucleus, where they bind to 
specific cognate DNA sequences and regulate the transcription of a 
large number of genes.153,154 The specifity of NF-κB to induce (a) 
certain (set of) genes may at least in part be determined by the 
distinct affinities of different DNA-binding sites, and the formation of 
unique transcriptional complexes between NF-κB and other 
molecules. It has been reported that critically ill patients who die 
demonstrate an increased activation of NF-κB in mononuclear cells 
and neutrophils.155 Since NF-κB may have a pivotal role in the 
regulation of the cytokine cascade, interventions aimed to inhibit the 
activation of NF-κB may down-regulate systemic inflammation to a 
much greater extent than blocking the production or action of a 
single cytokine.156
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6. Experimental models for sepsis 
Many of the clinical features of sepsis have been mimicked using 
various human and animal models,157 and numerous in vitro cell 
culture studies. In many in vivo studies, “sepsis” was induced by the 
infusion of viable or heat-killed micro-organisms,158 by cecal ligation 
and puncture,159 or by the administration of microbial products, such 
as endotoxin, or zymosan.160 Infusion of high doses of LPS in 
humans,90 and lower primates158 and in mammals is often lethal and 
induces many of the characteristic features observed in sepsis, 
including hemodynamic instability, shock, and disseminated 
intravascular coagulation.90 
LPS has also commonly been used to trigger the septic response in 
cell culture models. For example, stimulation of human161 and 
animal162,163 blood ex vivo with LPS has repeatedly been used as a 
model to investigate the release of different inflammatory mediators 
involved in sepsis.164,165 Freshly drawn anticoagulated blood, which 
can be obtained by simple venapuncture, contains a wide spectrum of 
viable circulating inflammatory cells. The addition of LPS or other 
pyrogens to whole blood results in a dose- and time-dependent 
production of various different cytokines and other inflammatory 
mediators.166-169 Recently, the capacity to generate cytokines in blood 
has also been associated with the risk of developing sepsis, and has 
lead to the identification of  “low” and “high” responders.170 In 
animal models and in patients with sepsis171, it was demonstrated 
that the ex vivo stimulation of blood with LPS resulted in a blunted 
cytokine response when compared to that obtained in healthy 
blood.172-174 This indicates that the pro-inflammatory response during 
sepsis is probably exhausted, or that the anti-inflammatory signal 
predominates in these patients, a phenomenon known as LPS-
tolerance.173,175
Thus, plasma obtained from whole blood after stimulation with LPS 
may yield a relevant pool of inflammatory mediators. It constitutes a 
valuable tool to study the mechanisms involved in the response of 
various targets, such as endothelial cells to “septic” stimuli. 
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6.1.  Human endothelial cell cultures as a tool to study septic 
responses 
The isolation and culture of human and animal endothelial cells has 
been widely used in studies aiming to elucidate the pathways that 
lead to malfunction and disease.176 Primary cultures of human 
umbilical vein endothelial cells (HUVEC) were successfully established 
early in the seventies177 and these cells display many of the 
characteristics that are also present in vivo. In the presence of an 
appropriate substrate (ECM proteins) and growth factors (either 
provided by serum and brain extracts, or by purified proteins) 
cultured HUVEC attach and grow into a single squamous layer of cells 
(or monolayer) that are connected to one another by tight junctional 
complexes. The phenotype of cultured endothelial cells depends on 
the species, and the organ that they were obtained from, and on the 
culture conditions.178,179 Many of the characteristic features of the 
endothelial phenotype may be preserved in primary endothelial cell 
cultures, although subculturing for longer periods generally tends to 
lead to a loss of these specific features. In spite of this limitation, in 
vitro endothelial cell studies have tremendously added to our current 
knowledge of the role of the endothelium in health and disease. 
Stimulation of cultured endothelial cells almost uniquely tends to 
activate a functional program leading to a pro-inflammatory, pro-
coagulatory, and hyperpermeable phenotype. The induction and 
expression of endothelial adhesion molecules by LPS and cytokines 
has been investigated extensively in cell culture studies. Almost all 
cultured stimulated endothelial cells express E-Selectin, ICAM-1 and 
VCAM-1 in vitro. Considerable variations may however exist between 
the maximum inducible levels of these molecules by endothelial cells 
from different origin. In addition, the maximum expression levels may 
decline during subculturing or immortalization of primary endothelial 
cell cultures. 
In the late eighties it has already been demonstrated that cultured 
endothelial monolayers may serve as a useful model for studying 
permeability characteristics of the endothelial barrier to 
macromolecules,18 despite the differences that exist with 
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permeability characteristics of blood vessels in vivo.17 Confluent 
endothelial monolayers are sealed by tight junctions, display a 
significant transendothelial electrical resistance, and largely restrict 
the passage of macromolecules, such as dextrans and 
albumin.17,18,180,181 The size-selective property of cultured endothelial 
monolayers has been studied with different tracer molecules, and 
demonstrated that molecules with a diameter less than two 
nanometer diffused quite unrestricted, whereas diffusion of 
molecules larger than 10 nm was completely restricted. Albumin, a 69 
kDa protein (Stoke-Einstein radius = 36 Å) is an important 
macromolecule that determines the balance of oncotic forces across 
the endothelium. Its transport is mediated by active uptake, but 
under pathologic conditions albumin may diffuse through the 
intercellular spaces. It has been demonstrated that endothelial 
monolayers are reorganized by inflammatory stimuli such as LPS,182 
TNF-α,183 and thrombin,32 and that these mediators increase the 
permeability to large molecules, such as albumin.184 However, 
endothelial cells from different species and organs have been used to 
study permeability characteristics, and various semi-permeable tissue 
culture membranes have been used as a model for this purpose. As a 
consequence, a true comparison of endothelial permeability under 
inflammatory conditions is not always possible. 
  
 32
INTRODUCTION AND OUTLINE OF THE THESIS  
 
OUTLINE OF THE THESIS 
 
The exact pathways that lead to endothelial permeability during 
sepsis are not fully understood. Elucidation of these pathways may 
help identify possible targets for effective prevention or treatment of 
sepsis-induced hypotension and shock. Despite the promising results 
that have been obtained from animal studies, these models have thus 
far failed to help improve survival in human sepsis. Cultured human 
endothelial cells may provide another relevant model to gain insight 
into sepsis-induced vascular dysfunction, and could therefore 
contribute to the identification of new targets for therapy. 
The purpose of the studies presented in this thesis was to examine 
mediators and mechanisms involved in sepsis-induced endothelial 
permeability in vitro. Therefore, the following questions have been 
addressed: 
• What is the effect of different, but commonly used, matrix 
proteins on the macromolecular permeability of stimulated and 
unstimulated endothelial cultures (Chapter 2)? 
• Is there a difference in the permeability response of endothelial 
monolayers to direct stimulation with bacterial LPS, and to 
plasma obtained from LPS-treated whole blood? What is the 
contribution of pro-inflammatory cytokines in the whole-blood 
mediated permeability response (Chapter 3)? 
• Does intervention with the same inhibitory agents prevent the 
plasma-induced expression of E-Selectin and ICAM-1 by 
endothelial cells (Chapter 4)? 
• Do Gram-positive and Gram-negative micro-organisms differ in 
their capacity to generate a plasma-mediated endothelial 
permeability and adhesion molecule response? Does this 
response depend on the presence of intact micro-organisms in 
blood? Does antibiotic killing of Gram-negative bacteria by 
different antimicrobial agents result in divergent permeability 
and adhesion molecule responses (Chapter 5)? 
• What is the time course of the of the plasma-induced 
permeability increase, and does this course allow post-
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stimulatory intervention? If so, does intervention with inhibitory 
agents that act against TNF and IL-1, or their downstream 
signalling pathways, prevent the plasma-induced permeability 
response (Chapter 6)? 
• Does plasma obtained from experimental human endotoxemia 
induce endothelial permeability, and if so, does this response 
correlate with plasma levels of TNF-α, IL-1β, or other 
inflammatory mediators (Chapter 7)? 
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ABSTRACT 
 
Objective: To investigate whether endothelial monolayer 
permeability changes induced by inflammatory mediators are 
affected by the extracellular matrix protein used for cell seeding. 
Methods: Human umbilical venular endothelial cells (HUVEC) were 
grown to confluent monolayers on membranes coated with either 
collagen, fibronectin or gelatin. The permeability  to albumin and 
dextran was then assessed, both under normal conditions and after 
treatment with tumor necrosis factor-alpha (TNF-α) and bacterial 
lipopolysaccharide (LPS). 
Results: With any of the three protein coatings, tight junctions were 
formed all over the monolayers. The permeability of the coated 
membranes to albumin and dextran was reduced strongly by 
confluent monolayers; the relative reduction was similar for the three 
matrix proteins used. Pre-incubation of the monolayers with either 
TNF-α or LPS increased permeability dose-dependently. However, the 
relative increase due to either treatment was independent of the 
protein used for membrane coating. 
Conclusion: The extracellular matrix protein used for initial seeding 
of endothelial cultures plays a minor role in determining the 
permeability changes induced in HUVEC monolayers by inflammatory 
mediators. 
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INTRODUCTION 
 
The vascular endothelium acts as a dynamic barrier that selectively 
restricts the passage of plasma and cells from the blood into the 
adjacent tissues. Local and reversible alterations of barrier function 
typically occur as part of the immune response during which 
inflammatory mediators cause a transient increase of vascular 
permeability resulting in the formation of tissue oedema. However, 
during the systemic inflammatory response syndrome (SIRS),1 
overproduction of inflammatory mediators may irreversibly damage 
vascular integrity and cause excessive loss of fluid from the 
circulation. This hazardous event may lead to prolonged tissue 
hypoperfusion, organ dysfunction, and death.2 Therefore, prevention 
of vascular damage could contribute to improved survival of patients 
suffering from SIRS.3,4 Many have studied the role of the endothelium 
in vascular permeability using in vitro models of endothelial 
monolayers cultured on semipermeable supports.5-7 Multiple 
mechanisms may be involved in increased endothelial permeability, 
such as cell contraction and retraction,8 enhanced transcellular 
vesicle transport,9 disruption of intercellular junctions,10 and 
apoptosis.11
Recently, it has been suggested that endothelial permeability may 
also depend on the composition and structure of the underlying 
extracellular matrix (ECM).12 For example, it has been shown that 
fibronectin significantly contributes to endothelial monolayer 
permeability by providing attachment sites for ECM proteins and 
endothelial cells.13 When monolayers cultured on fibronectin were 
treated with tumor necrosis factor-α (TNF-α), a permeability increase 
was observed which was accompanied by a loss of fibronectin from 
the ECM.14 TNF-α also affects the expression of other matrix 
receptors on endothelial cells, confirming a role for endothelial-ECM 
contacts in vascular permeability.15 Furthermore, stimulation of 
endothelial cells with TNF-α induced the expression of a 96-kDa 
matrix metalloproteinase,16 suggesting that matrix degradation may 
be involved in increased permeability.17
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For the purpose of studying endothelial permeability in vitro, these 
findings seem to imply that endothelial cells should be cultured on (a 
mixture of) ECM proteins, preferably containing fibronectin, but other 
ECM coatings like gelatin and different types of collagen are used 
frequently.18 It remains unclear if different coatings eventually result 
in different monolayer permeability changes under the influence of 
inflammatory mediators. A comparison of in vitro studies on 
endothelial permeability is hampered by the many differences in the 
origin and species of the endothelial cells and, particularly, by the 
differences in the design of the monolayer system, including the 
matrix used for cell seeding. 
Therefore, we have compared the permeability characteristics of 
human umbilical venular endothelial cells (HUVEC) seeded on 
membranes coated with either collagen, fibronectin, or gelatin. For 
this purpose, we have selected a suitable in vitro model that supports 
the attachment and growth of HUVEC, and allows restricted diffusion 
of macromolecules, visual examination by both bright field 
microscopy and ultramicroscopy, and easy and simultaneous 
permeability determinations. The inflammatory mediators TNF-α and 
bacterial lipopolysaccharide (LPS), which are involved in the onset of 
SIRS, have been shown to enhance endothelial permeability both in 
vivo and in vitro.19-22 We measured the permeability for both albumin 
and dextran in untreated HUVEC monolayers and in cultures after 
treatment with either TNF-α or LPS. 
 
 
MATERIALS AND METHODS 
 
Materials 
Culture medium M199, supplemented with 25 mmol/l HEPES, Earl’s 
salts, and L-Glutamine, as well as heat inactivated newborn calf 
serum (NCS), penicillin-streptomycin, and trypsin/EDTA were 
obtained from Life Technologies (Paisley, Scotland). Normal human 
serum was supplied by a local transfusion service. A pool of serum of 
at least five donors was first heat inactivated (30 min at 56°C), and 
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stored at –20°C before use. Transwell-well culture inserts, tissue 
culture plates and flasks were all from Costar (Cambridge, MA). 
Fluorescein-labelled bovine serum albumin (FITC-BSA), rhodamin-
labelled dextran (RITC-DEX, mean molecular weight 70,000), 
collagenase type I (from Clostridium hystolyticum), pig skin gelatin 
(type A), and LPS (E. coli, strain 055:B5) were purchased from Sigma 
Chemical (St Louis, MO). Human fibronectin was obtained from 
Boehringer Mannheim (Mannheim, Germany); A crude fraction of 
endothelial cell growth factors (ECGF) was kindly provided by the 
Department of Pediatrics, University Medical Center Nijmegen, The 
Netherlands. Heparin was obtained from Leo Pharmaceutical products 
(Weesp, The Netherlands). Recombinant human TNF-α (6 x 107 U/mg, 
endotoxin content < 1 EU / mg) was obtained from Bender & Co, 
Vienna. 
 
Isolation and culture of HUVEC 
Endothelial cells were isolated according to a modification of the 
method described by Jaffe and coworkers.23 Upon delivery the 
umbilical cords were placed in sterile, ice-cold cord buffer (140 
mmol/l NaCl, 4 mmol/l KCl, 11 mmol/l D-Glucose, 10 mmol/l HEPES, 
100 IU penicillin, and 0,1 mg/ml streptomycin, pH 7,3) and stored at 
4°C until use. In brief, the umbilical vein was rinsed with cord buffer 
to remove blood and debris from the lumen after which the vein was 
filled with medium M199 containing 0.1% (w/v) collagenase. 
Endothelial cells were detached by incubation for 20 min at 37° C and 
harvested by collecting the collagenase solution. After centrifugation 
(5 min at 300 x g), the cells were resuspended in complete medium 
(M199 with 10% NCS, 10% normal human serum, 50 U/ml penicillin, 50 
µg/ml streptomycin, 150 µg/ml crude ECGF and 5 U/ml heparin), and 
seeded onto 0.1% gelatin coated 25 cm2 culture flasks. The cultures 
were kept in a humidified incubator at 37° C under 5% CO2 / 95% air 
atmosphere. After one day, and then three times weekly, the culture 
medium was refreshed. Confluent cultures (typically yielding 105 
cells/cm2, or more) were passaged by detaching the cells with 0.5 
mg/ml trypsin and 0.2 mg/ml EDTA, which was followed by 
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centrifugation and resuspension in complete medium. For appropriate 
growth, a split ratio of 1:2 or 1:3 was used. All experiments were 
performed on cells that had been passaged less than four times. 
Endothelial origin of the cultures was confirmed by phase contrast 
microscopy, which revealed confluent cultures displaying a typical 
cobblestone morphology, while immunocytochemical analysis 
revealed positive staining for von Willebrand Factor and CD31 
(platelet endothelial cell adhesion molecule (PECAM)-1), while 
activation with TNF-α or LPS-induced the expression of intercellular 
adhesion molecule (ICAM)-1, and E-selectin (data not shown). 
 
Preparation of microporous membranes and cell seeding 
For permeability determinations, two different culture inserts were 
used, one containing a polyester (PE) membrane (Transwell Clear), 
and the other containing a collagen pre-treated 
polytetrafluoroethylene (PTFE) membrane (Transwell COL). Both 
types of membrane contained 0.4 µm diameter pores and a growth 
area of 1 cm2. However, differences existed in pore density and 
membrane thickness. While the PTFE membranes were obtained with 
a collagen (bovine, type I/III) coating in place, and thus were ready 
for culturing, the PE membranes were prepared for cell seeding by 
overnight incubation at room temperature with either fibronectin 
(10µg/cm2), or gelatin (10µg/cm2) in medium M199. No significant 
difference in permeability was observed between uncoated and 
coated PE membranes (data not shown). 
The inserts were placed in 12-well culture plates, resulting in a two-
compartment system separated by the membrane. Approximately 105 
cells/cm2 in 0.5 ml of complete medium were seeded at the upper 
side of the membrane, whereas 1.5 ml of complete medium was 
added to the lower compartment. These volumes prevented 
hydrostatic fluid pressures across the membranes. Both 
compartments were frequently replenished with complete medium as 
described. Cultures were grown for six days, resulting in the 
formation of confluent monolayers, which was confirmed by phase 
contrast light microscopy. 
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In one experiment, the confluent cell layer was selectively removed 
from the membranes. This was achieved by briefly incubating the 
monolayers with a 25 mmol/l NH4OH solution. Removal of attaching 
cells from the membrane was confirmed by transmission electron 
microscopy examination. 
 
Transmission electron microscopy of HUVEC monolayers 
Cultured cells on Transwell inserts were washed twice with serum-
free medium prior to fixation with 2% glutaraldehyde in phosphate 
buffered saline (PBS). After 60 min of fixation the Transwells were 
washed with PBS and treated with 1% OsO4 for 30 min and washed 
again with PBS. After several steps of dehydration, with 30% - 70% - 
90% - 100% alcohol, followed by 1:1 mix, 1:2 mix, and pure epon 812, 
the membranes were dissected from the Transwells with a small 
diamond knive and flat embedded in pure epon 812. Ultrathin 
sections were stained with uranyl acetate and lead nitrate. The 
sections were examined with a JEOL 1200 EX/II electron microscope 
(Tokyo, Japan) at 60kV. 
 
TNF-α and LPS treatment 
Dilutions of TNF-α (50, 500 pg/ml, and 10ng/ml) or LPS (50, 500 
ng/ml, and 10 µg/ml) were prepared in complete medium. In the LPS 
experiments, medium containing 20% normal human serum was used 
instead of heat-inactivated human and calf sera. At the start of the 
experiment 0,5 ml of TNF-α or LPS containing medium was added to 
the upper compartment of the chamber. After overnight incubation 
at 37° C, the permeability of the monolayers was determined. 
 
Permeability studies 
For the detection of macromolecular passage across the membranes, 
a tracer solution containing both FITC-labelled BSA (250 µg/ml) and 
RITC-labelled dextran (250 µg/ml) was prepared in complete 
medium. In the upper compartment, culture medium was replaced by 
0.5 ml of the tracer solution, while the lower volume was refreshed 
with 1.5 ml complete medium. After 1, 6 and 24 h of diffusion 250 µl 
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samples were drawn from the lower compartment, which was 
replenished with an equal volume fresh medium each time. The 
collected samples were diluted with 1 ml PBS and the concentrations 
of FITC-BSA and RITC-DEX were measured using a Hitachi 5000 
fluorophotospectrometer, at emission/excitation wavelengths of 
495/520 nm, and 560/580 nm, respectively. The albumin and dextran 
concentrations in the samples were calculated using linear regression 
of a diluted series of the tracer. 
 
Statistical analysis 
Differences between permeability to albumin and dextran were 
calculated by paired Student T-test. In order to control for the 
different membrane types used in our studies, the permeability of 
untreated HUVEC monolayers was calculated as a ratio of the 
corresponding unseeded membranes. Similarly, the effect of 
treatment of monolayers on different membranes was compared to 
control monolayers cultured on corresponding membranes. 
Differences between permeability ratios were calculated by Kruskall-
Wallis non-parametric ANOVA.  
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RESULTS 
 
Permeability of membranes with different protein coatings 
and without seeded cells 
 Membranes coated with collagen, fibronectin or gelatin showed 
different permeability rates. The diffusion of both albumin and 
dextran occurred faster across the collagen coated membranes than 
across the fibronectin or gelatin coated membranes (Figure 1). 
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FIGURE 1. Permeability of Transwell culture inserts for FITC-
albumin and RITC-dextran. Bars represent the abluminal 
concentration in µg/ml of permeated albumin (hatched bars) 
and dextran (filled bars) after 1 (left panel), 6 (middle panel) 
and 24 (right panel) h of equilibration. Data represent at 
least four independent measurements originating from two or 
more experiments and are expressed as mean ± SD. Culture 
inserts: COL = collagen coated, FN = fibronectin coated, GEL 
= gelatin coated. 
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Permeability to albumin and dextran appeared to be essentially the 
same, although average dextran concentrations in the lower 
compartment were almost invariably slightly less than albumin 
concentrations. 
After 1 h of diffusion, the concentrations of albumin and dextran in 
the lower compartment of the collagen-coated membrane inserts was 
11.2 ± 4.5 µg/ml and 10.1 ± 4.4 µg/ml, respectively. This accounted 
for approximately 17% of the calculated equilibrium concentration of 
62.5 µg/ml. Significantly less albumin and dextran accumulated in the 
lower compartment of the gelatine- or fibronectin-coated 
membranes, both allowing less than 2 µg/ml during the first hour, or 
about 5% of the calculated equilibrium concentration. At the end of 
the assay, after 24 h, these differences were still significant, 
although less explicit: the tracer concentration in the lower 
compartment of the collagen-coated membrane inserts were 49.4 ± 
4.3 µg/ml (for albumin) and 46.4 ± 4.9 µg/ml (for dextran), while less 
than 34 µg/ml of either molecule had accumulated in the lower 
compartment of the fibronectin or gelatin coated membrane inserts. 
 
Permeability of HUVEC monolayers 
Culturing of HUVEC for six days resulted in the growth of confluent 
monolayers that had formed tight junctions throughout the culture. 
As shown in figure 2, these junctions were present between cells 
grown on all three different matrix proteins. On all membranes the 
permeability to albumin or dextran was significantly restricted by 
HUVEC monolayers (Figure 3). Although monolayers cultured on 
collagen-coated PTFE membranes allowed more albumin and dextran 
passage than monolayers cultured on gelatine- or fibronectin-coated 
PE membranes, comparing the permeability to the corresponding 
unseeded membranes showed that the relative restriction to albumin 
and dextran by HUVEC monolayers was similar for the three coatings. 
For instance, after 1 h, monolayers cultured on collagen, fibronectin 
or gelatin reduced passage of albumin by 87.0 ± 4.8 % (n = 12), 79.8 ± 
5.6 % (n = 4) or 82.2 ± 4.7 % (n = 4), respectively, as compared to the 
passage across unseeded membranes. After 24 h, these percentages 
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were 55.5 ± 7.2, 61.7 ± 1.9 and 59.3 ± 8.2, respectively. Similar data 
could be calculated for the dextran permeability, but the relative 
restriction was not significantly different between the three coatings. 
FIGURE 2. Ultramorphologic 
characteristics of HUVEC 
monolayers cultured on 
different matrices. HUVEC 
cultured on (A) collagen;  (B) 
fibronectin;  and (C) gelatin 
coated membranes. Note 
junctional complexes between 
adjacent cells (arrowheads). 
Magnification 30,000 x. 
 
In order to investigate whether the extracellular matrix, produced by 
the cells during culture, differently contributed to the permeability 
after initial seeding on either protein, HUVEC were grown for six days 
and the permeability was measured. Thereafter, the cells were lysed, 
leaving membranes with matrix (coating plus the extracellular matrix 
laid down by the cells) only and the permeability was measured 
again. After cell lysis, albumin permeability measured after 1 h of 
diffusion was increased by a factor 4.4 ± 0.8 (n = 4) on collagen 
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coated membranes, 4.9 ± 0.1 on fibronectin coated membranes and 
4.5 ± 0.1 on gelatin coated membranes. Dextran permeability 
changed accordingly, but as with albumin, the permeability increase 
after cell lysis did not significantly differ between the collagen-, 
gelatine- and fibronectin coated membranes. 
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FIGURE 3. Permeability of HUVEC monolayers cultured on 
collagen, fibronectin, and gelatin.  Bars represent the 
abluminal concentration in µg/ml of permeated albumin 
(hatched bars) and dextran (filled bars) in time (cf. legend 
to Figure 1). Data represent at least four independent 
measurements originating from two or more experiments 
and are expressed as mean ± SD. 
Permeability of TNF-α or LPS-pretreated HUVEC monolayers 
Pre-incubation of the monolayers with increasing doses of TNF-α or 
LPS resulted in a dose-dependent increase in monolayer permeability. 
In order to allow a quantitative comparison of the effects induced by 
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these inflammatory mediators on the monolayers grown on the 
different coatings, permeability was expressed as the ratio between 
treated and untreated monolayers. While a dose of 50 pg/ml of TNF-α 
was insufficient to enhance the permeability for albumin, a dose of 
500 pg/ml of TNF-α induced a moderate permeability increase of the 
monolayers cultured on collagen, fibronectin, or gelatin (Figure 4a). 
A further stimulation was observed at a concentration of 10 ng/ml 
TNF-α. After 1 h of diffusion, the relative increase ranged from 2.0 ± 
0.4 (on gelatin) to 2.3 ± 0.2 (on collagen). The TNF-α effect could be 
observed on all the coatings and no significant differences were 
observed between monolayers cultured on either collagen, gelatine 
or fibronectin. After 6 and 24 h of diffusion, the permeability 
difference between TNF-α treated monolayers and control 
monolayers gradually declined, resulting in a ratio close to 1. Still, at 
the highest dose the effect seemed persistent for at least 24 h: at 
this time the ratio between treated and non-treated monolayers 
ranged between 1.2 ± 0.2 (on collagen) to 1.3 ± 0.04 (on gelatin). A 
similar picture emerged for the permeability to dextran (Figure 4b). 
Pre-incubation with bacterial LPS also induced a dose-dependent 
increase in permeability which, like in the TNF-α experiments, 
seemed qualitatively and quantitatively independent of the protein 
on which the monolayers were initially cultured. However, the 
enhanced permeability seemed less persistent after LPS pre-
incubation than after pre-incubation with TNF-α. After 1 h of 
diffusion, 500 ng/ml LPS had induced an albumin permeability which 
was a factor 1.2 ± 0.2 (on fibronectin) to 1.5 ± 0.3 (on collagen) 
higher than the permeability in untreated monolayers (Figure 5a). At 
10 µg/ml LPS a further increase was observed ranging from a factor 
1.9 ± 0.7 (on gelatin) to 2.3 ± 0.2 (on collagen). Similar values were 
obtained from dextran measurements (Figure 5b). However, during 
further incubation of albumin and dextran on LPS-treated monolayers 
a rapid decline towards control monolayer permeability was 
observed, reaching a ratio after 6 and 24 h that was not significantly 
different from 1. 
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FIGURE 4. Permeability of 
TNF-α-treated HUVEC 
monolayers. The increase in 
permeability to albumin (panel 
A) and dextran (panel B) is 
expressed as the permeability 
ratio (± SD, n = 4) between 
treated and untreated 
monolayers. In panels, from 
left to right, the permeability 
ratio of monolayers cultured 
on collagen (COL); fibronectin 
(FN), and gelatin (GEL), after 
1, 6 and 24 h of diffusion is 
shown. Open bars: 50 pg/ml 
TNF-α; grey bars: 500 pg/ml 
TNF-α; black bars: 10 ng/ml 
TNF-α. 
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FIGURE 5. Permeability of 
LPS treated HUVEC 
monolayers. The increase in 
permeability to albumin 
(panel A) and dextran (panel 
B) is expressed as the 
permeability ratio (± SD, n = 
4) between treated and 
untreated monolayers. In 
panels, from left to right, 
the permeability ratio of 
monolayers cultured on 
collagen (COL); fibronectin 
(FN), and gelatin (GEL), after 
1, 6 and 24 h of diffusion is 
shown. Open bars: 50 ng/ml 
LPS; grey bars: 500 ng/ml 
LPS; black bars: 10 µg/ml 
LPS. 
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DISCUSSION 
 
We have investigated the influence of different, but commonly used 
matrix protein substrates, on the permeability of resting, and TNF-α 
or LPS-treated HUVEC monolayers and found no essential differences 
between cells seeded on collagen, fibronectin or gelatin.  
One could think of several reasons for such a difference to exist. The 
attachment and growth of endothelial cells in vitro depends at least 
in part on specific binding-sites provided by the ECM. Also, the ECM is 
involved in mechanisms by which inflammatory mediators cause 
increased endothelial permeability and loss of monolayer integrity. 
These receptor-mediated mechanisms include: disruption of cell-cell 
contacts by cytoskeletal and/or junctional reorganization and 
alteration of endothelial adhesion molecule expression;24 disruption 
of cell-matrix contacts by altering endothelial matrix receptor 
expression and loss of cell attachments sites in the ECM;25 disruption 
of matrix-matrix contacts by proteolytic degradation, and 
remodelling of the ECM.16 Despite the apparent contribution of ECM 
proteins on endothelial permeability, different ECM proteins, as well 
as mixtures of ECM proteins, have been used for endothelial cell 
culturing. 
For the evaluation of endothelial monolayer permeability multi-well 
culture inserts suited with microporous membranes were used in this 
study. A major advantage of these culture inserts is that it allows an 
easy and multiple analysis of monolayer permeability, with only 
minor modifications of the standard culture conditions. Moreover, 
these inserts all allowed visual examination of the monolayer before 
and after the permeabilty assay. Across unseeded membranes, the 
accumulation of albumin appeared always slightly faster than that of 
dextran. Physical properties, like shape, diameter, and charge, of 
these molecules could be responsible for this difference. Untreated 
cultured HUVEC monolayers, and TNF-α or LPS-treated monolayers, 
did not show a clear preference for the passage of either albumin or 
dextran. Since albumin passage occurs by both active vesicular and 
paracellular transport, while dextran only passively diffuses through 
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the intercellular clefts,9,26 we conclude that in our experiments 
diffusion via the transcellular route contributes less to the 
permeability of resting and activated monolayers and that the 
majority of albumin and dextran pass the endothelial monolayer by 
means of the paracellular route. 
HUVEC monolayers cultured on collagen, fibronectin, or gelatine-
coated membranes, did not display different morphologic 
characteristics, as was revealed by light and transmission electron 
microscopy. All monolayers displayed typical cobblestone morphology 
and tight junctions were abundantly present between neighbouring 
cells. Confluence was usually achieved within six days, and was 
independent of the type of coating used. In the permeability 
experiments all differences observed between the monolayers 
cultured on the three proteins could be attributed to the original 
differences observed in the unseeded filters. Thus, collagen, 
fibronectin, and gelatin are all suitable as a substrate for the 
attachment and growth of endothelial cells in vitro, and in our 
model, these substrates do not induce different responses to 
inflammatory mediators. We assume that additional ECM proteins, 
produced by the endothelial cells and laid down into the ECM, 
mediate most of the endothelial-ECM interactions involved in 
monolayer permeability. The production of ECM proteins, including 
fibronectin, laminin and type IV collagen, by endothelial cells in vitro 
has been previously shown by others.27 In our experiments we did not 
see a difference in the membrane permeability changes induced by a 
procedure which removed the cells while leaving the ECM on the 
membrane. Although the eventual composition of the ECM may differ 
between monolayers cultured on collagen, fibronectin and gelatin, its 
contribution to the permeability of untreated and TNF-α or LPS 
HUVEC monolayers apparently is of minor significance. When the 
monolayers were exposed to TNF-α, a dose-dependent increase of 
permeability was observed, which is in accordance with previous 
observations.20 Although loss of fibronectin has been associated with 
a TNF-α-mediated increase of permeability,12 we did not observe a 
difference between monolayers cultured on collagen, fibronectin, or 
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gelatin-coated membranes. Possibly, in our experiments TNF-α 
treatment did not induce significant matrix degradation or matrix 
degradation equally affected the three ECM proteins investigated. 
When compared to TNF-α, LPS pre-treatment resulted in a moderate 
and more transient increase of permeability, suggesting that 
continuous exposure of LPS may be required for a prolonged 
permeability enhancement. Others have shown that the effect of LPS 
on endothelial permeability depends on the availability of soluble 
CD14 and lipopolysaccharide binding protein in serum.28 Further 
studies are needed to reveal eventual differences between TNF-α and 
LPS-induced endothelial permeability and the reversibility of these 
changes. 
In conclusion, we have demonstrated that cultured HUVEC 
monolayers seeded on various proteins are equally suitable as a 
model for vascular permeability, showing physiologically relevant 
responses to inflammatory stimuli. Apparently, the initial differences 
in cellular environment are unimportant with respect to the eventual 
permeability characteristics of the confluent monolayer, possibly as a 
result of additional ECM laid down during culture. 
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CHAPTER 3 
ABSTRACT 
 
Objective: To investigate the role of endotoxin-induced inflammatory 
mediators in blood on the permeability of endothelial monolayers. 
Design: Whole blood of healthy volunteers was treated with bacterial 
lipopolysaccharide (LPS; Escherichia coli, B55:05) and the resultant 
plasma was added to human umbilical venular endothelial cells 
(HUVEC) cultured on semipermeable membrane inserts (Transwells). 
Setting: University hospital laboratory. Subjects: Whole blood from 
healthy volunteers. Interventions: Donor plasma was treated with 
excess antibodies against either tumor necrosis factor(TNF)-α, or 
interleukin(IL)-1β, or both, before the incubation on HUVEC. 
Measurements and Main Results: The permeability of HUVEC 
monolayers to fluorescein-labeled albumin and dextran was measured 
over a 6-h period, after removal of the stimulus. The production of 
TNF-α and IL-1β in LPS-treated whole blood was determined by 
radioimmunoassay. Individually, LPS (10µg/mL), TNF-α (10ng/mL) and 
IL-1β (50ng/mL) all increased endothelial permeability by about 2.5-
fold. A much larger increase could be achieved by pre-incubation of 
LPS (10µg/mL) in whole blood: the resultant plasma induced a ten-
fold increase of the permeability. The permeability response after 
pre-incubation of LPS in whole blood was time- and dose-dependent. 
Moreover, this treatment increased the sensitivity of endothelial 
monolayers to LPS by a factor of several thousand-fold: Whereas high 
doses of LPS were required for direct stimulation of the permeability, 
picomolar amounts of LPS in whole blood induced a similar increase. 
Significant amounts of TNF-α and IL-1β were produced in blood at 
similar doses of LPS. The addition of antibodies against TNF-α or IL-1β 
to plasma partially but significantly abrogated the permeability 
increase. However, a complete inhibition could be achieved by the 
simultaneous addition of anti-TNF-α and anti-IL-1β to plasma. 
Conclusions: Although LPS is capable of directly inducing endothelial 
permeability, blood borne TNF-α and IL-1β mediate LPS-induced 
endothelial permeability at low endotoxin concentrations. These 
findings support the idea that multi-factorial inhibition of 
inflammatory mediators may improve survival in septic patients. 
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INTRODUCTION 
 
Systemic activation and damage of the vascular endothelium is a 
crucial feature of Gram-negative sepsis. As a consequence, the 
normal physiologic function of the vascular endothelium is abolished 
and peripheral edema develops as a result of excessive leakage of 
fluid and macromolecules from the circulation into the surrounding 
tissue. Despite treatment with vasoactive drugs and fluid 
resuscitation, hypoperfusion and septic shock may develop.1,2 During 
shock, oxygen supply and the distribution of metabolites to the 
surrounding tissues are limited and, if unresolved, this state 
potentially induces damage and dysfunction of vital organs, also 
known as the multiple organ dysfunction syndrome (MODS).3 In the 
intensive care unit shock and MODS are feared for their limited 
response to therapeutic intervention and poor outcome: Mortality 
rates of 30 – 80 % have been reported for patients developing 
MODS.4,5
Bacterial endotoxin or lipopolysaccharide (LPS) has been recognised 
as a key initiator of many of the events observed during Gram-
negative sepsis and MODS.6 Despite the observation that shock and 
MODS may develop in the absence of bacterial infection, septic 
patients are reported to exhibit significantly elevated plasma levels 
of LPS.7,8 In vivo administration of LPS to humans or animals mimics 
many of the clinical features observed in septic patients.9,10 On the 
cellular level, picomolar concentrations of LPS induce a massive 
production of proinflammatory cytokines, such as tumor necrosis 
factor (TNF)-α and interleukin (IL)-1β, by monocytes and 
macrophages.11 In sepsis, these cytokines correlate with disease 
severity.8,12 Despite the important role of endotoxin in Gram-negative 
infection and sepsis, therapies directed against LPS have not been 
very successful.13 Moreover, although specific inhibition of other 
individual inflammatory mediators seemed promising in animal 
models of sepsis and organ failure, as exemplified by a study in which 
TNF-antibodies improved survival in a mouse model of MODS14, in 
general this “magic bullet” approach has failed to improve survival in 
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septic patients.15,16
On the level of the endothelium, in vivo and in vitro studies have 
shown that LPS directly induces the expression of cell adhesion 
molecules for the attachment of circulating immune cells and 
increases endothelial permeability.17,18 However, relatively large 
amounts of LPS are required to achieve an effect, depending on the 
availability of LPS-binding proteins such as soluble CD14.19,20 We, and 
others have shown that endothelial permeability could also be 
increased by exposing the endothelial cells to TNF-α or IL-1β21,22, but 
again at doses not often found to occur in septic patients. 
So far, endothelial permeability has only been examined in vitro as a 
function of individual mediator molecules like LPS or individual 
cytokines, but the contribution of these cytokines to LPS-induced 
endothelial permeability is unknown. LPS-treated whole blood has 
been used as an in vitro model for the investigation of sepsis-induced 
mediators in the circulation.23,24 To examine the endothelial barrier 
function under septic conditions we have used an in vitro 
permeability model using monolayers of human endothelial cells 
cultured on a semi-permeable support.21 Here we describe the effect 
of plasma obtained from LPS-treated whole blood on endothelial 
permeability. In addition, we studied the role of TNF-α and IL-1β in 
this process by using neutralizing antibodies. 
 
 
MATERIALS AND METHODS 
 
Materials 
Culture medium M199 (containing 25 mmol/L HEPES, Earl’s salts, and 
L-Glutamine) and heat inactivated newborn calf serum, penicillin-
streptomycin, and trypsin/EDTA were obtained from Life 
Technologies (Paisley, Scotland). Normal human serum was supplied 
by a local transfusion service. A pool of serum of at least five donors 
was heat inactivated (30 min at 56°C), and stored at –20°C before 
use. Multiwell cell culture inserts (Transwell-COL), tissue culture 
plates, and flasks were all obtained from Costar (Cambridge, MA). 
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Fluorescein-labeled bovine serum albumin (FITC-BSA), rhodamin-
labeled dextran (RITC-DEX, mean molecular weight 70,000), 
collagenase type I (from Clostridium hystolyticum), pig skin gelatin 
(type A), and LPS (Escherichia coli, strain 055:B5) were purchased 
from Sigma Chemical (St Louis, MO). A crude fraction of endothelial 
cell growth factors was kindly provided by the Department of 
Pediatrics, University Hospital of Nijmegen, The Netherlands; heparin 
was obtained from Leo Pharmaceutical Products (Weesp, The 
Netherlands). Recombinant human TNF-α and IL-1β were kindly 
provided JW van der Meer (Department of Internal Medicine, 
University Hospital Nijmegen, the Netherlands). Antibodies to TNF-α 
and IL-1β were obtained from R&D Systems (Abingdon, UK). 
Incubation of 1µg/mL of these antibodies for 1 h at 37°C neutralized 
the bioactivity of 50 pg/mL and 0.25 ng/mL of recombinant human IL-
1β and TNF-α, respectively. 
 
LPS treatment of whole blood 
A modification of a previously described method was used.24 Briefly, 
blood from healthy volunteers was drawn in a sterile vacuum tube 
(Sherwood Medical, Balleymoney, N.Ireland) containing 50 IU/mL 
sterile pyrogen-free heparin as anticoagulant. Blood was then divided 
in endotoxin-free polypropylene tubes and 10 µL aliquots of LPS or 
solvent (0.1% BSA in saline) were added per milliliter of blood. Unless 
otherwise indicated, the samples were incubated for 24 h at 37°C, 
followed by centrifugation. Plasma was stored at -20°C until use. 
 
Detection of IL-1β and TNF-α 
Plasma concentrations of human IL-1β and TNF-α were measured by 
radioimmunoassay as described previously.25 Detection limits were 
0.04 ng/mL for both cytokines. 
 
Isolation and culture of Human Umbilical Venular 
Endothelial Cells (HUVEC) 
Endothelial cells were isolated as described previously, with minor 
modification.26 In brief, the umbilical vein was rinsed with cord buffer 
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(140 mM NaCl, 4 mM KCl, 11 mM D-Glucose, 10 mM HEPES, 100 IU 
penicillin, and 0.1mg/mL streptomycin, pH 7.3) to remove blood and 
debris from the lumen. The vein was filled with medium M199 
containing 0.1% (w/v) collagenase and incubated for 20 min at 37°C 
to detach the endothelial cells. The cells were harvested by 
centrifugation (5 min at 300 x g) of the collagenase solution. After 
resuspension in complete medium (M199 completed with 10% newborn 
calf serum, 10% normal human serum, 50 units/mL penicillin, 50 IU 
streptomycin, 150 µg/mL crude endothelial cell growth factors and 5 
units/mL heparin), the cells were seeded onto 0.1% gelatin-coated 25 
cm2 culture flasks. The isolates were cultured in a humidified 
incubator at 37°C under 5% CO2/95% air atmosphere. After one day, 
and then three times weekly, the cultures were replenished with 
fresh medium. Confluent cultures (typically yielding 105 cells/cm2, or 
more) were passaged by brief trypsinization (0.5 mg/mL trypsin and 
0.2 mg/mL EDTA). For appropriate growth, a split ratio of 1:2 or 1:3 
was applied. All experiments were performed on cells that had been 
passaged three times. 
Endothelial origin of the cultures was confirmed by phase contrast 
microscopy, which revealed confluent cultures displaying a typical 
cobblestone morphology, while immunocytochemical analysis 
revealed positive staining for von Willebrand Factor, and platelet 
endothelial cell adhesion molecule, and, on activation with TNF-α or 
LPS, showed increased expression of intracellular adhesion molecule-
1, and E-selectin (data not shown). 
 
Preparation of microporous membranes and cell seeding 
For permeability determinations, collagen precoated culture inserts 
(Transwell-COL) were used containing a polytetrafluoroethylene 
membrane with 0.4 µm diameter pores and a growth area of 1 cm2. 
The inserts were placed in 12-well culture plates. About 105 cells/cm2 
in 0.5 mL of complete medium were seeded at the upper (or luminal) 
side of the membrane, whereas 1.5 mL of complete medium was 
added to the lower (or abluminal) compartment. These volumes 
prevented hydrostatic fluid pressures across the membrane. Both 
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compartments were refreshed frequently with complete medium. 
Cultures were grown to confluence for 5 days. 
 
Incubation of monolayers with inflammatory mediators 
Dilutions of TNF-α, IL-1β, or LPS in complete medium were added to 
the upper compartment of the Transwell and incubated for 18 h at 
37°C. LPS-conditioned plasma was diluted in serum free culture 
medium to 20% and incubated similarly. 
  
Inhibition by antibodies 
Antibodies were diluted in saline containing 0.1 % BSA and added to 
LPS-conditioned plasma in a final concentration of 1 mg/mL. Plasma 
samples were incubated with or without anti-TNF-α, anti-IL-1β, or 
both antibodies for 1 h at 37° C, and subsequently were added to the 
luminal side of the HUVEC monolayer as described previously. 
 
Permeability studies 
For detection of macromolecular passage across the filter inserts, a 
tracer solution containing FITC-BSA (250 µg/mL) and RITC-DEX (250 
µg/mL) was prepared in complete medium. At the upper side of the 
monolayer, culture medium was replaced by 0.5 mL of the tracer 
solution, whereas the lower volume was replaced with 1.5 mL fresh 
medium. The tracer solution was allowed to equilibrate for 6 h. After 
1, 2, and 6 h of incubation, 250 µL samples were drawn from the 
lower compartment followed by immediate replenishment of the 
lower compartment with fresh medium. For the detection of FITC-BSA 
and RITC-DEX, the samples were diluted with 1 mL PBS, followed by 
measurement on a Hitachi 5000 fluorospectrophotometer, at 
emission/exitation wavelengths 495/520nm and 560/580nm, 
respectively. 
Data are expressed as the permeability ratio (experimental/control). 
However, stimulus-induced changes vary quantitatively between 
experiments. In order to allow quantitative comparison, data are 
expressed as relative permeability (with respect to a stimulus run in 
each individual experiment) in those figures where multiple 
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experiments are represented together. 
  
Statistical Analysis 
Permeability differences of stimulated versus control monolayers 
were analyzed with Kruskal-Wallis non-parametric analysis of 
variance and Dunn’s Multiple Comparisons Test by using GraphPad 
InStat version 2.04 software. 
  
 
RESULTS 
 
Effect of  IL-1β, TNF-α, and LPS on endothelial permeability 
Monolayers were exposed to these mediators for 18 h before the 
permeability was measured. When exposed monolayers were 
compared with untreated control monolayers, >20 pg/mL IL-1β, >50 
pg/mL TNF-α, or >500 ng/mL LPS, respectively, was required to 
significantly increase the permeability. This response was dose 
dependent within the range of concentrations used for each 
compound (Figure 1). 
At the largest doses of IL-1β (50 ng/mL), TNF-α (10 ng/mL), and LPS 
(10 µg/mL) used, the permeability increased by a factor of 2.38 ± 
0.36, 2.33 ± 0.19, and 2.23 ± 0.06, respectively. In general, 
permeability differences between stimulated and control monolayers 
persisted during the whole assay period. In this and all further 
experiments changes in albumin and dextran permeability were 
essentially similar. Therefore, in the following sections data pertain 
to albumin as measured at the end of the assay (after 6 h) unless 
otherwise indicated. 
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FIGURE 1. Permeability of HUVEC monolayers induced after incubation 
with interleukin (IL)-1β (dotted bars), tumor necrosis factor (TNF)-α 
(hatched bars) and lipopolysaccharide (LPS; grey bars). Bars represent the 
mean ratio (± SEM) of albumin permeability of experimental (n=4) over 
control (n=4) monolayers, during the first hour of the permeability assay. 
In panels from left to right: IL-1β (0.02, 1, and 50 ng/mL), TNF-α (0.05, 
0.5, and 10 ng/mL), and LPS (0.05, 0.5, and 10 µg/mL). *P < .05. 
Effects of LPS-conditioned plasma 
To produce a sepsis-like stimulus for the endothelial cells, LPS (10 
µg/mL) was preincubated in whole blood before the addition of the 
resultant plasma to endothelial monolayers. The highest plasma 
concentration caused a ten-fold increase in permeability (Figure 2). 
Serial dilution of this LPS-conditioned plasma in untreated control 
plasma of the same donor caused a gradual decline of permeability 
towards control levels. However, the capacity to significantly (P < 
.05) enhance permeability was maintained even at a concentration 
dilution of 0.02 %. Remarkably, the two-fold permeability increase 
observed at this plasma dilution, which would contain only 2 ng/mL 
LPS, was similar to that measured after direct addition of 10 µg/mL  
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FIGURE 2. Effect of LPS-conditioned plasma on monolayer permeability of 
HUVEC. Bars represent the mean ratio (± SEM) of albumin permeability of 
experimental (n=4) over control monolayers (n=4) during the first hour of 
the permeability assay. An amount of 0.02 % LPS-conditioned plasma and 
upward significantly increased monolayer permeability when compared to 
control monolayers (*P < .05). Note ten-fold increase induced by LPS-
conditioned plasma when compared to the same but directly added 
amount of LPS (10 µg/mL) shown in Figure 1. 
LPS to the incubation medium. This indicates that in whole blood 
approximately 5000-fold less LPS indirectly increases endothelial 
permeability equivalent to direct LPS stimulation. 
Similar results were obtained in a dose-response study where 
endothelial monolayers were incubated with plasma obtained from 
whole blood that had been treated with LPS doses ranging between 
10 pg and 10 µg/mL. When compared to control plasma, plasma from 
whole blood treated with 10 and 25 pg/mL induced a permeability 
increase, and at 50 pg/mL LPS this increase was significant (P < .01; 
Figure 3). The response increased with the LPS dose up to 1 ng/mL, 
whereas conditioned plasma from blood treated with higher doses of 
LPS did not further enhance permeability. In the dose-response study, 
100 pg/mL LPS typically induced a 1.7 to 3.6-fold increase of the 
permeability, and for comparison between the experiments this 
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FIGURE 3. Effect of LPS dose on the stimulation of HUVEC permeability by 
LPS-conditioned plasma. Data were obtained from two experiments using 
plasma from four different donors and are represented as median, quartiles 
and range of relative albumin permeability (the response to 0.1 ng/mL LPS, 
measured in both experiments, = 100 %). From doses higher than 0.025 ng/mL 
the permeability was significantly (*P < .05) increased versus control levels. 
response was set at 100 %. Blood from four healthy donors was used 
to investigate differences between donor plasma. The effects of 
individual LPS-conditioned plasma on endothelial permeability were 
independent from the donor at all LPS doses used. 
Figure 4 illustrates the activation of whole blood by increasing doses 
of LPS, as illustrated by the production of TNF-α and IL-1β. A dose of 
at least 25 pg/mL was required to induce significant (P < .05, one-
sided) production of both IL-1β and TNF-α, resulting in average 
concentrations of 109 and 203 pg/mL, respectively. Interestingly, 
about the same LPS doses were required to yield plasma that 
significantly increased endothelial permeability (see preceeding 
discussion). Increasing the LPS dose resulted in a dose-dependent 
stimulation of cytokine production, resulting in concentrations up to 
54 and 35 ng/ml for IL-1β and TNF-α, respectively, after incubation 
with 10 µg/ml LPS. 
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FIGURE 4. Effect of LPS on cytokine production in whole blood. Data were 
obtained with blood from four different donors and are represented on a 
logarithmic scale as mean (± SEM) of plasma interleukin (IL)-1β (grey bars) 
and tumor necrosis factor (TNF)-α (hatched bars) in ng/mL. From a dose of 
0.025 ng/mL upward, cytokine production was significantly (*P < .05) 
increased if compared with controls. 
 
To investigate the incubation time required for LPS to produce 
plasma that would increase endothelial permeability, LPS was added 
to whole blood for 0 - 24 h. A dose of 1 ng/mL of LPS was used since 
this had been proven to be maximally effective (Figure 3). A 
minimum of 4 h of exposure of LPS in whole blood was required to 
produce plasma that substantially increased the permeability (P < 
.05; Figure 5). An incubation time longer than 8 h did not produce 
plasma that could further enhance the permeability to albumin of the 
HUVEC monolayer. In the time-response experiments, treating blood 
for 8 h yielded plasma that typically induced a 1.9- to 2.4-fold 
 82
ENDOTHELIAL PERMEABILITY INDUCED BY LPS-TREATED WHOLE BLOOD 
increase of the permeability. For comparison between the 
experiments, this response was set to 100 %. Blood of two donors was 
used, and the response of the resultant individual plasma was 
essentially the same. In whole blood, 1 h of incubation with LPS was 
sufficient to induce significant (P < .05) production of TNF-α, whereas 
≥ 4 h were required to produce significant (P < .05) amounts of IL-1β. 
 
FIGURE 5. Induction of HUVEC permeability by conditioned plasma from LPS-
treated whole blood: Effect of LPS incubation time. Whole blood obtained 
from two different donors was treated with 1 ng/mL LPS. Data from two 
experiments are represented as median, quartiles and range of relative 
albumin permeability (response to 8 h of LPS stimulation, which was 
measured in both experiments, = 100 %). From an incubation time of 4 h and 
longer, the permeability was significantly higher (*P < .05) than control 
levels. 
Whereas peak concentrations of TNF-α (2.1 ± 0.2 ng/mL) were 
reached after 4 h, the concentration of IL-1β was highest (2.8 ± 0.2 
ng/mL) after 24 h (Figure 6). 
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Effect of neutralising antibodies 
Because the preceding results strongly suggest a causal role of IL-1β 
and/or TNF-α in the increase of endothelial permeability observed 
after exposure to plasma from LPS-treated whole blood, we 
investigated if neutralising antibodies to these cytokines could 
abrogate this effect. For this purpose, plasma from LPS-treated (1 
ng/mL) whole blood was preincubated with excess anti-IL-1β and/or 
anti-TNF-α before the incubation on to HUVEC monolayers. In four 
separate experiments, LPS-conditioned plasma caused a mean 
permeability increase of 3.9-fold (range 1.6 - 6.8-fold) after 1 h, 
while after 6 h the mean response was 2.3-fold (range 1.2 - 3.8-fold) 
when compared to control monolayers. For each experiment, the 
response on stimulation with LPS-conditioned plasma alone was set at 
100 % to allow comparison of results. Pre-incubation of LPS-
conditioned plasma with anti-IL-1β antibodies partially inhibited this 
response by 28 % (non significant) after 1 h, whereas after 6 h a 
significant (P < .05) reduction with 34 % was measured (Figure 7) 
 
 
FIGURE 6. Effect of LPS preincubation time on cytokine production in 
whole blood. Data were obtained from the same two donors as Figure 5 
and are represented as the mean (± SEM) of plasma IL-1β (grey bars) and 
TNF-α (hatched bars). From an incubation time of 1 h and 4 h upward, the 
production of TNF-α and IL-1β respectively, was significantly (*P < .05) 
increased when compared with controls. 
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FIGURE 7. Effect of antibody treatment of LPS-conditioned plasma on HUVEC 
permeability. Data were collected from four experiments with plasma of two 
donors. Box plots represent the median, 75-25th percentile, and 95-5th 
percentile of the relative albumin permeability. Control plasma (CP), and 
LPS-conditioned plasma treated with antibodies against either IL-1β (aIL1), 
or TNF-α  (aTNF), or both all induced a significantly lower permeability (*P< 
.05) when compared to monolayers treated with LPS-conditioned plasma (AP 
response, measured in all four experiments, = 100 %) of the same donor. The 
permeability induced by LPS-conditioned plasma after pretreatment with 
both antibodies was not statistically different from control monolayer 
permeability. Control plasma incubated with 1 ng/mL LPS (Clps), or with 
antibodies against IL-1β and TNF-α (CAb) was used as control. 
Pretreatment with anti-TNF-α antibodies reduced the permeability to 
LPS-conditioned plasma by 41 % (P < .01). The synergistic deleterious 
effect of LPS-induced TNF-α and IL-1β on endothelial integrity was 
demonstrated since the permeability increase was almost completely 
(by 83 %) abrogated by the simultaneous addition of anti-IL-1β and 
anti-TNF-α to LPS-conditioned plasma. The resulting permeability 
after preincubation of LPS-conditioned plasma with both antibodies 
was not statistically different from the permeability of monolayers 
that were exposed to control plasma of the same donor. Monolayers 
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that were exposed to control plasma treated with both anti-IL-1β and 
anti-TNF-α, or with 1 ng/mL of LPS (the amount that was used to 
stimulate whole blood) did not induce significantly different 
permeabilities when compared with monolayers treated with control 
plasma alone. 
 
DISCUSSION 
A persistent and systemic increase of vascular permeability may 
contribute to morbidity and mortality in Gram-negative sepsis.27,28 
Since bacterial endotoxin or LPS is a key initiator of Gram-negative 
sepsis, elucidation of the mediators and pathways involved in LPS-
induced endothelial permeability may contribute to the development 
of strategies for effective anti-sepsis treatment.29,30 To examine LPS-
dependent pathways involved in endothelial permeability, we have 
cultured human endothelial monolayers on semipermeable supports 
to simulate the vascular wall. This model has been validated before 
by us and others.21,31 In our experience, culturing confluent HUVEC 
monolayers almost completely restricted the passage of albumin and 
dextran through the supporting filters. Thus, the resulting 
permeability was determined by transport through the monolayer. 
Since albumin, but not dextran, transport is thought to be mediated 
through active uptake in vesicles, we measured the permeability to 
both macromolecules. However, the observation that no major 
differences were apparent between the permeability to albumin and 
dextran, which have similar molecular weights, suggests that in our 
model paracellular passage (i.e. between the cells) of these 
molecules predominated. 
Soluble mediators that supposedly are involved in Gram-negative 
infection were produced by challenging blood from healthy donors 
with LPS. The effects of these putative mediators on endothelial 
permeability were investigated by incubating whole blood with LPS 
and adding the resultant plasma to HUVEC monolayers. The present 
study shows that pretreatment of human blood with LPS doses as low 
as 50 pg/mL yields plasma that significantly enhances endothelial 
permeability. In contrast, direct stimulation (without prior incubation 
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in whole blood) of endothelial permeability required > 50 ng/mL of 
LPS. The addition of blood thus amplified the permeability response 
to LPS at least by a factor of 1000. This observation supports the idea 
that circulating LPS-responsive (i.e., CD14-bearing) immune cells are 
the key mediators in LPS-induced endothelial permeability. 
The results presented here indicate that both TNF-α and IL-1β are 
instrumental in enhancing permeability of the endothelial monolayer 
after exposure to LPS conditioned plasma. Firstly, large amounts of 
these cytokines are produced by monocytes on stimulation with LPS. 
Second, TNF-α and IL-1β are both capable of inducing endothelial 
permeability in vitro. Third, the dose- and time-dependent 
production of these cytokines on LPS challenge of whole blood runs 
almost completely parallel to the induction of endothelial 
permeability by the resulting plasma. Finally, the most direct 
evidence is provided by the finding that blocking of both TNF-α and 
IL-1β in the LPS-conditioned plasma by monoclonal antibodies almost 
completely abrogates the permeability response. 
The fact that plasma from LPS-treated whole blood greatly amplifies 
the endothelial cell response to LPS has also been found using the 
expression of the vascular cell adhesion molecule-1 as a variable.32 
Moreover, this up-regulation of adhesion molecule expression could 
be inhibited completely by the simultaneous addition of anti-TNF-α 
and IL-1 receptor antagonist, but only partly by each inhibitor 
separately.33 Here, we have demonstrated that the same is true for 
the permeability of the endothelial cell monolayer. Taken together, 
these findings suggest that, in an in vivo situation, prevention of 
endothelial leakage requires measures directed at neutralising both 
cytokines instead of either one alone. 
Several mechanisms may take part in the evolvement of endothelial 
permeability.28,34,35 For example, inflammatory mediators like LPS and 
TNF-α may induce cell contraction and subsequent disruption of cell-
cell contacts.36,37 Alternatively, cytokine-induced breakdown and 
remodelling of subendothelial matrix proteins by matrix 
metalloproteinases may result in loss of attachment sites for 
endothelial cells.38 In our experiments, plasma from LPS-treated 
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whole blood exhibits increased gelatinase activity on zymography 
(data not shown). Also, endothelial cells are a source of MMPs.39 One 
could speculate that matrix metalloproteinase activity may account 
for the slightly increased permeability, induced in the HUVEC 
monolayer even after the LPS-conditioned plasma was treated with 
TNF-α and IL-1β antibodies. A third pathway possibly involved in 
LPS/cytokine-mediated permeability is endothelial cell apoptosis, 
which results in a loss of cells from the monolayer.40 Cell counting 
and histologic examination of Hoechst 33342/propidium-iodide-
stained monolayers after exposure to LPS-conditioned plasma reveal a 
reduced number of attaching cells, many of which exhibit either 
condensed nuclei and propidium-iodide positive cytoplasm or a decay 
to cell debris (unpublished observations). Others have shown that LPS 
and TNF-α may induce apoptosis in cells of endothelial origin.41 These 
findings are consistent with a role for endothelial apoptosis  in 
models of septic shock.42 Still, the contribution of the various 
mechanisms to LPS/cytokine-induced permeability remains largely 
speculative and awaits further study. 
Our studies do not explain the occurrence of a persistent vascular 
leak during the course of the sepsis syndrome, because plasma TNF-α 
and IL-1β concentrations tend to decrease in later phases of sepsis43, 
possibly as a result of LPS-tolerance.44 Moreover, it has been 
suggested that during the course of the sepsis syndrome, the 
patient’s hyperinflammatory state may develop in a hyporesponsive 
state as a result of an excessive anti-inflammatory counterreaction, 
suggesting that the effect of intervention with inhibitors to pro- or 
anti-inflammatory mediators depends on the immunological state of 
the patient.45 Further studies with our model will be directed at 
finding measures to counteract the increased permeability of the 
HUVEC monolayer once it has been established by treatment with 
LPS- conditioned plasma (in contrast to the present results 
demonstrating prevention by an early addition of cytokine 
antibodies). If such measures prove to be possible in a model system, 
they could open new ways to the development of clinically 
meaningful interventions. 
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Conclusions 
In vitro, bacterial LPS induces endothelial permeability at picomolar 
concentrations after preincubation in whole blood. Neutralisation of 
both IL-1β and TNF-α in plasma obtained from LPS-treated whole 
blood completely abrogates the permeability increase. These findings 
support the idea that simultaneous inhibition of proinflammatory 
cytokines should be considered as a strategy for early treatment of 
the acute, proinflammatory phase of sepsis. 
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ABSTRACT 
 
 
 
 
 
 
 
 
 
 
 
 
Aim: The relative contribution of the pro-inflammatory cytokines 
tumor necrosis factor(TNF)-α and interleukin(IL)-1β and the 
lipopolysaccharide(LPS)-induced pathways that result in endothelial 
activation during sepsis are not fully understood. We have examined 
the effects of plasma obtained from LPS-treated human whole blood 
on the expression of E-Selectin and intercellular adhesion 
molecule(ICAM)-1 on human endothelial cells. Results: Stimulation of 
blood with 10 pg/mL of LPS is sufficient to produce plasma that 
induces E-Selectin and ICAM-1 expression, while direct induction by 
LPS alone requires a 100-fold higher concentration. Characteristics 
for the plasma-induced adhesion molecule expression were similar to 
the LPS-induced production of TNF-α and IL-1β in blood. A complete 
inhibition of E-Selectin and ICAM-1 expression was observed when 
antibodies against TNF-α and IL-1β were added to plasma prior to the 
incubation to endothelial cultures. Significant inhibition was even 
observed if antibodies were added to the cultures up until 3 h after 
LPS-conditioned plasma. The plasma-induced adhesion molecule 
response could also be prevented with inhibitors of nuclear factor 
(NF)-κB, such as pyrollidine dithiocarbamate. Conclusions: These 
findings emphasize the central role of TNF-α and IL-1β in LPS-induced 
endothelial activation and suggest that simultaneous neutralization of 
these cytokines or their common pathways may, even after the initial 
stimulus, prevent endothelial response during sepsis. 
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INTRODUCTION 
 
The (over)expression of endothelial cell adhesion molecules (CAMs) at 
sites distant from the primary infection may be crucial for the 
generation of tissue damage and organ failure as observed during 
Gram-negative sepsis and shock.1-3 Endothelial CAMs provide the 
anchoring sites required for rolling, arrest, and migration of various 
types of circulating immune cells, such as neutrophils and monocytes, 
across the endothelial barrier.4,5 The attraction and activation of 
these leukocytes in essentially healthy tissue can be damaging and 
may further deteriorate the condition of the host. 
Endothelial CAMs are expressed in a complex yet regulated manner, 
which depends on stimulus, timing, cell type, and organ 
characteristics. Leukocyte recruitment to inflammatory sites requires 
the coordinated expression of specific combinations of adhesion 
molecules. Diversity at each step of the adhesion cascade ensures 
that the appropriate leukocytes accumulate for a restricted period in 
response to a specific challenge.3,6 Furthermore, many CAMs signal 
inside the endothelial cell upon receptor engagement. The main 
endothelial CAMs involved in the inflammatory response are E-
Selectin (CD62e), and two members of the Ig-gene superfamily, 
Intercellular Adhesion Molecule (ICAM)-1 (CD54) and Vascular Cell 
Adhesion Molecule (VCAM)-1 (CD106). The expression of these 
adhesion molecules is controlled at least in part by the cytokine 
inducible nuclear transcription factor kappa B (NF-κB).7 The 
expression of E-Selectin peaks at 4 – 6 h after stimulation and rapidly 
declines to basal levels in the next 24 h. The expression of ICAM-1 
and VCAM-1 on the other hand increases 6 – 12 h after stimulation, 
respectively, and remains elevated for at least 48 h. The different 
peak levels and kinetics of these endothelial CAMs correspond to their 
functional role during the adhesion cascade: while E-Selectin mainly 
promotes the attraction of neutrophils, ICAM-1 and VCAM-1 are 
involved in monocyte trafficking. 
Several individual inflammatory mediators that are associated with 
Gram-negative infection and sepsis, such as bacterial 
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lipopolysaccharide (LPS) and the cytokines tumor necrosis factor 
(TNF)-α and interleukin (IL)-1β, induce the expression of E-Selectin, 
ICAM-1 and VCAM-1. The ultimate response of specific endothelial 
CAMs may be determined by the combination of different 
inflammatory stimuli, e.g. as was demonstrated for LPS, TNF-α and 
interferon(IFN)-γ.8,9 Thus, the presence of different circulating 
inflammatory mediators during Gram-negative infections and sepsis 
may cause (prolonged) endothelial CAM expression at sites not 
directly involved in the infection. 
The endothelial responses during sepsis have been studied extensively 
with respect to the effects of individual inflammatory mediators. 
Despite the identification of several important molecules that are 
involved in the induction of endothelial CAM expression, as well as in 
other sepsis related events, neutralization of these individual 
mediators in clinical trials has hardly improved survival.10-12 In the 
present study, we have investigated the combined effect of septic 
mediators on endothelial CAM expression. For this purpose, we have 
mimicked the production of these putative inflammatory mediators 
by incubating human whole blood with bacterial LPS ex vivo.13 The 
effect of the resulting activated plasma on the expression of E-
Selectin and ICAM-1 on cultured human endothelial cells (HUVECs) 
was characterized, with particular attention for the role of TNF-α and 
IL-1β. Intervention studies were performed with neutralizing 
antibodies and compounds thought to inhibit LPS-, TNF-α- and IL-1β-
induced intracellular signalling pathways. 
 
 
MATERIALS AND METHODS 
 
Materials 
Culture medium M199 (containing 25 mM HEPES, Earl’s salts, and L-
Glutamate) and heat-inactivated newborn calf serum, penicillin-
streptomycin, and trypsin/ethylenediaminetetraacetic acid (EDTA) 
were obtained from Life Technologies (Paisley, Scotland). Heat-
inactivated normal human serum was purchased from ICN (Costa 
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Mesa, CA, USA). Multi-well tissue culture plates were obtained from 
Costar (Cambridge, MA, USA); collagenase type I (from Clostridium 
hystolyticum), pig skin gelatin (type A) and bacterial LPS (Escherichia 
coli, strain 055:B5) were purchased from Sigma Chemical (St Louis, 
MO, USA). A crude fraction of endothelial cell growth factors (ECGF) 
was kindly provided by the Department of Paediatrics, University 
Medical Center, Nijmegen, The Netherlands; heparin was obtained 
from Leo Pharmaceutical products (Weesp, The Netherlands). 
Recombinant human TNF-α and IL-1β were kindly provided by dr. 
J.W. van der Meer (Department of Internal Medicine, University 
Hospital Nijmegen, The Netherlands). Monoclonal antibodies against 
human E-Selectin (clone ENA1) and ICAM-1 (clone HM2) were a 
generous gift of dr. W.A. Buurman, Department of Surgery, University 
Medical Centre, Maastricht, The Netherlands. Ortho-
phenylenediamine tablets and horseradish peroxidate(HRP)-
conjugated goat-anti-mouse antibodies were purchased from DAKO, 
Glostrup, Denmark. Neutralizing antibodies to human TNF-α and IL-1β 
were obtained from R&D Systems (Abingdon, UK). Incubation of 1 
µg/mL of these antibodies for 1 h at 37° C neutralised the bioactivity 
of 50 pg/mL and 0.25 ng/mL of recombinant human IL-1β and 0.25 
ng/mL TNF-α, respectively. Dexamethasone and hydrocortisone were 
both obtained from Sigma. Bisindolylmaleimide I (GF-109302X) was 
purchased from Kordia Life Sciences b.v. Leiden, the Netherlands, 
and SB 203580 from Promega Madison, WI, USA. Pyrollidine 
dithiocarbamate (PDTC) and N-Acetylcysteine were obtained from 
Sigma. 
 
LPS treatment of whole blood 
A modification of a previously described method was used.13 Briefly, 
blood from healthy volunteers was drawn in a sterile vacuum tube 
(Sherwood Medical, Balleymoney, N.Ireland) containing 50 IU/mL of 
pyrogen-free heparin as anticoagulant. Blood was then divided in 
endotoxin free polypropylene tubes and 10 µL aliquots of LPS or 
solvent [0.1% bovine serum albumin (BSA) in saline] were added per 
mL of blood. The blood samples were incubated at 37°C, routinely for 
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18 h except for one experiment where a series of shorter incubations 
was used. Subsequently, plasma was collected by centrifugation and 
stored at -20°C until use. 
 
Detection of IL-1β and TNF-α 
Plasma levels of human IL-1β and TNF-α were measured by 
radioimmunoassay as described previously.14 Detection limits were 
0,04 ng/mL for both cytokines. 
 
Isolation and culture of HUVEC 
Endothelial cells were isolated as described previously, with minor 
modification.15 In brief, the umbilical vein was rinsed with cord buffer 
[140 mM NaCl, 4 mM KCl, 11 mM D-Glucose, 10 mM HEPES, 100 IU 
penicillin, and 0.1mg/mL streptomycin, (pH 7.3)] to remove blood 
and debris. Endothelial cells were detached by collagenase (0.1 % 
w/v in M199) digestion for 20 min at 37°C. After collection and brief 
centrifugation (5 min at 300 x g) of the collagenase solution the cells 
were resuspended in complete medium (M199 completed with 10% 
heat-inactivated normal calf serum, 10% heat-inactivated normal 
human serum, 50 U/mL penicillin, 50 µg/mL streptomycin, 150 µg/mL 
crude ECGF and 5 U/mL heparin), and seeded onto 0.1% gelatin-
coated 25 cm2 culture flasks. The cells were cultured in a humidified 
incubator at 37°C under 5% CO2 / 95% air atmosphere. After one day, 
and then three times weekly, the cultures were replenished with 
fresh medium. Confluent cultures (typically yielding 105 cells/cm2, or 
more) were passaged by brief trypsinization (0.5 mg/mL trypsin and 
0.2 mg/mL EDTA). For appropriate growth, a split ratio of 1:2 or 1:3 
was applied. All experiments were performed on cells that had been 
passaged three times. In all experiments 104 cells/well were seeded 
on 96-well culture plates, and grown to confluence for 5 days. 
Endothelial origin of the cultures was confirmed by phase contrast 
microscopy, which revealed confluent cultures displaying a typical 
cobblestone morphology, while immunocytochemical analysis 
revealed positive staining for von Willebrand Factor and CD31 
[platelet endothelial cell adhesion molecule (PECAM)-1)]. 
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Incubation of monolayers  
Confluent cultures were incubated at 37°C in 100 µL complete 
medium, where the serum component had been replaced as indicated 
below. If stimulated directly with LPS, the medium contained 20% 
nonheat-inactivated normal human serum. In the experiments with 
LPS-conditioned plasma, the medium contained 20% plasma obtained 
after LPS stimulation of whole blood. In one experiment plasma was 
serially diluted with untreated plasma from the same donor before 
addition to the medium. 
Modulation of the increased adhesion molecule expression induced by 
LPS-conditioned plasma was investigated by the addition of specific 
antibodies or chemical compounds. 
Antibodies were diluted in M199 and added to the culture medium, in 
a final concentration of 1 mg/mL, at various time points after the 
addition of LPS-conditioned plasma. If examining the effects of 
preincubation, antibodies were added to medium containing LPS-
conditioned plasma and incubated for 1 h at 37°C prior to addition to 
the cells. 
PDTC, N-acetylcysteine, SB203580 (pyrinidylimidazole) and 
GF109203X (bisindolylmaleimide I) were diluted in complete medium 
and added to the cultures 1 h prior to the addition of LPS-conditioned 
plasma. Hydrocortisone and dexamethasone were added either 1 h 
prior to or immediately after addition of LPS-conditioned plasma. 
PDTC was investigated more extensively by also examining its effect 
if added at various time points after stimulation of the cells with LPS-
conditioned plasma. 
 
Enzyme-linked Immunosorbent Assay (ELISA) for detection of 
E-Selectin or ICAM-1 
The expression of E-Selectin and ICAM-1 was determined by a 
modified ELISA.16 E-selectin was measured 5 h and ICAM-1 24 h after 
stimulation. Briefly, the HUVEC cultures were washed with preheated 
M199 to remove serum components, and incubated with a 0.025 % 
glutaraldehyde solution in phosphate-buffered saline for 10 min. After 
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aspiration and briefly drying the tissue culture plates, the wells were 
pre-incubated with ELISA buffer (0.5 % BSA in PBS). A solution 
containing murine monoclonal anti-human E-Selectin (clone ENA1, 
1:1000) or anti-ICAM-1 (clone HM2, 1:1000) in ELISA buffer was added 
to each well and incubated for 1 h at 37°C, followed by incubation 
with second (detection) antibody (HRP-conjugated goat-antimouse, 
1:1000) for 1 h at 37°C. Plates were washed 4 times with buffer 
between all the incubation steps. Enzyme activity of the bound 
fraction was measured by orthophenyl diamine substrate and the 
reaction was analysed by measuring the optical density at 490 nm on 
a Bio-Rad 550 plate reader. 
 
Statistical Analysis 
Comparison of different treatments and differences between 
stimulated and control cultures were analysed by one-way ANOVA 
followed by Tukey and Dunnett Multiple Comparisons Test, 
respectively, using GraphPad InStat™ v3.05 software. 
 
 
RESULTS 
 
Effect of LPS and LPS-conditioned plasma on adhesion 
molecule expression 
The endothelial adhesion molecule response to LPS depends on the 
way in which LPS is presented to the endothelial cultures. When 
dilutions of LPS in culture medium with 20% human serum were added 
directly to the endothelial cells a significant increase in the 
expression of E-Selectin and ICAM-1 was observed at doses from 1.25 
ng/mL upwards (Figure 1a). Plasma obtained from LPS-treated (10 
µg/mL) whole blood and serially diluted in untreated plasma from the 
same donor prior to addition to the cells in a final plasma 
concentration of 20%, significantly induced the expression of E-
Selectin and ICAM-1 even at 2000- and 4000-fold dilutions, 
respectively (Figure 1b). 
 102
 CYTOKINE-MEDIATED ENDOTHELIAL ADHESION MOLECULE  EXPRESSION 
*
*
*
*
*
*
**
*
*
*
0,0
0,5
1,0
1,5
2,0
2,5
0,
00
00
0,
00
24
0,
00
49
0,
00
98
0,
01
95
0,
15
63
0,
62
50
20
,0
00
0
LPS-conditioned plasma v/v (%)
O
D
 4
90
 n
m
B
0
0.
62
5
0.
16
0.
02
0.
01
0.
00
5
0.
00
2 20
*
*
*
*
*
**
*
0,0
0,5
1,0
1,5
2,0
2,5
3,0
0 0,3 0,6 1,25 2,5 5 10
LPS (ng/mL)
O
D
 4
90
 n
m
A
ad
he
si
on
 m
ol
ec
ul
e 
ex
pr
es
si
on
 (O
D
 4
90
 n
m
)
FIGURE 1. Adhesion 
molecule expression 
induced by 
lipopolysaccharide (LPS) 
and LPS-conditioned 
plasma. Human 
umbilical vein 
endothelial cell 
cultures were incubated 
either (A) directly with 
increasing 
concentrations of LPS 
(in 20% serum) or (B) 
with serial dilutions of 
LPS-conditioned plasma 
(obtained from whole 
blood after incubation 
with 10 μg/ml LPS) and 
the expression of E-
selectin (open bars) and 
ICAM-1 (hatched bars) 
was measured. Data 
represent mean and SD 
(A: n = 5; and B: n = 4). 
* P < 0.05 versus 
untreated controls. 
 
The calculated LPS concentration at these dilutions was 0.5 and 1.0 
ng/mL, respectively, which were slightly lower than those necessary 
to induce adhesion molecule expression if LPS was added directly to 
the cells.  However, the response to LPS was much more amplified 
when endothelial cells were treated with plasma obtained after 
incubation of whole blood with lower doses of LPS (Figure 2a). 
From a concentration of 10 pg/mL upwards, incubation of LPS with 
whole blood produced plasma that caused a significant and LPS-dose-
dependent increase in the expression of both E-Selectin and ICAM-1 (P 
<0.01). When compared to the minimal LPS dose required for direct 
stimulation of E-Selectin and ICAM-1, which was 1.25 ng/mL, whole 
blood thus amplified the adhesion molecule response to LPS about 
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100 times. Repeated experiments with blood obtained from five 
healthy donors confirmed that the effect depicted in figure 2 did not 
depend on an individual response: in all cases the dose-response 
obtained proved to be reproducible and quantitatively and 
qualitatively quite similar (results not shown). 
Figure 2b illustrates that the production of both TNF-α and IL-1β in 
whole blood also increased with the same range of LPS 
concentrations. A dose of at least 25 pg/mL LPS was required to 
induce significant (P <0.05, one-sided) production of both IL-1β and 
TNF-α, resulting in average concentrations of 109 and 203 pg/mL, 
respectively. Interestingly, less LPS was required to yield plasma that 
significantly increased endothelial CAM expression (Figure 2a). 
Increasing the LPS concentration further enhanced cytokine 
production dose-dependently, resulting in cytokine concentrations up 
to 54 and 35 ng/mL for IL-1β and TNF-α, respectively, after 
incubation with 10 μg/ml LPS. 
In order to establish the incubation time minimally required for LPS 
to produce plasma that would subsequently increase adhesion 
molecule expression, LPS (1 ng/mL) was incubated with whole blood 
for various time periods. One hour of exposure of whole blood to LPS 
was sufficient to yield plasma that significantly increased the 
expression of both E-Selectin and ICAM-1 (P <0.05), while incubations 
longer than 8 h did not produce plasma that could further enhance 
the expression of either adhesion molecule (data not shown). On the 
level of cytokine production in whole blood, 1 h of incubation with 
LPS was sufficient to induce significant (P <0.05) TNF-α 
concentrations, while  8 h were required to significantly (P <0.05) 
increase IL-1β (Figure 3b).  
 
Prevention of adhesion molecule expression induced by LPS-
conditioned plasma   
Since the preceding results are very suggestive for a causal role of 
TNF-α and/or IL-1β in the plasma-induced increase of endothelial 
CAM expression, we investigated if neutralizing antibodies to these 
cytokines could abrogate this effect. For this purpose, plasma from 
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LPS-treated (1 ng/mL) whole blood was preincubated with excess 
anti-IL-1β and/or anti-TNF-α antibodies prior to the incubation on 
HUVECs. Pretreatment with either anti-TNF-α or anti-IL-1β 
significantly inhibited the subsequent upregulation of E-Selectin in a 
moderate, though significant, way (Figure 4a). However, upregulation 
of E-Selectin expression was almost completely prevented by 
pretreatment of plasma with both antibodies simultaneously. On the 
level of ICAM-1 expression the same phenomenon was observed: while 
anti-TNF-α or anti-IL-1β individually hardly affected the expression of 
ICAM-1, pretreatment of plasma with both antibodies together 
inhibited the ICAM-1 response by approximately 80 %. If LPS-
conditioned plasma was pretreated with polymyxin B prior to the 
addition to the cultures, in order to neutralize the influence of any 
residual LPS, the E-Selectin or ICAM-1 response remained unaffected 
(data not shown). The effect of neutralising antibodies was observed 
not only after preincubation with plasma but also if they were added 
to cultures already treated with LPS-conditioned plasma. Figure 4b 
demonstrates that addition of both antibodies together, up until 3 h 
after addition of LPS-conditioned plasma to the cells, could 
significantly reduce the expression of both E-Selectin and ICAM-1. 
A number of compounds that supposedly inhibit LPS, TNF-α and IL-1β- 
induced intracellular signalling pathways were investigated for their 
potential to prevent the induced adhesion molecule expression. The 
effects of preincubating HUVEC cultures for 1 h with increasing doses 
of either N-Acetylcysteine or PDTC prior to the addition of LPS-
conditioned plasma hardly affected the ICAM-1 expression, except at 
the highest doses (Figure 5). The effects on E-selectin were more 
pronounced, especially with PDTC. From a dose of 1 nM upwards, 
PDTC significantly inhibited E-selectin expression and at the highest 
dose used, 100 µM, its induction was prevented almost completely. At 
this latter dose, ICAM-1 expression was also reduced by 40% (Figure 
5b).  
 105
CHAPTER 4 
   
*
* *
*
*
*
* *
*
* *
* * *
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
0 25 100 10exp4
LPS (pg/mL) in whole blood
ad
he
si
on
 m
ol
ec
ul
e 
ex
pr
es
si
on
(4
90
 n
m
)
A
*
*
*
*
*
*
*
*
*
*
*
*
0,01
0,1
1
10
100
0 10 25 50 100 10exp3 10exp4 10exp7
LPS (pg/mL) in whole blood
cy
to
ki
ne
s 
(n
g/
m
L)
B
FIGURE 2. Adhesion molecule expression induced by LPS-
conditioned plasma in relation to LPS-induced cytokine 
production in whole blood: effect of LPS concentration. 
Whole blood was incubated for 18 h with increasing 
concentrations of LPS. The resulting plasma was either added 
(final concentration 20% v/v) to HUVEC cultures in order to 
measure induction of adhesion molecules (A) or used to 
measure cytokine concentrations (B). Data represent mean (n 
= 4) and SD for expression of E-selectin (open bars) and ICAM-
1 (hatched bars) and concentration of IL-1b (open bars) and 
TNF-α (hatched bars) in A and B, respectively. * P < 0.05 
versus plasma from untreated blood. 
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FIGURE 3. Adhesion molecule expression induced by LPS-
conditioned plasma in relation to LPS-induced cytokine 
production in whole blood: effect of LPS incubation time. 
Whole blood was incubated with LPS (1 ng/ml) for 
increasing time periods. The resulting plasma was either 
added (final concentration 20% v/v) to HUVEC cultures in 
order to measure induction of adhesion molecules (A) or 
used to measure cytokine concentrations (B). Data represent 
mean (n = 4) and SD for expression of E-selectin (open bars) 
and ICAM-1 (hatched bars) and concentration of IL-1β (open 
bars) and TNF-α (hatched bars) in A and B, respectively. * P 
< 0.05 versus plasma from untreated blood. 
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This high dose of PDTC did not change the E-Selectin response to 
untreated control plasma nor did it induce gross detachment of cells 
from the culture plate, which could otherwise account for decreased 
expression of adhesion molecules. Interestingly, PDTC remained 
effective in inhibiting E-Selectin expression, even if it was added to 
the cells one hour after LPS-conditioned plasma (Figure 6). 
Thereafter, no effect could be observed and the expression of ICAM-1 
remained entirely unaffected, except if the cells were pre-incubated 
with the drug. 
Pre- and co-incubation of the cultures with either hydrocortisone or 
dexamethasone, in concentrations between 0.1 and 1000 nM, did not 
consistently alter the plasma-induced expression of E-Selectin and 
ICAM-1 (data not shown). Other inhibitors that supposedly inhibit 
TNF-α and IL-1β-mediated intracellular signalling, such as SB203580 
(pyrinidylimidazole, 0.1 – 105 nM) and GF109203X 
(bisindolylmaleimide I, 0.1 – 105nM) only induced a significant 
decrease of plasma-induced E-Selectin and ICAM-1 at doses that were 
obviously toxic to the cultures as observed by the small numbers of 
cells that remained attached to the culture dish (data not shown). 
 
DISCUSSION 
Bacterial LPS is the key initiator of many of the harmful events 
observed in Gram-negative sepsis. During the sepsis syndrome, the 
LPS-induced expression of endothelial CAMs and the subsequent 
activation of leukocytes at sites not involved in the primary infection 
may be crucial for the generation of tisssue damage and organ 
failure, which is associated with increased mortality in septic 
patients.2 Elucidation of the mediators and pathways that are 
involved in LPS-induced E-Selectin and ICAM-1 expression could 
contribute to the development of effective anti-sepsis therapy.17 
Although LPS alone induces large quantities of E-Selectin and ICAM-1 
on HUVEC cultures, a considerably stronger CAM response is achieved 
when LPS is preincubated in whole blood prior to the addition of the 
resultant plasma to the endothelial cells. 
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FIGURE 4. Treatment with cytokine antibodies inhibits adhesion 
molecule expression induced by LPS-conditioned plasma. Data represent 
the mean (n=8) and SD adhesion molecule expression as a percentage of 
that induced by LPS-conditioned plasma [without antibodies (Ctr) = 
100%]. The latter was measured by incubating HUVEC cultures with 
plasma obtained from blood that had been incubated with 1 ng/mL LPS 
for 18 h. Open bars represent E-selectin and hatched bars ICAM-1. A) 
Culture medium containing LPS-conditioned plasma was pre-incubated 
for 1 h with anti-TNF-α, anti-IL-1β or both, prior to the addition to the 
cells. B) Both antibodies were either pre-incubated with culture 
medium containing LPS-conditioned plasma (-1h) or added directly to 
the cells at various time points after addition of the culture medium 
containing LPS-conditioned plasma. * P < 0.05 versus controls. 
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FIGURE 5. Effect of N-Acetylcysteine and PDTC on adhesion molecule 
expression induced by LPS-conditioned plasma. Data represent the 
mean adhesion molecule expression (+ SD, n=4) as a percentage of that 
induced by LPS-conditioned plasma (100%). The latter was measured by 
incubating HUVEC cultures with plasma obtained from blood that had 
been incubated with 1 ng/mL LPS for 18 h. Open bars represent E-
selectin and hatched bars ICAM-1. The effects of N-Acetylcysteine (A) 
and PDTC (B) were measured after adding increasing concentrations of 
either compound in culture medium containing LPS-conditioned plasma 
to the cells. * P < 0.05 versus controls (0). 
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FIGURE 6. Treatment with PDTC inhibits adhesion molecule 
expression induced by LPS-conditioned plasma. Data represent the 
mean adhesion molecule expression (+ SD, n = 6) as a percentage of 
that induced by LPS-conditioned plasma (Ctr = 100%). The latter 
was measured by incubating HUVEC cultures with plasma obtained 
from blood that had been incubated with 1 ng/mL LPS for 18 h. 
Open bars represent E-selectin and hatched bars ICAM-1. PDTC (200 
μM) was added to the cells at various time points in relation to 
addition of the culture medium containg LPS-conditioned plasma (= 
0 h). * P < 0.05 versus controls. 
 
The routing through whole blood amplifies the CAM response to LPS 
approximately 100-fold and requires the addition of picomolar 
concentrations of LPS only, which doses are relevant in sepsis.18 A 
similar effect has been demonstrated previously on HUVECs with 
respect to the expression of the functionally distinct adhesion 
molecule VCAM-1, although considerable differences exist with our 
study regarding culture conditions and whole blood treatment.19 
Pugin et al. have also shown that there is no differerence in the 
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VCAM-1 response between endothelial cultures that are incubated 
with diluted whole blood and LPS and cultures that are incubated 
with plasma resulting from LPS-treated whole blood.19 Furthermore, 
in our studies, pretreatment of LPS-conditioned plasma with 
polymyxin B prior to the addition to HUVECs did not alter the 
adhesion molecule response, indicating LPS did not contribute to the 
induction of E-Selectin and ICAM-1 (data not shown). We have 
recently demonstrated that the permeability response of HUVEC 
monolayers to LPS is also considerably amplified after preincubation 
of LPS in whole blood.20 Taken together, these findings provide 
evidence which supports the thesis that LPS-induced endothelial 
activation is mediated by the production of soluble mediators in 
blood rather than by LPS or cellular interactions. Most likely, CD14-
bearing monocytes mediate this LPS-response.21
Among the cytokines that are supposedly involved in the upregulation 
of endothelial CAMs we have focussed on TNF-α and IL-1β as the 
primary mediators for several reasons. Firstly, considerable amounts 
of these cytokines are produced in whole blood, mostly by CD14-
bearing monocytes, after stimulation with LPS. Secondly, HUVECs 
express receptors for TNF-α (i.e. p55 and p75)22, and for IL-1β (IL-
1R)23, and thirdly, individually these cytokines are potent inducers of 
E-Selectin and ICAM-1 in vitro. Indeed, the graphs for the LPS-induced 
dose- and time-dependent induction of TNF-α and IL-1β in blood 
prove to be quite similar to those for the plasma-induced E-Selectin 
and ICAM-1 expression by HUVECs. Although we have observed some 
differences in the LPS-induced cytokine response between individual 
donors, and also in the subsequent plasma-induced expression of E-
Selectin and ICAM-1 by HUVECs, in general these responses are always 
present after stimulation with LPS in the picomolar range. Still, the 
data do not completely exclude the possibility that individual 
differences in the response to LPS may be relevant.24
Neutralization of both TNF-α and IL-1β in plasma by monoclonal 
antibodies almost completely abrogates the expression of both E-
Selectin and ICAM-1. However, individually, anti-IL-1β and anti-TNF-α 
only marginally inhibit the plasma-induced expression of E-Selectin 
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and ICAM-1, indicating that the induction of endothelial CAMs by 
these two cytokines occurs in an independent manner. Although LPS 
may induce the production of several other cytokines in whole blood, 
such as IFN-γ, IL-2, IL-4, IL-6, IL-8 and IL-10,25,26 the complete 
inhibition achieved with antibodies to IL-1β and TNF-α indicates that 
other soluble mediators play only a minor role in LPS-mediated 
endothelial CAM expression. Similarly, neutralization of plasma IL-1β 
and TNF-α also prevents the LPS-induced endothelial permeability 
and VCAM-1 expression19 which confirms the major role of these 
cytokines in mediating LPS-induced endothelial activation in 
general.20 Although in our model both LPS-induced endothelial CAM 
expression and permeability are mediated by TNF-α and IL-1β, a 
causal relation between these phenomena remains to be 
established.27-29 It may well be possible that they represent separate 
inflammatory reactions of endothelial cells upon indirect stimulation 
with LPS. 
The observation that the expression of E-Selectin and ICAM-1 can be 
inhibited by the administration of antibodies against IL-1β and TNF-α 
up to 3 h after the addition of LPS-activated plasma to endothelial 
cells, is of particular interest. This indicates that continuous exposure 
of endothelial cells to these cytokines may be required for full 
expression of these adhesion molecules. Thus, neutralization of both 
IL-1β and TNF-α may be very effective for the prevention of 
endothelial inflammation and damage during sepsis. The fact that 
TNF-α and IL-1β appear in the circulation within 2 – 8 h after 
induction by LPS, while mitigation of the endothelial response 
remains possible if started within 3 h after the exposure to LPS-
activated plasma, may indicate that only a small time window of 
approximately 6 – 12 h after the exposure to LPS exists to begin 
treatment. While mortality increases with time during the 
development of sepsis, neutralization of both cytokines in a later 
phase is unlikely to be effective because of the decreasing presence 
of IL-1β and TNF-α in the circulation. 
The candidate intracellular signalling pathway for the endothelial 
response to LPS may involve the activation of NF-κB, a cytokine-
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inducible nuclear transcription factor that is involved in the 
expression of many inflammatory genes, including E-Selectin, ICAM-1, 
and various cytokines.30-32 In the present study, preincubation of two 
agents that interfere with NF-κB activation, PDTC and N-
acetylcysteine, inhibit, at least in part, the LPS-conditioned plasma-
induced expression of E-Selectin and ICAM-1 by HUVECs. PDTC is also 
capable of inhibiting E-Selectin expression when added up to 1 h after 
the stimulation of endothelial cells with LPS-activated plasma. The 
fact that IL-1β and TNF-α activity can be inhibited by antibodies up to 
3 h after the addition of LPS-activated plasma suggests that during 
the exposure to IL-1β and TNF-α other intracellular signalling 
pathways are also activated. The observation that PDTC has less 
effect on the expression of ICAM-1 may be explained by the fact that 
(a) peak levels of ICAM-1 normally occur after 18 h of incubation, 
during which PDTC is possibly metabolized and (b) ICAM-1 expression 
may be induced by other pathways than NF-κB.33 However, inhibition 
of other intracellular signalling pathways involved in inflammation, 
such as p38 (MAPK) and PKC, by pre-incubation of endothelial 
cultures with pyrinidylimidazole (SB203580)34 and bisindolylmaleimide 
I (GF109203X)35 respectively, only induce a significant decrease of 
plasma-induced E-Selectin and ICAM-1 expression at doses that are 
obviously toxic and result in gross detachment of cells from the 
culture dish. These findings further emphasize the role of NF-κB as 
the common regulatory pathway for LPS-induced endothelial 
inflammation.30,36-38 The finding that IL-1β and TNF-α together 
predominate in LPS-induced endothelial activation suggests both to 
be logical targets in anti-sepsis strategies and may explain why 
individual neutralization of these mediators has not been very 
successful in the treatment of septic patients.10 Together with in vivo 
results previously obtained by Remick et al39, these in vitro data 
clearly demonstrate that early and simultaneous inhibition of these 
cytokines may still provide a powerful tool to battle the immunologic 
cascade during sepsis. Furthermore, the possible involvement of NF-
κB in mediating the cytokine response points to this intracellular 
messenger as another possible target for immune therapy. 
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ABSTRACT 
 
Aim: To investigate whether the inflammatory response of cultured 
endothelial cells, as induced by conditioned plasma, depends on the 
bacterial species or type of antibiotic used for incubation with whole 
blood. Materials and Methods: Blood from healthy volunteers was 
stimulated ex vivo with different micro-organisms, and with bacteria 
killed with different antibiotics. The resultant plasmas were 
incubated on monolayers of cultured human endothelial cells, 
followed by measurement of their permeability to albumin and 
expression of E-Selectin and ICAM-1. Results: Incubation of 
Escherichia coli in blood yielded plasmas that induced a marked 
increase in endothelial permeability and E-selectin expression. The 
response to Bacteroides fragilis or Enterococcus faecalis was 
generally weaker. Similar effects were observed after incubation of 
whole blood with lipopolysaccharide (LPS). Much of the permeability 
and adhesion molecule response to E. coli remained after removal of 
intact micro-organisms from the culture. Whereas antibiotic 
treatment of E. coli with imipenem or cefuroxime resulted in a 
divergent production of tumor necrosis factor-α (TNF-α) in blood, no 
significant differences between these treatments were observed with 
respect to the plasma-induced endothelial response. Conclusion: 
Bacteria differ in their capacity to generate a whole blood-mediated 
increase of endothelial permeability and adhesion molecule 
expression; this response depends, at least in part, on the presence 
of soluble bacterial components such as LPS. Whereas treatment with 
various antibiotics may generate varying amounts of TNF-α, these 
differences are not translated into differences in endothelial 
permeability or adhesion molecule expression. 
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INTRODUCTION 
 
Systemic activation and damage of the endothelium is a key event in 
the pathogenesis of the sepsis syndrome.1,2 Whereas massive 
destruction of the endothelial barrier results in severe loss of fluid 
from the circulation into the surrounding tissue,3,4 systemic activation 
of the endothelium is characterised by the overexpression of cell 
adhesion molecules, such as E-Selectin (CD62e) and Inter Cellular 
Adhesion Molecule(ICAM)-1 (CD54), and the subsequent recruitment 
of leucocytes at non-infectious locations. Together, these events may 
induce the destruction of healthy tissue and represent a crucial step 
in the development of shock and multi-organ dysfunction.5
The endothelial response to sepsis is believed to be mediated, at 
least in part, by the generation of host-derived pro-inflammatory 
mediators, such as the cytokines tumor necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β), by monocytes and other circulating immune 
cells. The effects of these individual mediators on endothelial cells 
have been studied extensively in vitro. For example, we have 
previously demonstrated that IL-1β and TNF-α cause a dose 
dependent increase of the permeability of human umbilical vein 
endothelial cells (HUVEC) that were cultured on semiporous 
membranes.6
The generation of TNF-α, IL-1β, and other cytokines, is induced after 
the exposure to various Gram-positive and Gram-negative bacteria. In 
ex vivo stimulated whole blood Gram-negative bacteria have been 
shown to be more potent inducers of IL-1β and IL-6 than Gram-
negative organisms.7 In this respect, Escherichia coli was among the 
most potent micro-organisms, while Bacteroides fragilis and 
Enterococcus faecalis, which are also frequently isolated in 
abdominal sepsis, induced a lower cytokine response. These bacteria 
also induced the expression of E-Selectin on endothelial cells in 
vitro.8-10 However, despite the fact that increased plasma cytokine, 
e.g. IL-6, concentrations correlate positively with disease severity 
and mortality in septic patients11, the relationship between bacterial 
capacity to generate cytokines in vitro and the clinical course is less 
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obvious.7 Possibly, such a correlation may exist on the level of the 
endothelial response to bacteria. 
Bacterial cell wall components, or endotoxins have been considered 
key determinants of the inflammatory host response during sepsis. 
They include lipopolysaccharide (LPS) from Gram-negative bacteria, 
and to a lesser extent, their Gram-positive equivalents, lipoteichoic 
acid, and peptidoglycan. Endotoxins like LPS, which are released 
upon phagocytotic- or antibiotic-induced bacteriolysis, are not 
primarily cytotoxic but exert their effect by abusing physiological 
target cell functions to elicit an inappropriate host response.12 
Administration of LPS induces many of the characteristic features 
observed in sepsis. 
LPS also directly acts on endothelial cells through the plasma-
mediated binding and transfer to LPS-binding protein, and sCD14, 
respectively, which is followed by the association of the complex with 
Toll-like receptors (TLRs) present on endothelial cells.2 Activation of 
TLRs may ultimately result in transcriptional induction of pro-
inflammatory genes, including those for E-Selectin and ICAM-1.8 
However, indirect but more powerful activation of the endothelium is 
achieved by the LPS-induced production of IL-1β and TNF-α, that 
result from binding of LPS to the CD14 receptor present on monocytes 
and macrophages.13,14  
LPS may also be generated as a result of antibiotic therapy. Despite 
their undisputed beneficial effect for the treatment of sepsis, 
antimicrobial agents that liberate significant amounts of LPS from 
killed bacteria may induce or intensify the inflammatory host 
response. Numerous studies, predominantly performed in vitro, have 
demonstrated that various antibiotics may act differently in this 
respect.15-20 For example, treatment of E. coli with cefuroxime 
resulted in a marked activity in the Limulus amoebocyte lysate (LAL)-
assay and a significantly increased production of IL-1β and IL-6 in 
blood, when compared to that induced by imipenem.7 A similar 
phenomenon has been reported for IL-6 production by cultured 
endothelial cells,21 but as yet its relevance for further endothelial 
functions has not been investigated. Despite these distinct in vitro 
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effects, the clinical significance of antibiotic-induced endotoxin 
release remains to be clarified.22 Clinical studies, where 
administration of combinations containing -amongst others-  
imipenem and cefuroxime were compared in patients with severe 
acute pancreatitis or intra-abdominal infection, did not reveal any 
difference with respect to mortality.23,24
The potential effects of various bacteria, LPS and individual cytokines 
on endothelial functions have been investigated in vitro.25,26,10 
However, almost invariably the important and regulatory role of 
circulatory cells and mediators, which comprise the normal 
environment of the endothelium, has not been considered. In 
previous studies, we have investigated whole blood-mediated effects 
of LPS on endothelial adhesion molecule expression and 
permeability.27,28 In the present study, we used the same model to 
compare the effect of Gram-negative and Gram-positive bacteria, as 
well as the effect of antibiotic treatment. 
 
 
MATERIALS AND METHODS 
 
Materials 
Culture medium M199 (containing 25 mM HEPES, Earle’s salts, and L-
Glutamate), heat-inactivated newborn calf serum, penicillin-
streptomycin, and trypsin/EDTA were obtained from Life 
Technologies (Paisley, Scotland). Heat-inactivated normal human 
serum was purchased from ICN (Costa Mesa, CA, USA). Culture flasks 
and multi-well tissue culture plates were obtained from Costar 
(Cambridge, MA, USA); collagenase type I (from Clostridium 
histolyticum), pig skin gelatin (type A) was purchased from Sigma 
Chemical (St Louis, MO, USA). A crude fraction of endothelial cell 
growth factors (ECGF) was extracted from bovine brain and kindly 
provided by the Department of Paediatrics, University Medical 
Center, Nijmegen, The Netherlands. Heparin was obtained from Leo 
Pharmaceutical products (Weesp, The Netherlands). Monoclonal 
antibodies against human E-Selectin (clone ENA1) and ICAM-1 (HM2) 
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were a generous gift of Wim Buurman, Department of Surgery, 
University Medical Center, Maastricht, The Netherlands. 
Imipenem/cilastatin (Tienam®) was obtained from Merck Sharp & 
Dohme, Haarlem, The Netherlands, cefuroxime (Zinacef®) was 
obtained from Glaxo Smith Kline, Zeist, The Netherlands, while 
polymyxin B was obtained from Pfizer, Cappelle a/d IJssel, The 
Netherlands. 
 
Culture of microorganisms 
E. coli (ATCC 25922), B. fragilis (ATCC 10584), or E. faecalis (ATCC 
29212) were cultured in brain heart infusion broth, and the number of 
bacteria was adjusted to the required turbidity by reading the optical 
density. Diluted cultures (5 x 106 cfu/mL) were heat-killed (0.5 h at 
56°C) prior to the addition of the bacteria to human whole blood (see 
below). 
 
Whole blood incubation with bacteria or LPS 
A modification of a previously described method was used.29 Briefly, 
blood from healthy volunteers was drawn in a sterile vacuum tube 
(Sherwood Medical, Balleymoney, N.Ireland) containing 50 IU/mL of 
pyrogen-free heparin as anticoagulant. Blood was then divided in 2 
mL aliquots in endotoxin free polypropylene tubes and 10 µL aliquots 
of bacterial suspension (104 - 106 cfu/mL) or control (culture medium 
without bacteria) was added per mL of blood. Subsequently, the 
blood samples were incubated at 37°C for 18 h, and plasma was 
collected by centrifugation and stored at -20°C until use. In separate 
experiments LPS (from E. coli 055:B5; Sigma Chemical, St Louis, MO, 
USA) or control (0.1% BSA) was added to whole blood in a final 
concentration of 10-100 pg/mL and processed likewise. 
 
Antibiotic treatment 
In experiments where the effect of antibiotic treatment was 
investigated, E. coli were grown in TSB medium, diluted in broth to a 
concentration of 5 x 106 cfu/mL in the presence of either cefuroxime 
(80 µg/mL), imipenem/cilastatin (50 µg/mL), or polymyxin B (15 
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µg/mL) for 24 h at room temperature. The final concentrations of the 
antibiotics corresponded to serum peak levels that occur after the 
administration of therapeutic doses in humans. Heat-killed E. coli 
that showed morphological intact bacteria on Gram stain was used as 
control. The antibiotic-treated E. coli cultures were diluted to a final 
concentration of 105 bacteria/mL and incubated in whole blood as 
mentioned earlier. 
 
Isolation and culture of HUVEC 
Endothelial cells were isolated and cultured as described previously, 
with minor modification.30 Fresh umbilical cords were obtained after 
delivery and consent from healthy women at the Department of 
Obstetrics and Gynaecology at our hospital. Briefly, after harvesting 
the cells from the umbilical vein, the isolates were seeded on 
gelatinized culture flasks and cultured in medium M199 containing 
10% newborn calf serum, 10% normal human serum, 50 U/mL 
penicillin, 50 µg/mL streptomycin, 150 µg/mL crude ECGF and 5 
U/mL heparin. All experiments were performed on cells that had 
been subcultured by trypsinization for three times. The endothelial 
origin of the cultures was confirmed by phase contrast microscopy, 
which revealed confluent monolayers that displayed typical 
cobblestone morphology; meanwhile immunocytochemical analysis 
showed positive staining for von Willebrand Factor and CD31 (PECAM-
1). 
 
Incubation of HUVEC with plasma 
Plasma obtained from the whole blood incubations was diluted to 20 
% v/v in medium M199 without serum components, and further 
referred to as “plasma-mix”. For the induction of permeability, 
quadruplet samples of the plasma-mix were added to confluent 
HUVEC grown on Transwell-COL (0.4µm pore diameter size) 
membranes, and incubated for 18 h. For the induction and detection 
of E-Selectin and ICAM-1 quadruplet samples of the plasma-mix were 
incubated for 4 - 6 h, and 24 h, respectively, on HUVEC that were 
grown on gelatinised 96-well dishes. 
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Permeability studies 
The permeability of endothelial cultures was measured as previously 
described.6 Briefly, for detection of macromolecular passage across 
the endothelial monolayers, a tracer solution containing FITC-BSA 
(250 µg/mL) was prepared in complete medium. At the upper 
compartment of the Transwell insert, the plasma-mix was replaced 
by 0.5 mL of the tracer solution, while the volume in the lower 
compartment was replaced with 1.5 mL fresh medium. After 1 and 2 
h of equilibration of the tracer solution, 250 µL samples were drawn 
from the lower compartment and the amount of FITC-BSA in the 
samples was measured on a Hitachi F-3000 fluorescence 
spectrophotometer (Tokyo, Japan), at emission/exitation 
wavelengths of 495/520 nm. In order to allow quantitative 
comparison between multiple experiments, data are expressed as the 
relative increase in the amount of FITC-BSA (when compared to the 
concentration of FITC-BSA measured after a control stimulus run in 
each individual experiment). 
 
ELISA detection of E-Selectin or ICAM-1 
After incubation with plasma-mix, the expression of E-Selectin and 
ICAM-1 was determined by a modified ELISA.31 Briefly, the HUVEC 
cultures were washed with M199 to remove serum components, and 
fixed with a 0.025 % glutaraldehyde solution in phosphate buffered 
saline. The tissue culture plates were then pre-incubated for 1 h at 
37°C with murine monoclonal anti-human E-Selectin (clone ENA1, 
1:1000) or anti-ICAM-1 (clone HM2, 1:1000) in ELISA buffer (0.5 % BSA 
in PBS). After four washing steps, specific binding was detected by 
incubation with HRP-conjugated goat-anti-mouse (1:1000; DAKO, 
Glostrup, Denmark.) for 1 h at 37°C, and enzyme activity was 
analysed by using orthophenyl diamine substrate and measuring the 
optical density at 490 nm on a Bio-Rad 550 plate reader. 
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Detection of TNF-α 
The amount of TNF-α in plasma samples that were used for 
endothelial stimulation were measured by radio-immunoassay as 
described previously.32 The detection limit was 0.04 ng/mL. 
 
Statistical Analysis 
Comparison of different treatments and differences between 
stimulated and control cultures were analysed by one-way ANOVA 
followed by Tukey’s test and Dunnett’s Multiple Comparisons test, 
respectively, using GraphPad InStat ™ v3.05 software. Differences 
were considered statistically significant at P < 0.05. 
 
 
RESULTS 
 
Effects of bacteria and bacterial products 
Incubation of increasing concentrations of heat-killed E. coli (104 – 106 
cfu/mL) in blood produced plasmas that dose-dependently increased 
the amount of FITC-BSA that passed across the endothelial monolayer 
up to a concentration of 7.0 ± 0.5 µg/mL in 2 h, or 183 %, when 
compared to the amount of FITC-BSA that was measured after 
incubating the monolayers with control plasma (plasma obtained from 
blood without bacteria; 3.8 ± 0.6 µg/mL; Figure 1). In contrast, only 
the highest concentrations (106 cfu/mL) of B. fragilis or E. faecalis 
induced a significant permeability increase to 210 % and 155 %, 
respectively. In order to get an impression of the source that induced 
the plasma-mediated permeability response, the different bacterial 
cultures were filter sterilised through a 0.2 µm filter to remove intact 
micro-organisms. Incubation of the filtrates in whole blood produced 
plasmas that elicited a permeability response that was not 
significantly different from that induced by unfiltered cultures. The 
plasmas that were produced by incubating E. coli, B. fragilis or E. 
faecalis in whole blood dose-dependently induced the expression of 
E- 
Selectin (Figure 2a) on endothelial cells, while incubation with  
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FIGURE 1. Permeability response of HUVEC monolayers to plasma 
obtained from blood after incubation with bacteria. Dilutions of 
heat-killed E. coli (black bars), B. fragilis (dotted bars), or E. 
faecalis (hatched bars) were added to whole blood at final 
concentrations in the range 104 to 106 cfu/mL. Culture dilutions of 
105 cfu/mL were also filter sterilized (FS) prior to the incubation in 
blood. Bars represent mean + sem (n = 4) relative increase of the 
permeability to FITC-BSA, as compared with that induced by control 
plasma (i.e. plasma obtained from whole blood treated with culture 
medium without bacteria). Asterisks depict significant differences 
(P< 0.05) with control plasma (= 100 %). 
control plasma did not induce significant adhesion molecule 
expression (not shown). The magnitude of the E-Selectin response 
increased from E. faecalis to B. fragilis to E.coli. While E. faecalis 
also induced the weakest ICAM-1 response, all concentrations of E. 
coli and B. fragilis induced a marked and almost similar level of 
ICAM-1 expression (Figure 2b). Removal of intact bacteria by filter 
sterilization prior to the incubation in blood completely abrogated 
the adhesion molecule response to E. faecalis and reduced the ICAM-1 
response to B. fragilis, while the response to E. coli remained 
unaffected. 
These bacterial strains also differed in their capacity to induce TNF-α 
production in whole blood: E. coli (104 - 106 cfu/mL) induced a dose-
dependent production of TNF-α in whole blood up to 10.6 ng/mL, 
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while only the highest concentration of both B. fragilis and E. faecalis 
induced measurable amounts of TNF-α, of 11.1 ng/mL and 1.0 ng/mL, 
respectively. Furthermore, the TNF-α response to E. coli was hardly 
affected by filter sterilization of the culture prior to the incubation in 
whole blood (data not shown). 
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FIGURE 2. Effect of different bacteria on whole blood-induced E-
Selectin and ICAM-1 expression. For further explanations, see 
legends to Figure 1. Bars represent the mean + sem (n = 4) E-
selectin (A) and ICAM-1 (B) expression by HUVEC. 
 
 
 129
CHAPTER 5 
 
Plasma obtained from whole blood that had been exposed to heat 
killed E. coli thus significantly increased the permeability of HUVEC 
monolayers and endothelial adhesion molecule expression, while 
these responses were weaker after stimulation with E. faecalis and B. 
fragilis. Furthermore, the response to E. coli was maintained when 
intact micro-organisms were removed from the culture, suggesting 
that soluble components, such as LPS, are instrumental for these 
phenomena. 
 
Effects of LPS 
In separate experiments, the effect of incubation of low doses of LPS 
in blood on endothelial permeability and adhesion molecule 
expression was examined. As depicted in figure 3a, blood that had 
been treated with as little as 25 pg/mL of LPS produced plasma that 
induced a significant (P < 0.05) permeability increase when compared 
to that induced by control plasma, and the response was dose 
dependent over a range up to 100 pg/mL LPS. On the level of 
adhesion molecule expression, doses as low as 10 pg/mL of LPS in 
blood were sufficient to induce significant (P < 0.05) expression of 
both E-Selectin and ICAM-1 (Figure 3b). 
 
Effect of antibiotics on cytokine production 
In order to investigate if antibiotic killing of bacteria would lead to 
increased cytokine production, E. coli (105 cfu/mL) were incubated 
for 24 h with either polymyxin B (15 μg/mL), imipenem (50 μg/mL), 
or cefuroxime (80 μg/mL) prior to the addition to whole blood. All 
antibiotics adequately killed the E. coli, which was confirmed by the 
absence of viable bacteria in subcultures. In whole blood, bacteria 
treated with antibiotics, as well as heat-killed bacteria induced 
measurable amounts of TNF-α (Figure 4). However, large differences 
were present in the cytokine levels produced. When compared to 
heat-killed bacteria, which induced the production of 4.7 ± 1.6 ng/mL 
of TNF-α, both imipenem and cefuroxime treatment further increased 
the production to 6.9 ± 2.0 ng/mL (n.s.) and 10.4 ± 1.7 ng/mL (P < 
0.05), respectively. In contrast, polymyxin B treatment resulted in a 
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four-fold reduction of the TNF-α response, when compared to that 
induced by heat-killed bacteria. The inhibitory effect of polymyxin B 
was also present when this antibiotic was added to heat-killed 
bacteria, while the addition of imipenem or cefuroxime to heat-killed 
bacteria did not alter the TNF-α response. Similar, but non-significant 
effects were observed for the production of IL-1β (data not shown). 
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FIGURE 3. Effect of LPS on whole blood-induced endothelial 
permeability and adhesion molecule expression. Blood of four donors was 
incubated separately in four-fold. Data are represented as the mean 
(n=16) ± sem. (A): relative increase in permeability as compared with the 
response to control plasma (unconditioned plasma obtained from the 
same donor; (B): Expression of E-Selectin (hatched bars) and ICAM-1 
(black bars). Asterisks denote significant (P < 0.05) differences with 
control plasma. 
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FIGURE 4. The effect of antibiotic killing on TNF-α production. Viable E. 
coli (105 cfu/mL, open bars) were killed by polymyxin B (PolyB, 15 μg/mL), 
imipenem (IPM, 50 μg/mL), or cefuroxime (CXM, 80 μg/mL) and incubated 
in whole blood. Incubation of whole blood with heat-killed (HK, black 
bars) bacteria, or with heat-killed bacteria with subsequent antibiotic 
treatment (hatched bars), as well as untreated blood (C, grey bar) was 
used for comparison. Data are represented as the mean + sem of four 
repeat experiments. Asterisks denote a significant (P < 0.05) difference 
with heat-killed bacteria. 
 
Effects of antibiotics on endothelial function 
In order to examine if the antibiotic-induced differences in whole 
blood TNF-α production would be translated into altered endothelial 
function, HUVEC monolayers were exposed to the resultant plasmas. 
When compared to the effect of untreated control plasma, incubation 
of polymyxin B-, imipenem-, cefuroxime treated E. coli in blood all 
produced plasmas that significantly increased the permeability 
(Figure 5a), while addition of antibiotics without bacteria to whole 
blood or to endothelial monolayers had no effect on the permeability 
(data not shown). The permeability response to imipenem- and 
cefuroxime-treated bacteria was not significantly different from that 
induced by heat-killed bacteria. On the other hand, the response to 
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FIGURE 5. Effect of antibiotic killing on endothelial responses. Permeability 
(A): viable (open bars), and heat-killed (HK, hatched bars), E. coli were 
treated with polymyxin B (PolyB), imipenem (IPM), or cefuroxime (CXM) 
prior to the addition to whole blood (final concentration: 105 cfu/mL). The 
effect of the resultant plasmas on endothelial permeability was compared to 
that induced by plasma obtained from blood incubated with heat-killed 
bacteria without antibiotic treatment (black bar) and untreated control 
plasma (C, grey bar) and are represented as the mean ± sem (n = 16) relative 
increase of the permeability to FITC-BSA. Data were collected from four 
repeat experiments. (B) E-Selectin (hatched bars) and ICAM-1 (black bars) 
expression: data were collected from three repeat experiments and are 
represented as the mean ± sem (n = 12) optical density (OD 490 nm). Data 
were collected from three repeated experiments. Asterisks mark significant 
differences (P < 0.05) from the response elicited by heat-killed bacteria. 
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polymyxin B treated E. coli was approximately 50 % of that induced 
by heat-killed bacteria. This blunted response was also observed 
when polymyxin B was added to heat-killed cultures prior to the 
incubation in whole blood. The addition of imipenem or cefuroxime 
to heat-killed bacteria had no influence in the permeability response, 
when compared to that induced by heat-killed bacteria without 
antibiotics. 
The effects observed in endothelial permeability were also present 
for endothelial adhesion molecule expression (Figure 5b). Antibiotic 
or heat-killed E. coli produced plasmas that strongly induced the 
expression E-Selectin and ICAM-1 on HUVEC. However, again no 
significant differences were present between heat-killed, imipenem 
and cefuroxime treated bacteria, while a significant reduction of the 
E-Selectin response was induced by polymyxin treated E. coli. On the 
level of ICAM-1 expression, incubation of plasmas that were obtained 
from the different whole blood treatments resulted in small and non-
significant differences, when compared to the effect induced by 
heat-killed bacteria. 
 
 
DISCUSSION 
 
The incubation of different micro-organisms with whole blood results 
in the generation of plasmas that differ in their capacity to induce 
endothelial permeability, E-Selectin, and ICAM-1 expression. 
Furthermore, this endothelial response to bacteria roughly correlates 
with the levels of TNF-α produced in whole blood, and to the number 
of bacteria added. Incubation of HUVEC monolayers with plasma 
obtained from E. coli treated whole blood generally induced a 
stronger permeability and adhesion molecule response than that 
induced by B. fragilis, whereas weak effects were measured after 
incubation with E. faecalis. These different responses were also 
reflected in the production of TNF-α (this study) and various other 
cytokines, including IL-1β and IL-6, in whole blood.7 These 
observations in a relevant ex vivo model suggest that Gram-negative 
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infections with high cytokine induction may lead to a more acute and 
more severe clinical picture than infection with Gram-positive 
bacteria. However, Frieling, et al. showed that this relation is less 
obvious.7 It remains to be determined if micro-organisms that induce 
less cytokines but a serious clinical picture, such as Capnocytophaga 
canimorsus, are capable of inducing a strong endothelial permeability 
and adhesion molecule response. The observation that removal of 
intact micro-organisms from E. coli cultures, prior to incubation with 
whole blood, did not alter the permeability and adhesion molecule 
response, additionally proves that the inflammatory response to 
bacteria largely depends on the availability of soluble bacterial 
components, such as LPS.12
Incubation of bacteria in blood yielded plasma that increased 
adhesion molecule expression, sometimes even in the absence of 
measurable levels of plasma TNF-α, as was the case for lower 
concentrations of B. fragilis and E. faecalis. This finding indicates 
that in addition to TNF-α at least one other mediator must be 
responsible for regulating the endothelial responses. Despite the 
possible involvement of other bacterial components and host 
mediators, we propose that IL-1β is the other major molecule 
involved in this phenomenon. In previous studies it was demonstrated 
that, next to TNF-α, plasma IL-1β is instrumental in the induction of 
endothelial permeability, E-Selectin and ICAM-1 by LPS-stimulated 
whole blood.27,28
It has been demonstrated that different antibiotics can liberate 
widely ranging concentrations of LPS from bacterial cultures.15,17,19 
These variations in LPS-liberating potential may result in different 
production of TNF-α by monocytes16 or in whole blood.18 The clinical 
significance of this phenomenon remains to be established.22,33 In a 
murine sepsis model antibiotics significantly differed in their capacity 
to reduce mortality, but without changing the kinetic appearance of 
pro-inflammatory cytokines and LPS in plasma.20
The notion that the type of antibiotic, and thus its LPS (and TNF-α) 
generating capacity, may determine the inflammatory response to 
bacteria, and that this phenomenon may also be present on the level 
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of endothelial cells, was supported by two results from the present 
study. Firstly, soluble components in E. coli cultures seemed to be 
responsible for the induction of endothelial permeability and 
adhesion molecule expression, as was demonstrated by the effects of 
filter sterilized microbial cultures. Secondly, small differences in 
physiologically relevant concentrations of purified LPS in blood (of 
the same E. coli strain) yielded plasmas that induced different 
endothelial responses. In order to address the question if antibiotics 
differ in their capacity to ultimately induce endothelial permeability 
and adhesion molecule expression we have examined the effects of E. 
coli killed by three antibiotics that are supposed to have different 
LPS-generating capacity.7 Although differences between cefuroxime, 
imipenem, and polymyxin B treated E. coli were present on the level 
of TNF-α production in whole blood, imipenem or cefuroxime-treated 
E. coli induced a similar plasma-mediated permeability increase and 
adhesion molecule expression. In fact, the endothelial responses to 
imipenem and cefuroxime killed E. coli were not significantly 
different from that induced by heat-killed bacteria. On the other 
hand, polymyxin B treatment largely prevented the E. coli induced 
cytokine and endothelial responses, confirming the important role of 
LPS and the LPS-neutralizing capacity of polymyxin B. 
In this and and previous studies we have demonstrated that 
cefuroxime killed E. coli induced more TNF-α, IL-1β and IL-6 in blood 
than imipenem killed E. coli. Cefuroxime also induced increased 
activity of the culture supernatant in the LAL-assay, which indicated 
an increased production of bacterial fragments by this antibiotic.7 We 
have also previously demonstrated that TNF-α and IL-1β mediated the 
permeability and adhesion molecule response to LPS-treated whole 
blood.27,28 On the basis of these findings one might expect a 
difference between (classes of) antibiotics in their capacity to induce 
endothelial responses. However, the present results indicate that the 
initial antibiotic-dependent differences that occur on the level of 
cytokine (e.g. TNF-α) production in blood are not translated into 
endothelial permeability and adhesion molecule expression. One 
might still argue that the amount of TNF-α and other mediators that 
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are produced in blood upon a bacterial challenge would already 
exceed the levels that are required for maximum stimulation of 
endothelial cells. However, this seems unlikely since, in the present 
experiments, approximately two-fold permeability increases were 
observed over control values, while we have previously demonstrated 
the occurrence of approximately 10-fold increases, using high 
concentrations of LPS in whole blood.27  
In conclusion, our data do not support the opinion that the choice of 
antibiotic for the treatment of sepsis should mainly depend on its 
LPS-liberating properties.34,22,35 It remains to be clarified if the 
plasma-mediated endothelial responses to antibiotic killed bacteria 
are also prevented by neutralization of IL-1β and TNF-α. It is entirely 
possible that factors other than LPS that are released by E. coli 
explain the lack of a difference that is observed after cefuroxime and 
imipenem treatment. 
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ABSTRACT 
 
Objective: The aim of this study was to elucidate the time course of 
the permeability response of endothelial monolayers after exposure 
to plasma obtained from lipopolysaccharide (LPS)-treated human 
whole blood; to investigate the role of apoptosis in monolayer 
permeability; and to inhibit the permeability increase, particularly 
after addition of the plasma stimulus. 
Design: Human umbilical vein endothelial cells (HUVEC) were cultured 
on semi-porous membranes and the permeability for albumin was 
measured after exposure, according to different schedules, to LPS-
conditioned plasma. Apoptotic HUVEC were measured by both flow 
cytometry and ELISA. A variety of agents, including antibodies against 
cytokines, inhibitors of NF-κB, and a caspase inhibitor, were added to 
HUVEC, either prior to or after the stimulus. 
Results: A maximum increase of the permeability was achieved after 
4 – 6 h of exposure to LPS-conditioned plasma. This response was not 
accompanied by an increase in the number of apoptotic HUVEC. 
Administration of antibodies against both Tumor Necrosis Factor-α 
(TNF-α) and Interleukin-1β (IL-1β) to HUVEC within 1 h after 
stimulation significantly reduced the permeability increase. Similarly, 
pyrollidine di-thiocarbamate (PDTC), but not N-acetylcysteine, could 
prevent the permeability response, and was still effective when 
added within 2 h after LPS-conditioned plasma. 
Conclusions: The TNF-α/IL-1β signal present in LPS-conditioned 
plasma appears to increase endothelial permeability through 
intracellular pathways that very likely involve the activation of NF-
κB. Although post-stimulatory inhibition of the permeability response 
proves to be possible with agents such as PDTC, the window of 
opportunity appears very small if placed in a clinical perspective. 
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INTRODUCTION 
 
During severe sepsis and shock, endothelial barrier dysfunction causes 
massive leakage of fluid and components from the circulation into the 
surrounding tissue (systemic edema), severe hypotension, and organ 
hypoperfusion. These serious conditions may lead to the multiple 
organ dysfunction syndrome (MODS), which causes substantial 
mortality among septic patients.1  The critical role of the endothelial 
barrier in the pathogenesis of Gram-negative sepsis and associated 
syndromes thus has made it a valid target for prevention and 
treatment.2,3
Bacterial lipopolysaccharide (LPS), and in particular its lipid A 
component, appears to be a key initiator of endothelial barrier 
dysfunction during sepsis. After exposure to LPS, endothelial cells 
undergo several functional and morphological changes, such as cell 
contraction, disruption of inter-endothelial junctions, and loss of 
focal contacts with the underlying extracellular matrix.4 In addition, 
it has been demonstrated that LPS may also induce distinct apoptotic 
signalling pathways in endothelial cells, which would disrupt the 
integrity of the endothelial barrier.5 These direct actions require 
relatively high concentrations of LPS that have been infrequently 
observed in septic patients. The endothelial response to smaller 
amounts of LPS presumably occurs through the production of pro-
inflammatory cytokines and other mediators produced by blood 
monocytes and tissue macrophages,6 after activation of their Toll-like 
receptors.7  
The effect of LPS on endothelial permeability is widely studied in 
various animal models of sepsis,8,9 but human studies are few and 
limited to very low LPS doses.10 However, human whole blood treated 
ex vivo with LPS constitutes a relevant pool of cytokines and other 
inflammatory mediators, and remains a valuable and common tool in 
sepsis-related research.11,12 Addition of plasma obtained from LPS-
treated whole blood (and further referred to as “LPS-conditioned 
plasma”) to monolayers of cultured human umbilical venular 
endothelial cells (HUVEC) increases their permeability13 and their 
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expression of cell adhesion molecules (CAMS).14 This system can be 
considered as an in vitro model for the compromised endothelial 
(barrier) function observed in septic patients. As such, it allows 
investigations into the efficacy of various agents to prevent or reduce 
the plasma-induced permeability. In a prior experiment it was 
established that treatment of LPS-conditioned plasma with excess 
antibodies against both tumor necrosis factor-alpha (TNF-α) and 
interleukin-1beta (IL-1β), prior to its incubation on HUVEC, can 
prevent the permeability increase otherwise observed.13 This raises 
the question if intervention at a later stage, i.e. after addition of 
LPS-conditioned plasma to the cell layer, would also be effective. In 
this respect, not only the possible effect of specific antibodies is of 
interest but also that of agents that act against the intracellular 
pathways induced by TNF-α and/or IL-1β. This particularly targets 
nuclear factor-kappa B (NF-κB), a cytokine inducible transcription 
factor that is involved in the regulation of various pro-inflammatory 
genes, and that has been recognized as a treatment option for 
sepsis.15,16 It was demonstrated recently that pyrollidine di-
thiocarbamate (PDTC), an agent that supposedly interferes with the 
activation of NF-κB, can modulate CAM expression on endothelial 
cells after induction by LPS-conditioned plasma.14 A protective effect 
of PDTC has also been demonstrated in vivo in LPS-treated rats, 
where it prevents increases in microvascular permeability.17
In the present study, we have investigated the time course of the 
permeability response of HUVEC monolayers to LPS-conditioned 
plasma and the possibility that apoptosis is a mechanism which 
contributes to this phenomenon. Subsequently, we have examined 
the potential of both antibodies against TNF-α and IL-1β, and of PDTC 
to modulate the permeability response after addition of LPS-
conditioned plasma to the endothelial monolayer. 
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MATERIALS AND METHODS 
 
Materials 
Culture medium M199 (containing 25 mM HEPES, Earl’s salts, and L-
Glutamate) and heat-inactivated newborn calf serum, penicillin-
streptomycin, and trypsine/EDTA were obtained from Life 
Technologies (Paisley, Scotland). Heat-inactivated normal human 
serum was purchased from ICN (Costa Mesa, CA, USA). A crude 
fraction of endothelial cell growth factors (ECGF) was extracted from 
calf brain, and kindly provided by the Department of Paediatrics, 
University Medical Center Nijmegen, the Netherlands. Culture flasks, 
dishes, and multiwell tissue culture inserts containing collagen pre-
coated PTFE-membranes (Transwell-COL, 0.4 µM pore diameter, ± 1 
cm2 growth area) were obtained via Corning B.V. Life Sciences, 
Schiphol-Rijk, The Netherlands. Neutralising antibodies to human 
TNF-α and IL-1β (clone 1825 and 8516, respectively) were obtained 
from R&D Systems, Abingdon, UK. According to the manufacturer, 100 
ng/mL of anti-IL-1β and anti-TNF-α completely neutralised the 
bioactivity of 50 and 250 pg/mL of recombinant human IL-1β and 
TNF-α, respectively. 
 
Preparation of microporous membranes and cell seeding 
Endothelial cells were isolated from umbilical cords as described 
previously.18 Approximately 105 HUVEC/cm2 in 0.5 mL of serum-
completed medium were seeded at the upper (or luminal) side of the 
tissue culture inserts, while 1.5 mL of medium was added to the 
lower (or abluminal) compartment of the 12-well culture dishes. Both 
compartments were frequently replenished with fresh culture 
medium. Cultures were grown for five days, when confluence was 
confirmed through phase contrast microscopy. 
 
Incubation of monolayers with LPS conditioned plasma 
LPS-conditioned plasma was prepared as described previously.13 
Briefly, E. coli LPS (055:B5) was added to heparinised human whole 
blood in a final concentration of 1 ng/mL and incubated for 18 h at 
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37°C. Plasma and diluted to 20% v/v in culture medium without 
serum components, and incubated at 37° C on the luminal side of the 
tissue culture insert. In experiments where the time course of the 
permeability response was investigated, incubation with LPS-
conditioned plasma was preceded or followed by incubation with 
untreated control plasma of the same donor, at different time 
intervals. Plasma of the same donors was used throughout the 
experiments. Our previous study demonstrated that the response of 
HUVEC to plasma obtained from these donors was essentially 
similar.14
 
Intervention studies 
Neutralising antibodies to human TNF-α and IL-1β were diluted in 
M199 and added directly to the cultures at various time points after 
the addition of LPS-conditioned plasma, at a final concentration of 1 
mg/mL. In addition, LPS-conditioned plasma was pre-incubated with 
these neutralising antibodies for 1 h at 37° C, prior to the incubation 
of the mixture on the cultures, and served as a control. 
The following chemical compounds were tested individually on the 
capacity to inhibit plasma-induced endothelial permeability: 
Pyrollidine dithiocarbamate (PDTC), N-Acetylcysteine (NAC), both 
obtained from Sigma, and benzyloxycarbonyl-Val-Ala-Asp (OMe) 
fluoromethylketone (Z-VAD-fmk, R&D systems, Abingdon, UK). These 
compounds were diluted in complete medium and either pre-
incubated on the cultures for 1 h prior to the addition of LPS-
conditioned plasma, or added together with LPS-conditioned plasma. 
In case of significant inhibitory effects of pre- or co-incubation of 
these agents, intervention studies were performed where the 
compound was added to the cultures at various time points after the 
stimulation with LPS-conditioned plasma. 
 
Permeability measurement 
For detection of macromolecular passage across the Transwell culture 
inserts, a tracer solution containing FITC-BSA (250 µg/mL) was 
prepared in complete medium. At the upper side of the monolayer, 
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culture medium was replaced by 0.5 mL of the tracer solution. After 
1 and 2 h of incubation, duplicate 100 µL samples were drawn from 
the lower compartment and transferred to 96-well microtiter plates. 
For the detection of FITC-BSA, microtiter plates were read on a 
Wallac Victor II plate reader (Perkin Elmer, Boston, MA, USA) at 
emission and excitation wavelengths of 490 and 520 nm, respectively. 
In general, samples drawn 2 h after the start of the assay showed less 
variation in the concentration of FITC-BSA than samples drawn after 1 
h. In order to allow quantitative comparison, the 2 h data are 
presented, and expressed as relative permeability (with respect to a 
control stimulus run in each individual experiment). 
 
Apoptosis assay 
For the detection of endothelial cell death HUVEC cultured on 
gelatinized 6-well dishes were analysed for Annexin-V-FITC binding 
using a previously described method.19 Briefly, after incubation with 
stimulus, a pool of cells that contained both detached and 
(trysinized) adherent cells was incubated in the dark with 1% v/v 
FITC-conjugated Annexin-V (2 µg/mL, Bender Medsystems, Vienna, 
Austria) and 10 % v/v propidium iodide (PI, 100 µg/mL, Calbiochem) 
for 10 min on ice. Cells were analysed on a Coulter® Epics® XL-MCL 
cell sorter. Necrotic cells were defined as cells demonstrating 
positive staining for both Annexin-V-FITC and PI, while apoptotic cells 
were Annexin-V-FITC-positive and PI-negative. Viable cells were 
defined as double negative for both stains. Fluorescence of 5000 
events per sample was expressed on a double parameter histogram 
using log scales. 
 
Cell death detection assay 
A cell death detection ELISA (Roche Diagnostics GmbH, Mannheim, 
Germany) that determines cytoplasmic histone-associated DNA 
fragments was performed on plasma-stimulated and control HUVEC 
cultured on gelatinized 96-well microtiter plates according to the 
manufacturers manual, and absorbance of the samples was read at 
405 nm on a BioRad microtiter plate reader. 
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Statistical Analysis 
Comparison of different treatments and differences between 
stimulated and control cultures were analysed by one-way ANOVA 
followed by Tukey and Dunnett Multiple Comparisons Test, 
respectively, using GraphPad Prism version 4.00 for Windows, 
GraphPad™ Software, San Diego California USA.  
 
 
RESULTS 
 
Effect of LPS-conditioned plasma on endothelial 
permeability 
Under non-stimulated conditions (i.e. incubation with untreated 
control plasma), over a 2-h period the HUVEC monolayers allowed the 
passage of FITC-BSA from the upper compartment (250 µg/mL) into 
the lower compartment to a concentration of 4.1 ± 0.4 µg/mL (range 
1.6 – 7.7 µg/mL), or 6.6 % of the calculated equilibrium 
concentration. Incubation with plasma obtained from whole blood 
that was treated with 1 ng/mL of LPS resulted in the generation of 
plasma that always induced a significant increase (on the average 
80%) of the FITC-BSA concentration in the lower compartment. 
However, between the experiments considerable variations existed in 
the amount of FITC-BSA that passed the monolayer both under basal 
and stimulated conditions. In order to allow comparison between 
multiple experiments, in each experiment the response to 
unstimulated control plasma and LPS-conditioned plasma was set at 0 
and 100 %, respectively. 
 
Time course of the permeability response to LPS-conditioned 
plasma 
LPS-conditioned plasma was added to the HUVEC monolayer for 
periods of 0.5 – 24 h, immediately prior to the permeability analysis 
(Figure 1a). Incubations for 2 h induced a significant permeability 
increase, while more than 4 h was required to reach maximum 
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permeability. In a second experiment, LPS-conditioned plasma was 
added and subsequently replaced by control plasma at different time 
intervals over a 6 h period, prior to the permeability assay (Figure 
1b). If compared to continuous exposure for 6 h, replacement of LPS-
conditioned plasma after 1 h or 2 h with control plasma resulted in a 
half-maximal, though significant, rise in the permeability. 
Replacement of LPS-conditioned at or later than 3 h after the start of 
the incubation did not affect the permeability response. Finally, 
endothelial cultures were exposed to a submaximal 2-h stimulus with 
LPS-conditioned plasma followed by incubation with control plasma 
for extended periods, to a maximum of 22 h, prior to the 
permeability assay. As shown in figure 1c, the permeability increase 
to a 2 h stimulus with LPS-conditioned plasma reached maximum 
levels approximately 6 h later. Interestingly, at later stages the 
permeability response gradually decreased over time toward control 
levels. 
 
Role of apoptosis 
While serum starvation induced a marked increase of double-positive 
(dead) and Annexin-V only-positive (apoptotic) cells, endothelial 
cultures exposed to LPS-conditioned plasma did not reveal increased 
numbers of Annexin-V- and propidium iodide-positive cells if 
compared to cultures exposed to untreated control plasma (Table 1). 
Cell death was also analysed by an ELISA which measures the amount 
of cytoplasmic histone-bound DNA fragments (Figure 2). Again, cell 
cultures exposed to serum-free medium showed a high level of cell 
death. Lower, but still highly significant, levels of histone-bound DNA 
fragments were generated by incubation with either control plasma 
(OD 0.96 ± 0.08) or LPS-conditioned plasma (OD 1.17 ± 0.06). The 
generation of cytoplasmic DNA in both control and stimulated 
cultures was prevented almost completely by the presence of the 
apoptosis inhibitor Z-VAD-fmk. 
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FIGURE 1. Stimulation of endothelial permeability by LPS-conditioned 
plasma. HUVEC monolayers are incubated with LPS-conditioned 
plasma and albumin permeability is expressed relative to that 
induced under reference conditions (black bars). Data represent mean 
+ sem (n = 4) (A) Effect of increasing incubation times. (B) Effect of 
replacing LPS-conditioned plasma with control plasma after various 
time periods. (C) Effect of increasing incubation time with control 
plasma after a 2 h incubation with LPS-conditioned plasma. * P < 0.05 
versus incubation with control plasma (CP) alone. 
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TABLE 1. Effect of LPS-conditioned plasma on cell death of HUVEC. 
 Dead (%) Apoptotic (%) 
 Exp 1 Exp 2 Exp 1 Exp 2 
Serum free medium 29 40 21 38 
Culture medium 12 12 13 13 
Control plasma 5 6 16 19 
LPS-conditioned plasma 4 4 13 14 
Cells were incubated for 6 h with various media prior to analysis 
with flow cytometry. Data are derived from two independent 
experiments and represent the relative amount of positive cells 
(5000 events). 
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FIGURE 2. Endothelial cell death after exposure to LPS-
conditioned plasma. Data represent the absorbance (OD) 
value (n = 2) as a measure of cytoplasmic histone-bound DNA 
fragments in HUVEC cultures incubated for 6 h with serum-
free medium (M199), with 20 % control plasma (CP), and with 
20 % LPS-conditioned plasma (LPSCP). Cells were also pre-
incubated with the apoptosis-inhibitor Z-VAD-fmk. 
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Intervention studies with antibodies against IL-1β and TNF-α 
The permeability increase, induced by incubation with LPS-
conditioned plasma, could almost be completely prevented if the 
plasma was preincubated with antibodies against both TNF-α and IL-
1β (Figure 3). If the antibodies were added to the culture medium 30 
min after LPS-conditioned plasma, the increase in permeability could 
still be significantly reduced, to 47 % (P < 0.05) of the maximal 
response. If the antibodies were added at a later time point, average 
permeability was still somewhat reduced, although not significantly 
so. 
 
Effects of inhibitors of apoptosis and intracellular signalling 
pathways 
Pre- and co-incubation with the apoptosis inhibitor Z-VAD-fmk (100 
µM) or the anti-oxidant NAC (100 µM) did not affect the permeability 
response induced by LPS-conditioned plasma (data not shown). On the 
other hand, the addition of PDTC at a final concentration of 100 µM 
or more to endothelial monolayers prior to stimulation by LPS-
conditioned plasma almost completely prevented the permeability 
response (Figure 4a). Addition of PDTC (200 µM) to cultures up to 1 h 
after the stimulation with LPS-conditioned plasma significantly 
reduced the permeability response to approximately 48 %, while later 
additions of PDTC resulted in non-significant reductions of the 
permeability response, ranging from 64 – 88 % when compared to the 
effect induced by LPS-conditioned plasma alone (Figure 4b). 
 
 
DISCUSSION 
 
Model investigations into mediator-induced endothelial permeability 
may help understand the pathways and indicate means for prevention 
of systemic oedema and shock in septic patients. Such investigations 
require the exposure of endothelial cells to a relevant pool of 
inflammatory mediators, rather than to single molecules.
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FIGURE 3. Stimulation of endothelial permeability by LPS-
conditioned plasma: prevention by antibodies against TNF-α and IL-
1β. HUVEC monolayers are incubated with LPS-conditioned plasma 
(LPSCP) for 6 h and at various time points both antibodies are added. 
Data (mean + sem, n = 8) depict the permeability relative to that 
induced by LPSCP (black bar) alone (= 100 %) and to that induced by 
control plasma (CP, 0 %). * P < 0.05 versus LPSCP. 
 
So far, in most in vitro studies where endothelial permeability has 
been examined, the permeability response was measured after 
stimulation with single inflammatory mediators, including LPS 4 and 
TNF-α 20, but seldom a relevant combination of these mediators, such 
as present in LPS-stimulated whole blood. Furthermore, while 
examination of the time course of the permeability response to 
individual mediators, such as LPS or cytokines has been quite 
superficial, it has not previously been studied in the case of LPS-
stimulated whole blood. The latter system has been used widely as a 
model to investigate the production of inflammatory mediators during 
sepsis.21
At least 2 h of continuous exposure to LPS-conditioned plasma is 
required to induce a significant increase of endothelial monolayer 
permeability, and it reaches maximum levels 4 - 6 h after the start of 
the incubation. This result corresponds quite well to observations in 
studies where LPS was added alone to cultured endothelial cells 22,23 
and to studies where LPS was infused in vivo in animals.24
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FIGURE 4. Effect of PDTC on endothelial permeability induced by 
LPS-conditioned plasma. Data (mean + sem, n = 8) depict the 
permeability relative to that induced by LPS-conditioned plasma 
(LPSCP, black bars) alone (100% reflects increase versus incubation 
with control plasma, CP). (A) PDTC (10-103 µM) is added to the to 
the cultures 1 h prior to LPSCP. (B) Effect of administration of 200 
µM PDTC at various time points in relation to the addition of LPSCP 
(at 0 h). *  P < 0.05 versus LPSCP. 
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However, a significant permeability increase has not been reported in 
studies where healthy volunteers were exposed to single infusions of 
LPS.25 This apparent discrepancy may be explained by the fact that 
human studies only allowed the administration of low (and often 
single) doses of LPS, in contrast to the lethal doses often used in 
animals. It is conceivable that infusion with (single) low doses of LPS 
results in a short and submaximal raise in the plasma levels of various 
cytokines and other inflammatory host mediators, but insufficient to 
alter endothelial barrier function. In our model, short exposures (< 2 
h) to LPS-conditioned plasma (followed by incubation with control 
plasma) did not significantly increase the permeability, which agrees 
with the in vivo observations in humans. It has been shown that direct 
stimulation of endothelial permeability requires up to several ng of 
LPS,18,26 depending on the species and origin of the endothelial cells. 
In our experiments, a direct effect of LPS on the permeability seems 
unlikely, since the estimated amount of LPS in the plasma dilutions is 
approximately 0.2 ng, and maybe even lower, since LPS was pre-
incubated for 18 h in whole blood, prior to the addition of plasma to 
the endothelial cultures. 
The data also indicate that cell death or apoptosis does not to play an 
important role in the plasma-induced permeability increase. In fact, a 
significant and similar apoptotic signal was present in both control 
and stimulated HUVEC, and pre-incubation with the caspase-inhibitor 
Z-VAD-fmk blocked apoptosis in both cultures to an equal degree. 
Unsurprisingly, apoptosis, which is a common feature of primary cell 
cultures such as HUVEC, is found to occur here. However, the 
observation that stimulated cultures do not show an increased 
number of apoptotic cells is somewhat surprising, since the major 
mediators of increased permeability (e.g. IL-1β, TNF-α and LPS) have 
also proven to be at least partially involved in the induction of 
apoptosis signalling pathways.27 We have indeed observed an 
increased number of detached cells in HUVEC cultures that were 
stimulated with plasma obtained from LPS-treated (10 µg/mL) whole 
blood (unpublished observations). This suggests that LPS-conditioned 
plasma at least can influence the growth and turnover of HUVEC 
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cultures to a certain extent. However, in the experiments presented 
here a 104-fold lower amount of LPS was used. 
In a prior experiment we have shown that LPS needs to be incubated 
in whole blood for at least 2 h in order to generate plasma that 
enhances endothelial permeability.13 Here, it is demonstrated that at 
least another 2 h of incubation of endothelial cells with such plasma 
is required to significantly enhance the permeability, and that it 
takes an additional 4 – 6 h to achieve a maximum permeability 
response. In theory, this would leave, at the very most, 
approximately 8 – 10 h after the first encounter with LPS to 
successfully interfere with its actions. 
Previously, we have reported that inhibition of the plasma-induced 
permeability increase required the pre-incubation of neutralising 
antibodies against both IL-β and TNF-α in LPS-conditioned plasma, 
prior to its addition to the endothelial monolayer.13 The present data 
show that a partial inhibition of the permeability response remains 
possible when these antibodies are added to HUVEC within 1 h after 
addition of LPS-conditioned plasma. Apparently, during this relatively 
short period, the antibodies can still prevent to some extent the 
binding of the inflammatory cytokines to their receptors on the 
endothelial cells. 
Several other agents that are supposed to interfere with the 
intracellular signals generated by LPS, IL-1β or TNF-α, were tested on 
the capacity to inhibit the plasma-induced permeability increase. The 
fact that pre- or co-incubation of HUVEC with ZVAD-fmk did not 
prevent the permeability response to LPS-conditioned plasma 
supports the conclusion that apoptosis of HUVEC is not the mechanism 
responsible. 
The decisive role of TNF-α and IL-1β suggest that activation of NF-kB 
may be involved in the mediation of the permeability response. At 
higher concentrations, the anti-oxidant PDTC, which supposedly 
inhibits the activation of NF-κB, appears to be capable of reducing 
the plasma-induced permeability response, and was effective even if 
added to the endothelial cells after LPS-conditioned plasma. PDTC 
has been reported to reduce the LPS-induced and NF-κB-mediated 
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expression of endothelial tissue factor28 in vitro and to reduce 
mortality in a rat model for endotoxin-induced shock.29 We have 
previously demonstrated that PDTC also reduces the expression of E-
Selectin on endothelial cells that were stimulated with LPS-
conditioned plasma.14 Together these findings support the idea that 
NF-κB-activation constitutes a key mechanism in the mediation of 
endothelial inflammation and permeability. 
We could not demonstrate a protective effect of the anti-oxidant NAC 
on endothelial permeability, either added prior to or after LPS-
conditioned plasma. Like PDTC, NAC inhibits the formation of 
intracellular reactive oxygen species, and may subsequently prevent 
the activation of NF-κB in endothelial cells.30 However, it has also 
been shown that at higher concentrations of LPS, NAC does not 
prevent endothelial cell activation.31 It has even been suggested that 
the inhibitory effect of PDTC on NF-κB activation in endothelial cells 
may be reversed by NAC.32
In conclusion, it has been shown that there exist several possibilities 
for post-stimulatory intervention in the development of the LPS-
induced, plasma-mediated, increase in endothelial permeability. 
Further exploration of the IL-1β and TNF-α-dependent intracellular 
pathways may be helpful to diminish or prevent the consequences of 
generalized capillary leakage observed in sepsis. However, the data 
indicate the presence of only a relatively small window of opportunity 
where effective intervention is possible. The latter finding, together 
with the fact that in patients the actual onset moment of sepsis 
remains mostly unknown, raises serious questions as to the clinical 
feasibility of such a strategy. 
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CHAPTER 7 
ABSTRACT 
 
 Aim: To gain insight in the pathogenesis of increased vascular 
permeability during sepsis, we studied the effect of plasma obtained 
during human experimental endotoxemia on the permeability of 
cultured endothelial monolayers. Materials and Methods: Eight 
healthy subjects received an i.v. dose of 2 ng/kg E. coli O:113 
lipopolysaccharide (LPS). The concentration of various plasma 
mediators that supposedly induce vascular permeability was 
measured over time. Plasmas that were obtained before, and 2 and 4 
h after the administration of LPS were added to human umbilical 
venular endothelial cells (HUVEC) that were cultured on 
semipermeable membranes. Results: The permeability of the 
endothelial monolayers to fluorescein isothiocyanate-labeled bovine 
serum albumin was determined and expressed as the relative 
concentration of fluorescein isothiocynate bovine serum albumin 
when compared to that measured across empty Transwell-COL 
membranes (i.e. without endothelial monolayers). The permeability 
levels were correlated with the concentrations of various mediators. 
Results: Experimental endotoxemia resulted in elevated levels of 
TNF-α, IL-1β, IL-6, IL-8, IL-10, and vascular endothelial growth factor, 
and a moderate increase of IL-12 and IFN-γ (all P-values < 0.01). 
Incubation of HUVEC with plasma obtained 2 h and 4 h after the 
administration of LPS increased the relative permeability from a 
baseline level (median) of 17% (range, 14 - 31%) to 23% (range, 12 - 
39%; P = not significant) and 28% (range, 11 - 40%; P < 0.05), 
respectively. Plasma levels of vascular endothelial growth factor and 
IL-10, but not TNF-α or any of the other mediators, significantly 
correlated with the increase in endothelial permeability (r = 0.47, P = 
0.038; and r = 0.43, P = 0.038, respectively). Conclusions: The data 
presented here demonstrate that plasmas obtained from 
experimental human endotoxemia increase endothelial albumin 
permeability in vitro. Thus, cultured human endothelial monolayers 
provide a model to study sepsis-associated vascular changes. 
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INTRODUCTION 
 
Sepsis and septic shock represent the most serious forms of infection 
and result in approximately 200,000 fatalities each year in the United 
States alone.1 One of the key steps in the development of shock is 
increased microvascular permeability leading to massive edema 
formation, organ hypoperfusion, and tissue hypoxia. Impaired 
diffusion of oxygen to cells as a result of the extracellular edema may 
explain sepsis-induced organ injury.2
Several plasma mediators involved in sepsis increase vascular 
permeability including not only tumor necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β) 3, but also IL-6 4, IL-8 5, interferon-γ (IFN-γ) 6, 
leptin 7, complement 8, and vascular endothelial growth factor 
(VEGF).9 These and other mediators may also act in synergy. For 
example, it was shown that endothelial permeability induced by VEGF 
could be abrogated by anti-TNF antibodies,10 whereas differences in 
the systemic TNF-α response are modulated by the terminal 
complement component C5.11
Bacterial endotoxin or lipopolysaccharide (LPS) is a key initiator of 
the inflammatory cascade during sepsis. The administration of LPS to 
human volunteers is an established model to investigate the release 
of these cytokines and other inflammatory mediators.12 However, in 
contrast to septic patients, experimental human endotoxemia was not 
associated with an increase in microvascular permeability in vivo.13 
This may be explained by the limited duration of high levels of 
circulating cytokines and other mediators in human endotoxemia 
when compared to those in patients with sepsis and previous ex vivo 
studies. 
Stimulation of human whole blood ex vivo with LPS has been used to 
mimic the release of sepsis-associated inflammatory mediators, and 
results in a massive production of TNF-α and IL-1β. We have 
previously demonstrated that plasma obtained after these 
stimulations induced a marked increase in the permeability of 
cultured monolayers of human umbilical venular endothelial cells 
(HUVEC). Furthermore, the permeability increase of HUVEC 
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monolayers seemed to be mediated by TNF-α and IL-1β.3 However, 
the ex vivo stimulation of whole blood does not necessarily reflect 
the in vivo inflammatory response, which -in addition to blood- is 
predominantly regulated by several other organs. Therefore, despite 
the important role of TNF-α and IL-1β in our previous in vitro studies 
and the key function these cytokines may have in the pathogenesis of 
sepsis, the clinical relevance of these findings remains unclear. 
Nevertheless, cultured human endothelial monolayers may yet 
provide a more sensitive model to study changes in permeability 
when compared to the methods that can be used in humans. 
We have used this model to investigate the permeability-inducing 
capacity of plasma obtained from human experimental endotoxemia. 
In addition, we simulated the short in vivo exposure to high levels of 
plasma cytokines during human experimental endotoxemia by 
comparing short and long incubations of endotoxic plasma on the 
monolayers. Furthermore, we studied the possible correlations 
between the plasma concentrations of TNF-α, IL-1β and several other 
mediators and endothelial permeability. These analyses may help 
identify possible targets for the future treatment of sepsis. 
 
 
MATERIALS AND METHODS 
 
Human endotoxemia 
With approval from the local ethics committee and written informed 
consent of the volunteers, we have previously determined the effect 
of LPS administration on microvascular permeability measured in vivo 
in healthy volunteers.13 The investigation conformed with the 
principles outlines in the Declaration of Helsinki.14 Citrate-
anticoagulated blood was drawn from 8 subjects (4 men, 4 women) 
for determination of several cytokines and other possible mediators 
of vascular permeability, immediately before and serially after (time 
[t] = 15, 30, 60 min and 2, 4, 6, 8, 12, and 22 h) infusion of 2ng/kg 
LPS. The plasma samples obtained at t = 0, 2, 4 h after the 
administration of LPS were used to conduct the permeability 
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experiments for the present study. 
Screening of the subjects before the LPS-challenge revealed no 
abnormalities in medical history, physical examination, routine 
laboratory tests and electrocardiogram. Heart rate was continuously 
monitored using a 3-lead electrocardiogram, and blood pressure was 
measured intra-arterially throughout the experiment. All subjects 
received an i.v. infusion of a glucose/saline solution (2.5% glucose / 
0.45% saline, 75 mL/h) through a cannula in an antecubital vein. At t 
equals 0 h, Standard Reference LPS (E. coli O:113; US Pharmacopeia, 
Rockville, MD, USA) was injected intravenously (2 ng/kg). 
 
Detection of permeability mediators 
Blood was drawn from the arterial cannula and immediately 
centrifugated at 2000 g at 4 °C for 15 min and stored at –80°C until 
use. Concentrations of TNF-α, IL-1β, IL-6, IL-8, IL-10, IL-12, and IFN-γ 
were determined using a simultaneous Luminex Assay.15 A 
commercially available enzyme-linked immunosorbent assay (ELISA)  
for the measurements of VEGF (DuoSet ELISA development system, 
lower limit of detection of 16 pg/mL) and leptin (Quantikine DLP00, 
lower limit of detection of 8 pg/mL) was purchased from R&D 
systems, Minneapolis, MN, USA. Complement activation was measured 
by determining the concentration of soluble terminal complement 
complexes using an in-house ELISA.16
 
Isolation and culture of HUVEC 
Endothelial cells were isolated and cultured as described previously, 
with minor modifications.3 Fresh umbilical cords were obtained after 
delivery and informed consent from healthy women at the 
Department of Obstetrics and Gynaecology in our hospital. Briefly, 
endothelial cells were harvested from the umbilical vein by 
proteolytic detachment using collagenase type I (Sigma Chemical, St 
Louis, MO, USA). The isolates were seeded on gelatinized culture 
flasks (Corning, Cambridge, MA, USA), and cultured in medium M199 
(containing 25 mmol/L HEPES, Earle’s salts, and L-Glutamate; Life 
Technologies, Paisley, Scotland) with 10% heat-inactivated newborn 
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calf serum (Life Technologies, Paisley, Scotland), 10% heat-
inactivated normal human serum (ICN, Costa Mesa, CA, USA), 50 
U/mL penicillin, 50 µg/mL streptomycin, 150 µg/mL endothelial cell 
growth factors and 5 U/mL heparin. A crude fraction of endothelial 
growth factors was extracted from bovine brain and kindly provided 
by the Department of Paediatrics, University Medical Center, 
Nijmegen, The Netherlands. The cultures were grown in a humidified 
incubator at 37°C under 5% CO2 / 95% air atmosphere. A split ratio of 
1:3 was applied for subculturing. All experiments were performed on 
HUVEC that had been subcultured by trypsinization for 3 times. 
 
Incubation of HUVEC with plasma and conduction of albumin 
permeability studies 
Plasma obtained before and 2 and 4 h after the administration of LPS, 
was diluted to 20 % v/v in medium M199 without other serum 
components. The diluted plasma samples were added in quadruplet 
aliquots of 500 µL to confluent HUVEC monolayers subcultured on 
Transwell-COL membrane inserts (filter area, 1cm2;  pore diameter 
size, 0.4 µm; Corning, Cambridge, MA, USA) and incubated for 6 h at 
37°C. After the incubation, the albumin permeability of endothelial 
cultures to macromolecules was measured as previously described.3 
Briefly, a tracer solution containing fluorescein isothiocynate (FITC)-
labelled bovine serum albumin (BSA; 250 µg/mL) in complete medium 
was added to the upper compartment of the Transwell-COL insert. 
After 2 h of equilibration of the tracer solution, duplicate 100 µL 
aliquots were drawn from the lower compartment and the 
fluorescence of the samples was measured on a Wallac Victor II™ 
platereader (Perkin Elmer, Boston, MA, USA) at an emission/exitation 
wavelength of 495/520 nm.  
The amount of FITC-BSA in the samples was calculated according to a 
diluted series of FITC-BSA in culture medium. To allow quantitative 
comparison between multiple experiments, data are expressed as the 
relative concentration of FITC-BSA when compared to that measured 
across empty Transwell-COL membranes (i.e. without endothelial 
monolayers). 
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In a separate experiment, plasma samples (n = 3) were selected that 
induced the largest permeability increase in the previous experiment 
(i.e. after 6 h of incubation), but were now incubated for shorter 
periods (0.45, 2, and 6 h, respectively), and followed by incubation 
with control plasma of the same donor to complete a total incubation 
time of 6 h. The albumin permeability was compared to that induced 
by 6 h of incubation with baseline (unstimulated) plasma of the same 
individuals. 
 
Statistical Analysis 
Student paired t-test was used to analyse the effects of LPS on the 
peak levels of cytokines and other permeability mediators. 
Differences in the permeability between stimulated and control 
monolayers were analysed using analysis of variance and Dunnett’s 
Multiple Comparisons post hoc test, and correlations between 
permeability and plasma mediator concentrations were analysed by 
making use of the Spearman rank correlation tests using GraphPad 
InStat™ (GraphPad Software Inc., San Diego, CA) v3.05 software.  A P 
value of less than 0.05 was considered to indicate statistical 
significance. Data are expressed as medians with 25th and 75th 
percentile and range (in parentheses), or mean ± SEM of n 
observations, as appropriate.  
 
 
RESULTS 
 
Human endotoxemia 
The age, height, and weight of the subjects averaged 23.9 ± 1.0 yrs, 
176 ± 5 cm and 71.8 ± 4.9 kg, respectively. After the administration 
of LPS, body temperature was raised to a maximum of 38.7 ± 0.3 °C 
at t equals 4 h (P < 0.0001). Mean arterial blood pressure decreased 
from 79.4 ± 3.6 to 69.2 ± 2.7 mm Hg at t equals 6 h (P < 0.0001) and 
heart rate increased from 63.0 ± 2.7 to 90.6 ± 3.0 beats per minute at 
t equals 6 h (P < 0.0001). 
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Detection of permeability mediators 
As shown in table 1 and figure 1a-c, LPS infusion induced a significant 
increase in the pro- and anti-inflammatory cytokines and VEGF. 
Plasma concentrations of IL-12 and IFN-γ were only marginally but 
significantly elevated, whereas complement activation and leptin 
plasma levels were not increased. Because the LPS-induced increase 
in proinflammatory mediators typically peaked between 2 and 4 h, 
baseline samples and samples drawn 2 and 4 h after LPS 
administration were incubated on HUVEC monolayers. 
 
TABLE 1. Inflammatory mediators during human endotoxemia. 
Mediator 
Baseline 
value 
(pg/mL) 
Peak 
Concentration 
(pg/mL) 
Time of peak 
value (range) 
h 
P 
TCC  0.32±0.05 * 0.69±0.11 * NA NS 
TNF-α  <8 856±158 1.5 [1.5 - 2] 0.0009 
IL-1β  <8 23.9±2.2 2 [2 - 6] 
< 
0.0001 
IL-6  <8 10086±2516 3 [2 – 6] 0.0036 
IL-8  <8 1400±192 3 [2 – 3] 0.0002 
IL-10 <8 94±20 3 [2 – 3] 0.0018 
IL-12  <8 8.2±1.3 3 [2 – 6] 0.0074 
IFN-γ  101±58 145±59 2 [1.5 -– 4] 0.0044 
VEGF  36.1±5.9 80.9±8.0 4  [4 -12] 0.0002 
Leptin 
  (men) 
  (women) 
 
2079 ± 674 
20,898 ± 2881 
 
2573 ± 701 
31,194 ± 669 
 
NA 
NA 
 
NS 
NS 
Plasma concentrations of inflammatory mediators during experimental 
human endotoxemia. Baseline values and peak concentrations are 
expressed as mean ± SEM. Levels lower than the detection limit are 
expressed as less than 8. The time at which the peak occurred is expressed 
as mode [range]. * TCC is expressed in arbitrary units per mL. NA indicates 
not applicable; NS, not significant. 
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FIGURE 1. Plasma cytokine levels and plasma-induced endothelial 
permeability during the first 4 h after endotoxin administration. The 
endotoxin-induced increases in plasma TNF-α (A), IL-10 (B) and VEGF 
(C) were all significant. Data are expressed as mean with SEM. The 
box whisker plots in panel D illustrate endothelial permeability, 
induced by plasmas obtained 0, 2 and 4 h after the administration of 
LPS. The relative permeability is represented by medians (bars), 
interquartile ranges (boxes), and range (whiskers). 
CHAPTER 7 
Endothelial albumin permeability measurements 
When incubated with control plasma (obtained before to the 
administration of LPS), cultured HUVEC monolayers restricted the 
passage of FITC-BSA into the lower compartment to approximately 
1.84 µg/mL or 17.2% (range, 13.5 - 30.9%) of the amount that 
diffused across empty filters without HUVEC. Incubation of HUVEC 
monolayers with plasma that was drawn 2 h after the in vivo 
administration of LPS resulted in a nonsignificant increase of 
endothelial permeability to 23.1% (range, 12.4 - 39.2%; P = not 
significant) (Figure 1d). Plasma samples that were drawn 4 h after 
administration of LPS induced a larger and significant increase in the 
albumin permeability to 28.2% (range, 10.8 - 40.3%; P < 0.05). 
A moderate but significant positive correlation with the increase in 
endothelial albumin permeability was observed with plasma levels of 
VEGF (r = 0.47, P = 0.038) and IL-10 (r = 0.43, P = 0.038), but not of 
the other mediators (Table 2). 
 
TABLE 2 Correlation between 
inflammatory mediators and permeability. 
Parameter Spearman r P 
TNF-α 0.13 NS 
IL-1 0.19 NS 
IL-6 0.22 NS 
IL-8 0.22 NS 
IL-10 0.43 0.0376 
IL-12 0.11 NS 
IFNγ -0.19 NS 
VEGF 0.47 0.0379 
Spearman correlation between levels of 
inflammatory mediators and endothelial 
permeability. NS: not significant. 
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Plasma samples of 3 subjects that induced the largest albumin 
permeability increase in the first experiment induced a similar 
response in a second experiment where shorter incubation times were 
applied (Figure 2). Whereas control plasma of these subjects induced 
an albumin permeability of 18.8% (range, 11.0 - 31.4%), plasma 
obtained after the LPS-challenge and incubated for only 45 min on 
the monolayers increased the albumin permeability to 29.3 % (range, 
18.2 - 46.2%; P = 0.0038). This increase was quite similar to that 
induced by 2 and 6 h of incubation with the same plasma (29.5% 
[range, 22.6-40.5%]; P = 0.0011, and 32.1% [range, 16.6 - 38.1%]; P = 
0.0051, respectively). 
 
 
 
Baseline 3/4 2 6
0
10
20
30
40
50
exposure time (h)
p = 0.0051
p = 0.0011
p = 0.0038
Relative permeability (%)
60
p = NS p = NS
p = NS
FIGURE 2. Effect of short exposure of endothelial monolayers to 
endotoxic plasma. Box whisker plots represent the relative permeability 
after different incubation times (h) of endotoxic plasma. Short 
incubations with endotoxic plasma were followed by incubation with 
control plasma to complete a total incubation time of 6 h. Permeability 
between treatments were compared to that obtained after incubation 
with control plasma (baseline) for 6 h. Data are expressed as medians 
(bars), interquartile ranges (boxes), and range (whiskers). 
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DISCUSSION 
 
Although plasma levels of several cytokines and other inflammatory 
mediators are increased during sepsis, it remains unclear which of 
these mediators play a decisive role in edema formation and shock 
during systemic inflammation in humans in vivo. We exposed healthy 
subjects to a single i.v. dose of LPS and induced a significant increase 
in the plasma levels of various mediators that may alter vascular 
permeability. Indeed, plasma obtained after the LPS-challenge 
increased the albumin permeability of cultured endothelial 
monolayers; this response correlated with the plasma levels of VEGF 
and IL-10, but, surprisingly, not with the proinflammatory cytokines 
TNF-α, IL-1β or IL-6. 
Experimental endotoxemia is an established model to study 
cardiovascular changes and coagulation that occur during systemic 
inflammation. In contrast with the present study, we were unable to 
demonstrate a significant change of microvascular permeability in 
vivo during human endotoxemia.13 Differences between the exposure 
time to inflammatory mediators, and the sensitivity of the two 
permeability models may explain this inconsistency. We speculated 
that the LPS-induced peak levels of proinflammatory mediators could 
be sufficient to increase endothelial permeability in vitro, but the 
limited exposure to these cytokines during human experimental 
endotoxemia was insufficient to cause a permeability increase in 
vivo. 
Previous in vitro permeability studies were conducted with plasma 
obtained from ex vivo LPS-stimulated whole blood, which contained 
relatively high levels of inflammatory cytokines, and which was 
incubated on the endothelial monolayers for several hours to induce a 
full permeability response. In the present study we show that, even 
at relatively short incubations of 45 min, plasma obtained from 
human endotoxemia significantly increased endothelial albumin 
permeability in vitro. We therefore conclude that cultured 
endothelial monolayers may represent a more sensitive model to 
study the effect of LPS-induced vascular permeability than our 
 172
HUMAN ENDOTOXEMIA AND ENDOTHELIAL PERMEABILITY 
 
previous in vivo measurements. The sensitivity may result from the 
fact that cultured endothelial monolayers lack the influence of 
several factors present in their original environment, such as 
circulating inflammatory cells, fibroblasts, and other soft tissue 
components. In addition, endothelial function in vivo is regulated by 
the integrated response of the immune-, coagulation-, and endocrine 
systems, which may prevent or downregulate the permeability 
increase induced by plasma obtained during experimental human 
endotoxemia.  
During the first hours after LPS administration, the concentrations  of 
some cytokines, such as TNF-α, highly exceed the levels measured in 
plasma of patients with septic shock.17 Various other mediators of 
microvascular permeability were not (complement activation, leptin), 
or only moderately (IL-12, IFNγ) increased during human 
endotoxemia. Plasma concentrations of the potent proinflammatory 
cytokines TNF-α and IL-1β did not correlate with endothelial 
permeability. In fact, the strongest albumin permeability response 
was induced by plasma that was obtained 4 h after the administration 
of LPS, i.e. when the concentration of these mediators had returned 
to baseline levels. This observation excludes the possibility that in 
human experimental endotoxemia these cytokines act as direct 
mediators of vascular permeability and indicates that other molecules 
are involved in this phenomenon. This is a quite surprising finding, 
since we have previously demonstrated that both TNF-α and IL-1β 
mediated the permeability increase induced by plasma obtained from 
LPS-stimulated whole blood.3 This inconsistency may be explained by 
the fact that the stimulation of whole blood ex vivo with LPS results 
in TNF-α and IL-1β concentrations that are much higher when 
compared to the maximum levels that were achieved during human 
endotoxemia. Another possible explanation for the observed 
difference is that TNF-α and IL-1β may (also) indirectly increase 
permeability by sensitizing endothelial cells to respond to other 
mediators, such as VEGF. It has been demonstrated that the presence 
of TNF-α is required to modulate the VEGF-mediated increase in 
permeability.10 Neutralization of TNF-α may therefore abrogate the 
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VEGF-induced permeability response, rather than prevent direct 
stimulation. 
Our finding that VEGF is induced during human endotoxemia confirms 
a previous study.18 Although our finding that the levels of VEGF in 
plasma obtained during human experimental endotoxemia correlated 
with the permeability increase does not necessarily reflect a cause-
and-effect relation, the possible role of VEGF in mediating 
endothelial permeability is in accordance with the pathophysiologic 
effects of VEGF.19,20 We have recently demonstrated that increased 
VEGF concentrations correlate with fluid balance in patients with 
septic shock,21 which further supports the idea that VEGF is a 
mediator of microvascular permeability in patients with sepsis. More 
direct evidence was obtained with plasma of patients with adult 
respiratory distress syndrome, which also increased endothelial 
permeability in vitro - an effect that could be abrogated by the 
addition of a soluble VEGF inhibitor.22 Recently, an anti-VEGF 
antibody became available for human use.23 Combined with the 
finding that inflammation-mediated capillary leakage is associated 
with elevated VEGF concentrations, this is of particular interest 
because VEGF may be considered as a new therapeutic target for the 
treatment with anti-VEGF antibodies.  
In addition to VEGF, the anti-inflammatory cytokine IL-10 also 
correlated significantly with endothelial permeability. Although high 
concentrations of IL-10 are associated with an increase in mortality in 
patients with sepsis,24,25 there is abundant evidence that IL-10 does 
not induce but protects against microvascular leakage.26-28 
Apparently, this observation is caused by an epiphenomenon or larger 
increases of microvascular permeability which may induce a stronger 
IL-10 increase to protect the vasculature against further damage. 
In view of the moderate correlations between VEGF and IL-10 levels 
on the one hand and endothelial permeability on the other, we do not 
exclude the possibility that plasma obtained from human 
endotoxemia contains other yet unidentified inflammatory mediators, 
that may follow the same kinetic profile as VEGF and IL-10 and are 
involved in the increase in permeability. 
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In conclusion, the present study shows that plasma obtained during 
human experimental endotoxemia increases endothelial permeability 
in vitro. This response was independent of the incubation time (45 
minutes to 6 hours) of endotoxic plasma on the endothelial 
monolayers. The largest increase in endothelial permeability was 
induced after incubation with plasma that was obtained 4 h after the 
administration of LPS, when plasma TNF-α and IL-1β levels had 
returned to baseline. The increase in endothelial permeability was 
moderately correlated with VEGF and IL-10 levels in plasma. Our 
observations may facilitate future experiments that try to elucidate 
the pathophysiology of increased vascular permeability during 
systemic inflammation. 
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SUMMARY AND CONCLUSIONS 
 
 Sepsis is characterised by a documented or suspected infection 
in combination with a systemic inflammatory response. This response 
is accompanied by fluid retention, the formation of peripheral 
oedema, hypotension, and a decreased cardiac index. As a result 
tissues become badly perfused and oxygenated, which may lead to 
organ dysfunction. The endothelium, which covers the whole vascular 
tree, plays a key role in the pathogenesis of the sepsis syndrome. 
Endothelial cells serve both as a target and a source of inflammation. 
Also, the endothelium acts as a highly selective barrier that regulates 
the exchange of oxygen, fluid, nutrients, and immune cells, between 
the intra- and extravascular compartments. Damage of the 
endothelial barrier results in increased vascular permeability. In 
sepsis, overproduction of inflammatory mediators may result in 
systemic vascular leakage and shock. The widespread activation of 
endothelial cells during sepsis, which is reflected by the expression of 
endothelial cell adhesion molecules, leads to the attraction and 
migration of blood monocytes and neutrophils from the bloodstream 
to the extravascular compartment. These activated immune cells may 
aggravate the generalised inflammatory response, and promote tissue 
damage and organ dysfunction. 
 
Bacterial endotoxin, or lipopolysaccharide (LPS), which comprises 
part of the outer membrane of Gram-negative bacteria, is considered 
one of the key triggers of the sepsis syndrome. It induces the 
production of inflammatory host mediators, such as the cytokines 
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Massive 
production of these cytokines may be responsible for endothelial 
damage and increased vascular permeability observed in septic 
patients. The use of potent antimicrobial agents may aggravate this 
response because massive killing of micro-organisms may induce the 
liberation of large amounts of LPS. 
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To study the pathophysiological role of the endothelium in sepsis and 
to identify factors that are involved in vascular dysfunction, an in 
vitro model of cultured human endothelial monolayers was used in 
the present studies. Cultured endothelial cells possess much of their 
original in vivo phenotype, including morphology, adhesion molecule 
expression, and permeability characteristics (Chapter 1). 
 
In order to study the effects of various inflammatory mediators on 
vascular permeability, human umbilical vein endothelial cells 
(HUVEC) have been grown to monolayers on semi-permeable 
supports, which allow the passage of small and large molecules. For 
this purpose, several permeability models have been used in the past, 
which differed in their membrane type, matrix protein substrates, 
and/or permeability tracer molecules. Our fist objective concerns the 
selection of an appropriate combination of these. Therefore, we have 
studied the influence of three commonly used matrix proteins on the 
growth and permeability of both untreated and stimulated HUVEC 
monolayers that were cultured on commercially available 
membranes. The matrix proteins used in our studies, collagen, 
gelatin, and fibronectin, are involved in the attachment and growth 
of endothelial cells, and play an important role in wound healing and 
tissue remodelling. It has been suggested that inflammatory stimuli 
such as TNF-α may mediate proteolytic breakdown of matrix proteins 
such as fibronectin, which in turn influences the barrier function of 
the endothelium. Surprisingly, no essential differences existed 
between the growth and permeability characteristics of endothelial 
monolayers cultured on these three different substrates. 
Furthermore, while incubation of HUVEC monolayers with TNF-α or 
LPS induced a dose-dependent increase of the permeability, this 
response was not influenced by the type of matrix substrate. 
Apparently, the initial differences in cellular environment are 
unimportant with respect to the permeability characteristics of the 
endothelial monolayer, possibly as a result of additional matrix 
proteins produced and laid down by the endothelial cells. The finding 
that there was no difference in the passage of either albumin (a 69 
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kDa protein, which is both actively and passively transported) or 
dextran (a 70 kDa carbohydrate, which diffuses only passively) 
suggests that the majority of these large molecules diffuses across 
the endothelial monolayer by means of the paracellular route 
(Chapter 2). 
 
Even in the presence of sufficient serum components, high 
concentrations of LPS were required to increase endothelial 
permeability. This supports the opinion that LPS may be the trigger, 
but not the primary mediator of sepsis-induced endothelial 
permeability. In order to generate a pool of soluble mediators that 
are supposedly involved in the onset of sepsis, human blood was 
challenged ex vivo with LPS, and the resultant plasma was incubated 
with the endothelial cells. In contrast to direct stimulation by LPS, 
the incubation of picomolar concentrations of this molecule in blood 
was sufficient to generate plasma that induced a significant 
permeability increase. The calculated amount of LPS that was present 
in these plasmas was approximately a hundred-fold less that that 
required for direct induction of permeability. At picomolar 
concentrations, LPS induced a dose-dependent production of TNF-α 
and IL-1β in blood. The increase in endothelial permeability induced 
by the resultant plasma appeared to depend on the time-dependent 
generation of these cytokines. The decisive and complementary role 
of TNF-α and IL-1β in the mediation of the permeability response 
induced by LPS-conditioned plasma was demonstrated in experiments 
where neutralising monoclonal antibodies directed against these 
cytokines were pre-incubated in plasma prior to the addition to the 
endothelial cells. Most notably, the addition of both anti-TNF-α and 
anti-IL-β to plasma, but not either one alone, was required to 
completely inhibit the permeability response (Chapter 3). 
 
The induction of cellular adhesion molecules (CAMs) E-Selectin and 
ICAM-1 by endothelial cells could be (partially) inhibited by the 
administration of antibodies against TNF-α and IL-1β up to several 
hours after the addition of LPS-conditioned plasma. Apparently, a full 
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CAM-response depends on the continuous presence of these cytokines 
in plasma. Pre-incubation with PDTC and, to a lesser extent, N-
Acetylcysteine could prevent the plasma-induced CAM-response. 
However, intervention with PDTC partially inhibited the E-Selectin 
response, but not ICAM-1 expression, and only when this drug was 
administered within 1 h after the addition of LPS-conditioned plasma. 
Intervention with N-Acetylcysteine did not modulate the plasma-
induced expression of CAMs at all. Nevertheless, the inhibitory 
capacity of PDTC suggests the involvement of NF-κB in the plasma-
induced mediation of CAM-expresssion. Although we did not further 
elucidate the exact mechanism by which TNF-α and IL-1β induce CAM 
expression, our data indicate that more than one signalling pathway 
is involved in the LPS-induced mediation of de novo expression of 
endothelial cell adhesion molecules (Chapter 4). 
 
The endothelial response in sepsis may well depend on the origin of 
the infection. In whole blood, pathogenic bacteria that are frequently 
isolated in sepsis differ in their capacity to generate cytokines. In our 
model, the resulting plasmas also differed in their capacity to 
increase endothelial permeability and adhesion molecule expression, 
and the amount of TNF-α in the plasmas roughly correlated to the 
endothelial response. Furthermore, the endothelial response seems 
to depend, at least in part, on the generation of soluble components 
such as LPS. This was demonstrated by the observation that plasmas 
obtained from the incubation of whole blood with culture 
supernatants without intact E. coli induced a similar permeability 
response when compared to incubation with dead but intact 
microorganisms. Gram-positive bacteria lack LPS in their membranes 
and this may explain why in our experiments incubation with 
Enterococcus faecalis results in a moderate endothelial response 
when compared to that induced by E. coli or Bacteroides fragilis. 
Significant amounts of LPS may be released by killing bacteria with 
antibiotics, and these could be detrimental in the course of sepsis. 
Although this phenomenon has been demonstrated in several in vitro 
studies, the clinical relevance of these observations remains unclear. 
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As a major target for LPS and its triggered mediators, the endothelial 
response to antibiotic-induced liberation of endotoxin serves as an 
appropriate model to test this relevance. Pre-treatment of E. coli 
with different antibiotics (i.e. cefuroxime, imipenem, and polymyxin 
B) resulted in different levels of TNF-α in blood, and this finding 
substantiates previous observations. However, these differences were 
not fully translated into the plasma-induced endothelial response, 
and this may explain the lack of significance observed on the patient 
level. Yet, the treatment of Gram-negative bacteria with LPS-
neutralising agents, such as polymyxin B, may help to limit the 
systemic response to infection, since such treatment resulted in a 
blunted endothelial permeability and adhesion molecule expression 
(Chapter 5). 
 
From a clinical perspective, intervention studies that are aimed 
against the LPS-induced permeability increase may identify new 
targets for therapy. In our model, successful intervention requires the 
presence of a “window of opportunity” where the addition of 
inhibitory drugs some time after the incubation with LPS-conditioned 
plasma may alter the permeability response. Therefore, we examined 
the time-related characteristics of the plasma-induced permeability. 
At least 2 h of continuous exposure to LPS-conditioned plasma was 
required to induce a full permeability response, and that the peak of 
this response was reached 4 – 6 h after the start of the incubation. 
These findings seem to correspond quite well to in vivo observations 
where LPS was infused in animals. Within the apparent 6 h window of 
opportunity, the permeability response could partly be inhibited by 
the addition of neutralising antibodies against TNF-α and IL-1β within 
1 h after stimulating the endothelial cells. Several drugs that 
supposedly interfere with the signalling pathways of LPS, TNF-α and 
IL-1β were tested for their capacity to inhibit the plasma-induced 
permeability increase. Only early (< 2 h) intervention with pyrollidine 
di-thiocarbamate (PDTC) appeared effective in this respect. PDTC 
supposedly inhibits the activation of NF-κB, a nuclear transcription 
factor that is activated by LPS, TNF-α, and IL-1β, and which is 
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involved in the regulation of many inflammatory genes. The 
observation that the (supposed) inhibition of NF-κB by PDTC partly 
abrogated the permeability response suggests that that NF-κB was not 
completely inhibited, or that other pathways are involved in TNF-α 
and IL-1β mediated permeability. Apoptosis might well represent such 
a pathway, but in our studies cell death did not play a significant role 
in the induction of permeability by LPS-conditioned plasma (Chapter 
6). 
 
In humans, a controlled but systemic response to endotoxin can be 
generated by the infusion of limited doses of LPS. This model differs 
in many ways from the ex vivo stimulation of whole blood that we 
have used in the previous studies. Because of its extreme toxicity 
infusion of only small doses of LPS is possible in man, and this results 
in circulating cytokine levels that are much lower than those 
generated in whole blood. As a consequence, the amount of cytokines 
released after the in vivo LPS-challenge in humans may have been too 
small to induce a significant increase of microvascular permeability in 
these subjects. To the contrary, the plasmas that were obtained after 
the in vivo administration of LPS significantly increased the 
permeability of cultured endothelial monolayers. We expected that 
plasma levels of TNF-α and/or IL-1β would correlate with this 
response, but instead only the levels of vascular endothelial growth 
factor (VEGF) and interleukin-10 showed a moderate but significant 
correlation with the permeability increase. The pro-inflammatory 
mediator VEGF is a potent permeability-increasing factor, is up-
regulated by TNF-α and IL-1β, and has a wide range of effects on 
endothelial cell functions, including permeability. Also, plasma levels 
of VEGF are significantly increased in septic patients and suggest that 
this mediator is critically involved in the pathogenesis of the sepsis 
syndrome. 
While small LPS-challenges in whole blood and in healthy volunteers 
both generate plasma that increases endothelial permeability in 
vitro, different mechanisms seem to contribute to this phenomenon. 
However, a true comparison between these two models is hardly 
 186
 SUMMARY AND CONCLUSIONS 
 
possible, and any conclusion should be drawn with great care. 
Although one could argue that the in vivo LPS-challenge is a more 
relevant model to study sepsis related vascular barrier dysfunction, a 
major concern is that it doesn’t induce any permeability increase in 
vivo. In this respect it would be interesting to see what the ex vivo 
generated plasma would do in healthy volunteers, but more 
conveniently, to study the role of VEGF in plasma obtained from LPS-
treated whole blood (Chapter 7). 
 
In conclusion, cultured human endothelial monolayers serve as a 
sensitive model to study the effect of inflammatory mediators on 
vascular permeability and adhesion molecule expression. Although 
endothelial cells respond directly to bacterial lipopolysaccharide, the 
main pathway involved in LPS-induced endothelial changes seems to 
occur through the LPS-induced generation of cytokines (TNF-α and IL-
1β). These potent pro-inflammatory cytokines may also induce the 
production of various other host mediators, such as VEGF, and 
thereby both directly and indirectly induce endothelial barrier 
dysfunction. In addition to neutralisation of these circulating 
mediators, inhibition of intracellular signalling pathways induced by 
TNF-α and IL-1β, which typically involve the activation of NF-κB, may 
serve to prevent multiple mechanisms of endothelial activation and 
damage. However, the clinical applicability of such a strategy seems 
hindered by the limited window of opportunity where successful 
intervention is possible. 
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SAMENVATTING EN CONCLUSIES 
 
Het septisch syndroom wordt gekenmerkt door een (verdenking op) 
infectie, in combinatie met een  systemische ontstekingsreactie. Deze 
reactie gaat gepaard met vochtretentie, de vorming van perifeer 
oedeem, hypotensie, en een afname van de cardiale index. Hierdoor 
raken weefsels slecht doorbloed en onvoldoende van zuurstof 
voorzien, hetgeen kan leiden tot orgaanfalen. Het endotheel, dat de 
bekleding vormt van het gehele vaatstelsel, speelt een belangrijke rol 
in de pathogenese het septisch syndroom. 
Endotheelcellen zijn zowel  doelwit als bron van de 
ontstekingsreactie. Bovendien vormt het endotheel een uiterst 
selectieve barrière die de uitwisseling van zuurstof, vocht, 
voedingsstoffen en ontstekingscellen tussen het intra- en 
extravasculaire compartiment reguleert. Beschadiging van deze 
barrière leidt onherroepelijk tot een toename van de vasculaire 
permeabiliteit. De (te) grote hoeveelheden ontstekingsfactoren die 
tijdens sepsis vaak aangemaakt worden leiden tot grootschalige 
beschadiging van de vaatwand, met als gevolg systemische 
vaatlekkage en shock. Tijdens sepsis treedt er ook een systemische 
activering van endotheelcellen op welke gekenmerkt wordt door de 
expressie van cel adhesiemoleculen, en die leidt tot het aantrekken 
en migreren van monocyten en neutrofiele granulocyten vanuit de 
bloedbaan naar de omringende weefsels. De aanwezigheid van deze 
geactiveerde ontstekingscellen verergert de systemische 
ontstekingsreactie, waarmee nog meer weefsel- en orgaanschade 
wordt berokkend. 
 
Eén van de belangrijkste factoren die verantwoordelijk is voor het 
ontstaan van het septisch syndroom is bacterieel endotoxine, oftewel 
lipopolysaccharide (LPS), een molecuul afkomstig uit de buitenste 
membraan van Gram-negatieve bacteriën. Blootstelling aan dit 
molecuul leidt tot de productie van ontstekingsmediatoren, zoals de 
cytokinen tumor necrose factor-α (TNF-α) en interleukine-1β (IL-1β). 
De overproductie van deze cytokinen bij septische patiënten is 
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waarschijnlijk verantwoordelijk voor beschadiging van het endotheel 
en de toegenomen permeabiliteit van de vaatwand. Deze respons 
wordt mogelijk nog versterkt door het gebruik van krachtige 
antibiotica, omdat bij het massaal doden van bacteriën mogelijk 
grote hoeveelheden LPS vrijkomen. 
Om de rol van het endotheel tijdens sepsis en van mediatoren die 
hierbij betrokken zijn te bestuderen is in de huidige studie gebruik 
gemaakt van een in vitro model met gekweekte endotheel 
monolagen. Gekweekte endotheelcellen behouden grotendeels hun 
fenotypische (in vivo) eigenschappen, zoals morfologie, expressie van 
cel adhesiemoleculen en permeabiliteitskenmerken (Hoofdstuk 1). 
 
Om de het effect van verschillende ontstekingsmediatoren op de 
permeabiliteit van endotheel te bestuderen, zijn monolagen van 
endotheelcellen afkomstig uit de vena umbilicalis (humane 
navelstreng) gekweekt op een semi-permeabel membraan, waar 
doorheen kleine en grote moleculen kunnen diffunderen. In het 
verleden zijn hiervoor verscheidene modellen gebruikt, die onderling 
verschilden in het gebruik van type membraan, het substraat van 
matrixeiwitten, en de gebruikte tracer moleculen om de 
permeabiliteit te meten. Het eerste doel is dus om een geschikte 
combinatie uit deze variabelen te kiezen. Hiertoe is het effect van 
drie verschillende matrix eiwitten, die vaak als substraat gebruikt 
worden, getest op de groei en permeabiliteit van zowel 
gestimuleerde als onbehandelde HUVEC monolagen. Deze monolagen 
werden bovendien gekweekt op verschillende, in de handel 
verkrijgbare, kunststof membranen. 
De matrixeiwitten die in deze studie gebruikt zijn, te weten 
collageen, gelatine en fibronectine, zijn alle betrokken bij de 
hechting en groei van endotheelcellen, en spelen een belangrijke rol 
in wondgenezing en weefselherstel. Ontstekingsmediatoren, zoals 
TNF-α, kunnen de proteolytische afbraak van matrixeiwitten (o.a. 
fibronectine) sturen, en beïnvloeden daarmee mogelijk de 
barrièrefunctie van het endotheel. 
Opmerkelijk genoeg bleken er echter geen essentiële verschillen te 
 190
 SUMMARY AND CONCLUSIONS 
 
bestaan bij de groei en de permeabiliteitskenmerken van 
endotheelmonolagen die gekweekt waren op de drie verschillende 
substraten. Bovendien bleek het type substraat niet van invloed te 
zijn op de dosis-afhankelijke toename van de permeabiliteit na 
behandeling van HUVEC monolagen met TNF-α of LPS. Blijkbaar zijn 
de aanvankelijke verschillen in de cellulaire omgeving onbelangrijk 
voor de permeabiliteitskenmerken van volgroeide HUVEC monolagen. 
Dit komt mogelijk doordat endotheelcellen tijdens het kweken zelf 
matrixeiwitten produceren en deze toevoegen aan de initiële matrix. 
De constatering dat er onder de verschillende omstandigheden geen 
verschil was tussen de permeabiliteit voor albumine (een 69 kDa-eiwit 
dat zowel actief als passief diffundeert door endotheel) als dextraan 
(een 70 kDa carbohydraat dat alleen passief diffundeert) vormt een 
sterke aanwijzing dat het overgrote deel van deze macromoleculen 
via de paracellulaire route door de endotheelmonolaag diffundeert 
(Hoofdstuk 2). 
 
Zelfs in de aanwezigheid van voldoende serumcomponenten zijn hoge 
concentraties LPS nodig om de permeabiliteit van endotheel te 
verhogen. Hiermee wordt de algemene gedachte bevestigd dat LPS 
weliswaar de aanstichter, maar niet de belangrijkste oorzaak is van 
de verhoogde permeabiliteit die optreed tijdens sepsis. Een pool van 
mediatoren waarvan verondersteld wordt dat deze verantwoordelijk 
zijn voor het ontstaan van sepsis kan verkregen worden door humaan 
bloed ex vivo te stimuleren met LPS. Met het resulterende plasma dat 
uit deze volbloedstimulatie is verkregen, zijn vervolgens 
endotheelcellen behandeld. In tegenstelling tot de directe stimulatie 
van endotheelcellen met LPS blijkt dat de toevoeging van uiterst 
geringe (picomolaire) hoeveelheden van dit molecuul aan volbloed 
voldoende waren om plasma te genereren waarmee een significante 
toename van de permeabiliteit kan worden bewerkstelligd. De 
berekende hoeveelheid LPS die in dit plasma aanwezig is plasma is 
ongeveer honderd maal zo weinig als de hoeveelheid die nodig is voor 
directe stimulatie van de permeabiliteit van endotheel. Bij deze 
picomolaire concentraties veroorzaakt LPS een dosis-afhankelijke 
 191
CHAPTER 8 
productie van TNF-α en IL-1β in volbloed. Bovendien is de mate 
waarin de permeabiliteit van endotheel na behandeling met plasma 
toeneemt mede afhankelijk van de tijdsduur waarin deze cytokinen 
onder invloed van LPS in volbloed worden geproduceerd. In 
experimenten waarbij vooraf neutraliserende monoclonale 
antilichamen tegen TNF-α en IL-1β zijn toegevoegd aan het plasma 
dat is verkregen uit de volbloedstimulatie kon worden aangetoond dat 
deze twee cytokinen een bepalende en overlappende rol spelen bij 
de inductie van permeabiliteit. Het meest opmerkelijke hierbij is dat 
toevoeging van beide antilichamen, maar niet van elk afzonderlijk, 
aan het plasma nodig blijkt om de permeabiliteitsverhoging volledig 
te voorkomen (Hoofdstuk 3). 
 
Ook de expressie van de celadhesiemoleculen (CAM) E-Selectine en 
ICAM-1 op endotheelcellen kan op deze wijze geremd worden, 
waarbij de toevoeging van antilichamen gericht tegen TNF-α en IL-1β, 
tot enkele uren na de toediening van LPS-geconditioneerd plasma, 
deels effectief blijkt. Blijkbaar is het noodzakelijk dat voor een 
volledige CAM-respons deze plasma cytokinen continu beschikbaar 
zijn. De plasma-geïnduceerde CAM-respons kan daarnaast ook geremd 
worden door de endotheelcellen vooraf incuberen met pyrollidine di-
thiocarbamaat (PDTC), en in mindere mate met N-Acetylcysteine. Een 
partiele remming van de E-Selectine expressie treedt ook op indien 
PDTC binnen 1 uur nadat de endotheelcellen aan LPS-geconditioneerd 
plasma zijn blootgesteld wordt toegevoegd. Deze interventie heeft 
echter geen invloed op de expressie van ICAM-1. Het naderhand 
toevoegen van N-Acetylcysteine had in het geheel geen effect op de 
plasma-geïnduceerde CAM-expressie. De remmende werking van PDTC 
wijst echter in de richting van NF-κB als mogelijke mediator van de 
plasma-geïnduceerde CAM respons. NF-κB is een nucleaire 
transcriptiefactor die geactiveerd wordt door LPS, TNF-α en IL-1β en 
die betrokken is bij de transcriptie van een groot aantal 
inflammatoire genen. Hoewel in deze studie de precieze 
mechanismen die betrokken zijn bij de expressie van CAM onder 
invloed van TNF-α en IL-1β niet zijn onderzocht, duiden de resultaten 
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van dit onderzoek erop dat er bij de LPS-geïnduceerde de novo 
expressie van CAM echter mogelijk meer dan één signaalpad 
betrokken is (Hoofdstuk 4). 
 
De mate waarin het endotheel tijdens sepsis reageert is mogelijk 
afhankelijk van de infectiebron. Een aanwijzing hiervoor is dat 
verscheidene pathogene micro-organismen, die regelmatig bij 
patiënten met sepsis aangetoond worden, substantieel verschillen in 
de mate waarin zij in volbloed de productie van cytokinen 
veroorzaken. Het blijkt ook dat de corresponderende plasmas die 
hieruit worden  verkregen in verschillende mate de permeabiliteit en 
de expressie van CAM verhogen. Hierbij correleert de hoeveelheid 
TNF-α die aanwezig is in de plasmas ruwweg met de CAM expressie en 
de verhoogde permeabiliteit van het endotheel. Ook lijkt het erop 
dat deze respons mede afhankelijk is van de aanwezigheid van 
oplosbare moleculen, zoals LPS, in volbloed. Dit blijkt uit de 
bevinding dat toevoeging van kweeksupernatant (zonder intacte E. 
coli) aan volbloed plasma oplevert dat een identieke 
permeabiliteitsrespons veroorzaakt als plasma afkomstig van 
incubatie met gedode, maar intacte E. coli in volbloed. Gram-
positieve bacteriën bezitten geen LPS in hun membraan en dit 
verklaart mogelijk de bevinding dat incubatie met Enterococcus 
faecalis een veel geringere respons van het endotheel veroorzaakt in 
vergelijking met incubatie met Gram-negatieve bacteriën zoals E. coli 
of Bacteroides fragilis. 
Bij het doden van bacteriën kan een significante hoeveelheid LPS 
vrijkomen met als mogelijk gevolg dat dit leidt tot een verergering 
van het klinisch beloop bij sepsis. Hoewel het verschijnsel in 
verscheidene in vitro onderzoeken is aangetoond, is het onduidelijk 
of het op deze wijze vrijkomen van LPS van enige klinische betekenis 
is. Omdat de endotheelcel een belangrijk doelwit is van LPS en 
andere ontstekingsmediatoren, is de endotheelrespons op vrijkomend 
LPS bij het doden van bacteriën met antibiotica mogelijk een geschikt 
model om deze relevantie te testen. De toevoeging van E.coli die 
vooraf gedood zijn met verschillende antibiotica (cefuroxime, 
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imipenem, of polymyxine B) aan volbloed leidt tot aanzienlijke 
verschillen in de productie van TNF-α en dit is in overeenstemming 
met bevindingen van andere onderzoekers. Het blijkt echter dat deze 
verschillen niet volledig vertaald worden in de respons van het 
endotheel op de plasmas die uit de volbloedstimulaties zijn 
verkregen. Dit verklaart mogelijk waarom bij patiënten met sepsis 
geen duidelijk verband is aangetoond tussen het gebruik van 
antibiotica en de ernst van de ziekte. Desondanks zou bij de 
behandeling van Gram-negatieve infecties de systemische 
ontstekingsreaktie mogelijk beperkt kunnen worden door behandeling 
met LPS-neutraliserende middelen, zoals bijvoorbeeld polymyxine B. 
In vitro leidt behandeling van E. coli met polymyxine B namelijk tot 
een verminderde reactie van het endotheel voor wat betreft de 
permeabiliteit en de CAM-expressie (Hoofdstuk 5). 
 
Vanuit klinisch oogpunt kunnen interventiestudies die gericht zijn op 
het voorkomen van  de verhoging van de permeabiliteit onder invloed 
van LPS belangrijke aangrijpingspunten opleveren voor behandeling 
van sepsis. In het onderhavige model is zinvolle interventie alleen 
mogelijk indien er een na toediening LPS-geconditioneerd plasma een 
tijdsbestek is waarbinnen de toevoeging van inhibitoire agentia van 
invloed kunnen zijn op de permeabiliteitsrespons. Daarom is eerst 
gekeken naar het tijdsverloop van de plasma-geïnduceerde 
permeabiliteit. Het blijkt dat de endotheelcellen gedurende een 
periode van tenminste 2 uur moeten worden blootgesteld aan LPS-
geconditioneerd plasma om een maximale permeabilteitsrespons te 
genereren. De piek van deze respons wordt bereikt na 4 – 6 uur na 
aanvang van de incubatie met LPS-geconditioneerd plasma. Deze 
bevindingen lijken aardig overeen te komen met het effect van LPS 
toediening in vivo bij proefdieren. 
Binnen het schijnbaar geboden tijdsbestek van 6 uur na aanvang van 
de incubatie met LPS-geconditioneerd plasma, blijkt dat de 
permeabiliteitsrespons deels geremd kan worden indien binnen 1 uur 
neutraliserende antilichamen tegen TNF-α en IL-1β aan de reeds 
gestimuleerde cellen worden toegevoegd. Ook zijn verscheidene 
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andere stoffen, waarvan verondersteld wordt dat deze invloed 
hebben op de intracellulaire signaalpaden van LPS, TNF-α en IL-1β, 
getest op hun vermogen om de plasma-geïnduceerde 
doorlaatbaarheid te remmen. Het bleek dat alleen een vroege 
(binnen 2 uur na aanvang van incubatie met LPS-geconditioneerd 
plasma) interventie met PDTC hierbij een gunstig effect had. Van 
PDTC wordt verondersteld dat dit de activering van NF-κB remt. De 
bevinding dat de (veronderstelde) remming van NF-κB door PDTC de 
permeabiliteitstoename slechts ten dele wist te voorkomen wekt de 
indruk dat NF-κB hierbij niet volledig geremd was, of dat er andere 
signaalpaden betrokken zijn bij de TNF-α- en IL-1β-gemedieerde  
toename van de permeabiliteit. Hoewel apoptose (geprogrammeerde 
celdood) mogelijk een van de betrokken mechanismen is, blijkt dat 
dit bij de plasma-geïnduceerde permeabiliteit in het huidige model 
geen rol van betekenis speelt (Hoofdstuk 6). 
 
Bij gezonde vrijwilligers kan een gecontroleerde systemische 
ontstekingsreaktie worden opgewekt door het intraveneus toedienen 
van kleine hoeveelheden LPS. Deze aanpak verschilt in vele opzichten 
van de ex vivo stimulatie van volbloed die in de voorgaande studies 
gebruikt zijn. Echter, omdat LPS zeer toxisch is kunnen alleen zeer 
geringe doseringen bij mensen toegediend worden en dit heeft tot 
gevolg dat hiermee veel geringere cytokineconcentraties worden 
bereikt dan de hoeveelheden die onder invloed van in LPS in volbloed 
gegenereerd worden. De consequentie van het toedienen ven 
dergelijke kleine hoeveelheden LPS is ook dat de cytokinerespons 
waarschijnlijk te gering is om een significante toename van de 
microvasculaire permeabiliteit in vivo te bewerkstelligen. Echter, het 
blijkt dat met het plasma dat afgenomen wordt na de infusie van LPS 
in vrijwilligers weldegelijk een toename van de permeabiliteit van 
endotheelmonolagen is te bewerkstelligen. Hierbij werd 
verondersteld dat de plasmaconcentraties van TNF-α en IL-1β verband 
zouden houden met de permeabiliteitstoename, echter er kon alleen 
een significante doch zwakke correlatie worden aangetoond tussen de 
permeabiliteit en de plasmaconcentraties van vascular endothelial 
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growth factor (VEGF) en interleukine-10. Van VEGF is bekend dat dit 
een sterk permeabiliteitsverhogende pro-inflammatoire mediator is 
die wordt opgereguleerd door TNF-α en IL-1β, en die effect heeft op 
een groot aantal functies van het endotheel, waaronder ook de 
permeabiliteit. In septische patiënten is de plasmaconcentratie VEGF 
significant verhoogd en dit duidt op een essentiële rol die dit 
molecuul speelt bij de pathogenese van het septisch syndroom. 
Hoewel het toedienen van geringe hoeveelheden LPS aan volbloed en 
in gezonde vrijwilligers in beide gevallen plasma oplevert waarmee 
de permeabiliteit van endotheel in vitro verhoogd wordt, lijkt dit 
verschijnsel te berusten op verschillende mechanismen. De grote 
verschillen die bestaan tussen de twee gebruikte modellen maakt het 
vergelijken van de resultaten eruit echter lastig en kan een 
definitieve conclusie slechts met het nodige voorbehoud getrokken 
worden. Men zou kunnen pleiten voor het gebruik van LPS in vivo in 
gezonde vrijwilligers als een meer relevant model voor sepsis-
gerelateerde vasculaire dysfunctie. Echter, een belangrijke beperking 
hierbij is dat deze benadering geen toename van de permeabiliteit in 
vivo veroorzaakt. Het zou daarom interessant zijn om te zien wat het 
effect van plasma van ex vivo LPS-gestimuleerd volboed is in gezonde 
vrijwilligers, of wat praktischer, om te kijken naar de rol van VEGF in 
plasma dat verkregen is uit LPS-gestimuleerd volbloed. 
 
In het huidige onderzoek wordt aangetoond dat gekweekte 
monolagen van humaan endotheel gebruikt kunnen worden als een 
gevoelig model waarmee de effecten van ontstekingsmediatoren op 
vasculaire permeabiliteit en de expressie van adhesiemoleculen 
kunnen worden bestudeerd. Hoewel endotheelcellen direct reageren 
op bacterieel lipopolysaccharide lijkt het belangrijkste mechanisme 
bij LPS-geïnduceerde veranderingen in het endotheel te verlopen via 
de LPS-geïnduceerde productie van cytokinen (TNF-α en IL-1β). Deze 
sterke pro-inflammatoire cytokinen induceren op hun beurt ook de 
productie van verschillende andere mediatoren, zoals VEGF, en 
kunnen daarmee zowel direct als indirect een rol spelen bij het 
beschadigen van de barrière van het endotheel bij sepsis. Behalve de 
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directe neutralisatie van deze circulerende mediatoren kan remming 
van de intracellulaire signaalpaden die geïnduceerd worden door TNF-
α en IL-1β en die de activatie van NF-κB bewerkstelligen, als doelwit 
dienen om aan te grijpen op de verschillende mechanismen die leiden 
tot activatie en beschadiging van endotheel. De klinische 
toepasbaarheid van deze aanpak wordt echter ernstig beperkt door 
de beperkte tijdsduur waarbinnen interventie mogelijk is. 
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DANKWOORD 
De consequentie van een vrij lang promotietraject is een vrij lang 
dankwoord. 
Eenendertig jaar geleden behaalde ik onder toeziend oog van mijn eigen 
-en vele andere- ouders, het diploma B in het gemeentebad Te Werve te 
Rijswijk (Z.-H.). De toon werd toen al gezet. Ik deed hier namelijk nogal 
lang over. Met name de indertijd beruchte “zeven meter onder water” 
bleek een bijna niet te nemen hindernis. Niet dat ik niet zwemmen kon, 
maar op autoritair gezag kunstjes vertonen, dat was wat veel gevraagd. 
Bij de derde poging die de strenge doch geduldige badmeester mij ten 
overstaan van het stilgevallen publiek liet ondernemen, besloot ik om 
voorlopig dan maar helemaal niet meer boven te komen. Ik nam 
derhalve een enorme hap lucht en sprong, nog nat van de vorige duik, 
weer in het diepe. Ik raakte onder water de weg en de tel van mijn 
slagen kwijt en besloot voor de zekerheid er nog maar een stuk of zeven 
bij te doen in de hoop dat ik inmiddels niet 180 graden gedraaid was. Bij 
de laatste tel moet ik met mijn kruin zowat de betegelde wand aan de 
overzijde geraakt hebben toen mijn longen schreeuwden: “Omhoog, 
idioot!”. Eenmaal boven hoorde ik het enthousiaste geklap van de 
aanwezige vaders en moeders. Ik was nog te jong en te verbouwereerd 
om te realiseren van welke belangrijke verworven vaardigheid ik 
rekenschap had gegeven (ik zou tenslotte nooit meer verzuipen), laat 
staan dat ik op de gedachte kwam om er ook maar iemand voor te 
bedanken. “I did it my way”, moet ik gedacht hebben, toen ik onder 
goedkeurend oog van mijn trotse en duidelijk opgeluchte ouders het 
voorbedrukte vel papier met daarop mijn naam in sierlijke letters 
uitgereikt kreeg. 
Hoewel er ontegenzeggelijk overeenkomsten zijn met de totstandkoming 
van dit proefschrift liggen de zaken nu gelukkig toch heel anders. 
Toegegeven, ik deed er ook nu weer langer over dan nodig, en er was 
meestal meer dan één poging vereist om de verschillende artikelen 
gepubliceerd te krijgen. Het was andermaal een sprong in het diepe en 
wederom vroegen een aantal toeschouwers zich vertwijfeld af of ik het 
wel redden ging – en ikzelf niet minder. Maar het hoofd kwam en bleef 
gelukkig ook nu boven water. Echter, zonder de steun van vele anderen 
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zou dat nimmer zijn gelukt. Al deze betrokkenen dank ik daarom voor 
hun oprechte interesse, hun wetenschappelijke- en mentale 
ondersteuning en de broodnodige afleiding. Een aantal van hen wil ik 
hierbij graag in het bijzonder noemen. 
Veel lof komt aan u toe, professor Bleichrodt, voor het adopteren en 
begeleiden van een wees-promovendus. Beste Rob, tussen de 
verschillende werkzaamheden door was het niet altijd even makkelijk 
om in het juiste spoor te blijven, maar mede dankzij jouw inspanningen 
is het eindstation toch bereikt. En wellicht dat mijn schrijfvaardigheid 
ingezet kan worden als positieve controle bij toekomstige pijnstudies. 
Dr. Thijs Hendriks, beste co-promotor, uiteindelijk deed ik het ook vaak 
“Your Way” en dat is maar goed ook, want jouw inbreng was van 
doorslaggevende betekenis. Ik bedank je voor je jarenlange steun, je 
betrokkenheid, scherpte en geduld, maar ook voor je gevoel voor 
humor, je  relativeringsvermogen en de blik van verstandhouding als 
Feyenoord weer eens had verloren. En gelukkig had je al grijze haren 
voordat je mij ging begeleiden… 
Ik wil echter ook jou, dr. Cees van der Linden, beslist niet overslaan. Als 
initieel promotor heb je me geïnspireerd om aan deze klus te beginnen 
en jouw no-nonsense aanpak heeft me de eerste resultaten opgeleverd. 
Toen je onderweg een ander pad koos, heb je je AiO-zorg toevertrouwd 
aan Thijs en die was daar in goede handen. 
Nog meer goede handen vond ik bij Ben de Man en Roger Lomme, het 
kloppend hart van het research lab en de atoomklok van de koffiepauze. 
Met jullie praktische en altijd vriendelijke aanpak hebben jullie al menig 
promovendus weggewerkt. Net zoals vele voorgangers heb ik veel aan 
jullie te danken en ik zal aan de periode met jullie op, maar zeker ook 
buiten het lab altijd met veel plezier terugdenken. Het “laatste 
experiment” kan nu eindelijk naar Thema. 
Erwin Waas en Thomas Volman, jullie zijn onvergetelijk en 
onverbeterlijk. Dankzij (of: ondanks) het delen van onze werkplek is de 
A.i.O.-trilogie nu volbracht en hebben we daarbij de grenzen van 
collegialiteit verlegd van een stoffige kamer tot besneeuwde heuvels in 
Castle Wolfenstein –ik bedoel- het buitenland. “Woeha”! 
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Ook mijn oud collega’s wil ik graag betrekken bij dit proefschrift. 
Monique Jansen, Johan Frieling en Wilfried Seifert, jullie zorgden, al 
dan niet gesteund door de vele stagiairs, voor de juiste sfeer en gaven 
middels jullie doctorstitel allen reeds het goede voorbeeld. De perioden 
met stagiairs Claartje Schrover en Ignace de Hingh waren voor mij ook 
zeer plezierig en leerzaam. Ignace, je hebt als student het labrecord 
“96-wells-platen pipetteren” op scherp gezet en je hebt me daarbij aan 
mijn eerste internationale presentatie geholpen (n = 1). En passant heb 
je me op bekwame wijze (maar helaas ten dele) verlost van wat 
overtollig vet en ben je ruim voor mij gepromoveerd. Petje af! 
Behalve door medewerkers van de afdeling heelkunde is ook de 
ondersteuning vanuit andere afdelingen onmisbaar geweest voor de 
totstandkoming van dit proefschrift. Graag bedank ik hiervoor de 
hoofden en medewerkers van het lab algemene interne geneeskunde 
(Prof.dr. Jos M. van der Meer, Trees Jansen, Liesbeth Jacobs en 
Johanna van der Ven) voor de cytokine bepalingen; het lab 
kindergeneeskunde (dr.Bert van den Heuvel, Thea van der Velden, Frans 
van den Brandt, e.v.a.) voor de celkweken, -materialen en de vele 
nuttige tips; de medische microbiologie (Carla Bartels, Twan Klaassen en 
Paul Rutten) voor de bacteriekweken en –uitslagen; dr. Jo Curfs voor de 
fluorescentiemicroscopie; het lab hematologie (Arie Pennings zaliger) 
voor de rappe uitleg van de FACS; de afdeling pathologie (dr. Rob de 
Waal en Irene Ottehöller) voor hun microscopische blik; de intensive 
care (Prof.dr. J.G. van der Hoeven, dr. Peter Pickkers en Lucas van Eijk) 
voor de constructieve en gezellige samenwerking. Ook bedank ik graag 
Prof.dr. Wim A. Buurman van het AZM voor zijn kritische blik, het leren 
van de ELISA en de materialen die hij hiervoor aan mij beschikbaar heeft 
gesteld. 
Verder wil ik mijn (ex)kamergenoten, Tjarda Tromp, Otmar Buyne, en 
Ivo van Kampen bedanken. Ondanks dat ik vaak elders zat heb ik jullie 
verbale, digitale en muzikale onderbrekingen zeer op prijs gesteld. 
Van je vrienden moet je het maar hebben en van de velen van wie ik 
“het” heb gekregen, wil ik er een paar noemen, zonder de bedoeling om 
anderen tekort te doen: Luuk en Desiree, veel dank voor jullie 
“daklozenopvang”; Wouter, Jan-Willem en Thomas, voor de vele 
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muzikale hoogte- en dieptepunten; medewerkers van PNF, voor het 
“Maradona” gevoel; Zeban, voor het “Musical Box” gevoel. De Heren van 
Vrijdagavond, voor de vele korte doch aangename verblijven op Puerto 
Rico; MVP Menno, voor het “Touch Down” gevoel; en Douwe, voor de 
liters koffie die nodig waren om überhaupt iets op papier te krijgen. 
Casper en Laura, voor jullie geweldige vriendschap. Veel prestaties 
vallen in het niet bij de wijze waarop jullie door een hele moeilijke 
periode zijn gegaan. En Cas, jouw boek is veel meer een proeve van 
bekwaamheid dan het mijne, en ik hoop dat je daarmee het begin hebt 
ingeluid van een periode vol voorspoed. “Bram Breedveld rules!” 
Paranimfen Ben en Menno, gekleed in rok of spijkerbroek, ik bewonder 
jullie trouw, sympathie en optimisme. Echte steunpilaren! En Men, je 
mag het nu eindelijk lezen. 
Ook mijn familie zal ik in dit dankwoord niet overslaan. Het cliché: 
“Dankzij hen ben ik geworden wie ik nu ben” is door de jaren heen reeds 
van vele kanten belicht. Jullie fysieke of geestelijke aanwezigheid is, 
gewild of ongewild, richtingbepalend geweest voor mijn bestaan. Ik ben 
trots en dankbaar dat ik nu de kans krijg om mijn eigen nest te warmen 
met de liefde die het nodig heeft en met de onvoorwaardelijke steun die 
het verdient. 
 
Ik ben een bevoorrecht mens dat ik daarbij jouw hulp krijg, lieve 
Corinne. Acht jaar geleden heb ik blijkbaar een verpletterende indruk 
op je achtergelaten met de stellige opmerking: ”Volgend jaar promoveer 
ik”. Ik geloof niet dat je er in de zeven daaropvolgende jaren en even 
zovele herhalingen al teveel onder geleden hebt, maar even goed, ik zal 
het nooit meer doen. 
 
En dan nog tot slot jullie twee. Kleine Cathelijne en nog kleinere 
Juliette (maar geluk hoeft niet persé groot te zijn). Jullie zijn de 
Tovenaars van de Glimlach. Jullie bezorgen mij de mooiste titel: die van 
een trotse vader! 
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